



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁷ : C12N	A2	(11) International Publication Number: WO 00/65028 (43) International Publication Date: 2 November 2000 (02.11.00)
(21) International Application Number: PCT/US00/11564 (22) International Filing Date: 26 April 2000 (26.04.00) (30) Priority Data: 09/299,473 26 April 1999 (26.04.99) US 09/459,813 13 December 1999 (13.12.99) US (71) Applicant: STEM CELL PHARMACEUTICALS, INC. [US/US]; Suite 700, 562 First Avenue South, Seattle, WA 98104 (US). (72) Inventors: TWARDZIK, Daniel, R.; 10195 South Beach Drive, Bainbridge Island, WA 98110 (US). PASKELL, Stefan; 6075 NE Tolo Road, Bainbridge Island, WA 98110 (US). FELKER, Thomas, S.; 11344 SW McCormick Place, Vashon, WA 98070 (US). (74) Agent: HAILE, Lisa, A.; Gray Cary Ware & Friedenrich LLP, Suite 1600, 4365 Executive Drive, San Diego, CA 92121-2189 (US).		(81) Designated States: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG). Published <i>Without international search report and to be republished upon receipt of that report.</i>
(54) Title: TGF- α POLYPEPTIDES, FUNCTIONAL FRAGMENTS AND METHODS OF USE THEREFOR (57) Abstract Disclosed are peptides related to human TGF- α , having TGF- α biological activity, which are useful for many of the indications that full-length TGF- α polypeptide is useful. Also provided are methods of use of such peptides, as well as human TGF- α and biologically related polypeptides. For example, methods for treating or preventing cachexia in subjects are provided as well as methods for stimulating hematopoiesis in patients undergoing cytotoxic chemotherapy. In addition, the use of TGF- α related peptides to related neurodegenerative diseases is also provided. Methods of the invention also provide protection for patients undergoing cytotoxic therapy from side effects such as gastrointestinal (GI) mucositis.		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

TGF- α POLYPEPTIDES, FUNCTIONAL FRAGMENTS AND METHODS OF USE THEREFOR

FIELD OF THE INVENTION

The invention relates generally to transforming growth factor alpha () and
5 more specifically to methods of using TGF- α for stimulating hematopoiesis, for
suppressing immune function associated with autoimmune diseases, for suppressing
inflammatory responses mediated by excessive histamine release and by expression
of TNF-receptors and associated pro-inflammatory cytokines, and for treating
cachexia or for treating or preventing mucositis and gastrointestinal-associated
10 disorders.

BACKGROUND

There are several disease treatments that could significantly benefit by having
cells regenerate after injury or lesion formation, particularly in the CNS, in the
immune system and in the gastrointestinal tract. In some instances, a particular
15 treatment for a disease often detrimentally affects the subject being treated. For
example, administration of chemotherapeutic agents to subjects results in destruction
of healthy cells, for example, cells of the gastrointestinal tract. A number treatment-
related disorders are related to the choice of chemotherapeutic agent. Such agents
include carmustine (BCNU), chlorambucil (Leukeran), cisplatin (Platinol),
20 Cytarabine, doxorubicin (Adriamycin), fluorouracil (5-FU), methoxetrate (Mexate),
taxol, CPT111, etoposide, and plicamycin (Mithracin) which are known for their
direct stomatotoxic potential (Sonis, 1993, "Oral Complications in Cancer Therapy,"
In: Principles and Practice of Oncology, pp. 2385-2394, DeVitta *et al.*, Eds., J. B.
Lippincott, Philadelphia) and hence incidence of mucositis.

25 Oral mucositis can be initiated by the cytotoxic effects of chemotherapy
and/or radiotherapy on the rapidly dividing epithelial cells of the oropharyngeal
mucosa, and is exacerbated by infection with both endogenous oral flora and
opportunistic bacterial and fungal pathogens. Complications related to oral mucositis
30 vary in the different patient populations affected, but typically include pain, poor oral

intake with consequent dehydration and weight loss, and systemic infection with organisms originating in the oral cavity. The pain associated with oral mucositis may be severe requiring narcotic analgesics, and the difficulty in eating can result in patients receiving total parenteral nutrition.

5

Current therapies have been directed at decreasing oral flora and the extent of infection of oral ulcerations. Systemic treatment with G- and GM-CSF has been shown to result in a decreased incidence of oral mucositis, presumably by allowing for more rapid neutrophil recovery and thus an improved ability to combat infection, although it has been postulated that the CSFs may have a more direct effect on the oral mucosa (Chi *et al.*, 1995, J. Clin. Oncol. 13:2620-2628). In one study, GM-CSF was reported to exacerbate mucositis. (Cartee *et al.*, 1994, Cytokine 7:471-477). Benzydamine hydrochloride, a nonsteroidal drug with analgesic and antimicrobial properties, has been studied both in patients undergoing radiation therapy and in patients receiving intra-arterial chemotherapy.

In addition, diseases associated with epithelial cell depletion in the gastrointestinal tract often increase the risk of related disorders. Such related disorders include infection by opportunistic pathogens as well as weight loss associated with the loss in nutrient uptake in the gastrointestinal tract.

SUMMARY OF THE INVENTION

The present invention is based on the seminal discovery that TGF- α and functionally related polypeptides, TGF- α mimetics, functional TGF- α peptides, and polynucleotides encoding such polypeptides and peptide fragments are effective for treating or preventing weight-loss in subjects having disorders or diseases associated with weight-loss (*e.g.*, cachexia). In addition, the polypeptides of the invention have mitogenic and barrier function (*e.g.*, protective) effects on stem cells and their differentiated progeny from a variety of tissues including the gastrointestinal system, the nervous system and the hematopoietic system.

In a first embodiment, the invention provides a method of treating a subject having or at risk of having cachexia comprising administering to the subject a transforming growth factor-alpha (TGF- α) polypeptide in an amount effective to prevent or reduce weight-loss. In one aspect, the invention provides a method of increasing the body weight of a subject comprising administering to the subject, prior to, simultaneously with, or substantially following chemotherapy, a transforming growth factor-alpha (TGF- α) polypeptide in an amount effective to increase the weight of the subject. In one aspect the subject has AIDS related complex (ARC) or AIDS and cachexia associated with such diseases.

10

In another embodiment, the invention provides a method for treating or preventing mucositis of the gastrointestinal tract in a subject, comprising administering a TGF α or related polypeptide in an amount effective to treat or prevent mucositis in the subject. For example, a subject undergoing chemotherapy can be treated by the method of the invention.

15

The invention also provides a polypeptide comprising a peptide having a sequence NH₂- X_{1a} - Cys - His - Ser - X_{1b} - X₂ - X_{1a} - X_{1b} - X_{1a} - X₃ - Cys - COOH (SEQ ID NO:4) wherein X_{1a} and X_{1b} are independently Val, Gly or Ala; X₂ is Tyr or Phe; X₃ is Arg or Lys; and the two Cys moieties are linked via a disulfide bond to form an at least 11-amino acid functional peptide having TGF- α activity.

20

In another embodiment, the invention provides a polypeptide comprising a peptide having a sequence NH₂- X_{1a} - Cys - His - Ser - X_{1b} - X₂ - X_{1a} - X_{1b} - X_{1a} - X₃ - Cys - COOH (SEQ ID NO:4) wherein X_{1a} and X_{1b} are independently Val, Gly or Ala; X₂ is Tyr or Phe; X₃ is Arg or Lys; and the two Cys moieties are linked via a disulfide bond to form an at least 11-amino acid functional peptide having TGF- α activity and wherein at least one or more of the following amino acids are linked to the C-terminal Cys moiety of SEQ ID NO:4: - X₄ - His - X_{1c} - X₄ - X₅ - X₆ - X_{1c} (SEQ ID NO:5) wherein X₄ is Glu or Asp; X₅ is Leu or Ile; and X₆ is Asp or Glu.

25

30

In yet another embodiment, the invention provides a pharmaceutical composition comprising a polypeptide having a sequence NH₂- X_{1a} - Cys - His - Ser - X_{1b} - X₂ - X_{1a} - X_{1b} - X_{1a} - X₃ - Cys COOH (SEQ ID NO:4) wherein X_{1a} and X_{1b} are independently Val, Gly or Ala; X₂ is Tyr or Phe; X₃ is Arg or Lys; and the two Cys moieties are linked via a disulfide bond to form an at least 11-amino acid functional peptide having TGF- α activity, and a pharmaceutically acceptable carrier. In addition, at least one or more of the following amino acids are linked to the C-terminal Cys moiety of SEQ ID NO:4: - X₄ - His - X_{1c} - X₄ - X₅ - X₆ - X_{1c} (SEQ ID NO:5) wherein X₄ is Glu or Asp; X₅ is Leu or Ile; and X₆ is Asp or Glu.

10

The invention also provides a compound that acts as a TGF- α mimetic, comprising a compound of formula: loop peptide N-terminus-linker-cyclic C₄H₈N₂-linker-loop peptide N-terminus wherein the linker moiety is designed to link the N-terminus of the loop peptide to a nitrogen atom of the ring C₄H₈N₂ and wherein the loop peptide has a sequence NH₂- X_{1a} - Cys - His - Ser - X_{1b} - X₂ - X_{1a} - X_{1b} - X_{1a} - X₃ - Cys COOH (SEQ ID NO:4) wherein X_{1a} and X_{1b} are independently Val, Gly or Ala; X₂ is Tyr or Phe; X₃ is Arg or Lys; and the two Cys moieties are linked via a disulfide bond to form an at least 11-amino acid functional peptide having TGF- α activity.

20

BRIEF DESCRIPTION OF THE FIGURE

Figure 1 shows the structure of rat TGF α polypeptide and its 50 amino acids arranged into three loops (SEQ ID NO:2). The human TGF α sequence is provided in SEQ ID NO:1 with a similar tertiary structure and a close sequence homology.

25

Figure 2 shows a graph comparing TGF α biological activity of the three loop peptide regions of TGF α (see Figure 1) wherein Loop A is amino acids 1-21 (starting at the N terminus), Loop B is amino acids 16 to 32 and Loop C is amino acids 33 to 50. Only Loop C showed significant TGF α activity as determined by cell proliferation and in a dose response fashion.

30

Figure 3 shows a graph of mouse spleen weights that were treated with Cis Platinum (CP) at either 5 µg/g or 10 µg/g and with TGFα at concentrations of 10 ng/g or 50 ng/g. These data show that TGFα treatment caused a return to normal spleen weights despite CP treatment that reduced spleen weights significantly.

5

Figure 4 depicts a summary of histological data that measured average crypt height of the three groups of mice. TGFα 57 treatment (50 ng/g) was able to more-than-restore crypt height loss from CP treatment.

10 **Figure 5** shows a graph depicting the effects of cisplatin-alone, cisplatin and a TGF-α polypeptide, and a TGF-α alone on weight loss of mice.

Figure 6 shows weight loss in mice following cisplatin administration with and without concurrent TGF-α treatment. The graph shows (from left to right) the proportion of weight-loss in the presence of PBS alone, TGF-α alone, cisplatin alone, and cisplatin+TGF-α.

15

DETAILED DESCRIPTION OF THE INVENTION

The present invention provides compositions of TGF-α polypeptides, TGF-α mimetics, TGF-α related polypeptides and functional fragments thereof as well as polynucleotides encoding the polypeptides and fragments thereof. In addition, the invention provides methods of using the polypeptides and polynucleotides of the invention for treating or preventing a number of diseases and disorders.

20

Transforming Growth Factor-α

TGF-α is a member of the epidermal growth factor (EGF) family and interacts with one or more receptors in the EGF-family of receptors. TGF-α stimulates the receptor's endogenous tyrosine kinase activity which results in activating various cellular functions, such as stimulating a mitogenic or migration response in a wide variety of cell types. TGF-α and EGF mRNAs reach their highest levels and relative abundance (compared to total RNA) in the early postnatal period and decrease thereafter, suggesting a role in embryonic development. From a histological

25

perspective, TGF- α is found in numerous cell types and tissues throughout the body. The active form of TGF- α is derived from a larger 30-35 kD precursor and contains 50 amino acids. Human TGF- α shares only a 30% structural homology with the 53-amino acid form of EGF, but includes conservation and spacing of all six cysteine residues. TGF α is highly conserved among species. For example, the rat and human polypeptides share about 90% homology compared to a 70% homology as between the rat and human EGF polypeptide. The amino acid sequence of human TGF α is shown in SEQ ID NO:1. TGF α shares cysteine disulfide bond structures with a family of proteins including vaccinia growth factor, amphiregulin precursor, betacellulin precursor, heparin binding EGF-like growth factor, epiregulin (rodent only), HUS 19878, myxomavirus growth factor (MGF), Shope fibroma virus growth factor (SFGF), and schwannoma derived growth factor. Such TGF- α related polypeptides are also useful in the methods of the invention.

TGF- α is an acid and heat stable polypeptide of about 5.6 kDa molecular weight. It is synthesized as a larger 30-35 kDa molecular weight glycosylated and membrane-bound precursor protein wherein the soluble 5.6 kDa active form is released following specific cleavage by an elastase-like protease. TGF- α binds with high affinity in the nanomolar range and induces autophosphorylation of one or more members of EGF receptor family (*e.g.*, ErbB1 through 4) to transduce subsequent signal pathways with the EGF receptors. TGF- α is 50 amino acids in length and has three disulfide bonds to form its tertiary configuration. All three disulfide bonds are required for activity. TGF- α is stored in precursor form in alpha granules of some secretory cells. Moreover, the primary amino acid sequence is highly conserved among various species examined, such as more than 92% homology at the amino acid level as between human and rat TGF α polypeptides.

Human TGF α is a polypeptide of 50 amino acids. The corresponding rat sequence is shown in Figure 1. The human or rat TGF α polypeptide can be divided roughly into three loop regions corresponding roughly (starting at the N terminus) to amino acids 1-21, to amino acids 16-32, and to amino acids 33-50. As discussed

more fully below, the invention provides functional fragments of TGF- α that retain TGF- α biological activity. "Functional fragment" as used herein means a TGF- α peptide that is a fragment or a modified fragment of a full length TGF- α polypeptide or related polypeptide so long as the fragment retains some TGF- α related biological activity (*e.g.*, interacts with an EGF family receptor, stimulates proliferation or migration of stem cells, useful for treating or preventing cachexia). Other biological activities associated with the polypeptides of the invention include, for example, mitogenic effects on stem cells and their more differentiated progeny of various tissues (*e.g.*, epithelial stem cells, hematopoietic stem cells, neural stem cells, liver stem cells, keratinocyte stem cells, and pancreatic derived stem cells).

The mucosal epithelium of the intestine is in a continually dynamic state known as "epithelial renewal" in which undifferentiated stem cells from a proliferative crypt zone divide, differentiate and migrate to the luminal surface. Once terminally differentiated, mucosal epithelial cells are sloughed from the tips of the villi. The turnover of the crypt-villus cell population is rapid and occurs every 24-72 hours. Continuous exfoliation of the cells at the villus tip is counterbalanced by ongoing proliferation in the crypt so that net intestinal epithelial mass remains relatively constant. The rapidly-proliferating epithelium of the gastrointestinal tract is extremely sensitive to cytotoxic drugs that are widely used in cancer chemotherapy. By "gastrointestinal tract" is meant, for example, the tissues of the mouth, esophagus, stomach, small intestine, large intestine, rectum and anus. This "side effect" reduces the tolerated dose of such drugs as it can cause a breakdown of the GI barrier function and septic propagate a septic condition in a patient already immuno-compromised. This can also lead to life-threatening hemorrhage. Therefore, there is a need in the art for the development of products and delivery systems that stimulate the repair and rejuvenation of mucosal epithelium in the gastrointestinal tract to provide benefit to subjects having, for example, weight-loss disorders associated with chemotherapy and radiation therapy for cancer as well as disorders or diseases associated with pathogens such as HIV.

Accordingly, the invention provides a class of peptides, including TGF- α and those smaller than the 50 amino acid human TGF- α , yet retaining TGF- α biological activity, which are useful as pharmacologic and therapeutic agents. Other polypeptides or fragments thereof include TGF-related polypeptides that have the biological activity of TGF- α (e.g., amphiregulin, vaccinia growth factor, myxomavirus growth factor (MGF), Shope fibroma virus growth factor (SFVG), heparin-binding EGF-like growth factor (HB-EGF)).

The invention also provides methods of using TGF- α , related polypeptides and peptide fragments thereof as disclosed herein to stimulate hematopoiesis in subjects undergoing cytotoxic cancer chemotherapy and to act as a cytoprotective agents and in treatments for subjects at risk of or having weight-loss disorders associated with cancer cytotoxic therapy. Such disorders include for example, gastrointestinal (GI) mucositis, which can be the result of cytotoxic therapy. While not wanting to be bound to a particular theory, it is believed TGF- α may alleviate GI mucositis, in part, through its mitogenic activity for GI epithelial stem cells.

TGF α has been investigated extensively and has recently been identified as useful for treating subjects with neurological deficits. This mechanism is thought to stimulate proliferation and migration of stem cells of neural origin to those sites or lesions in a deficit. For example, Parkinson's Disease is characterized by resting tremor, rigidity, inability to initiate movement (akinesia) and slowness of movement (bradykinesia). The motor deficits are associated with progressive degeneration of the dopaminergic innervation to the nucleus accumbens and degeneration of noradrenergic cells of the locus ceruleus and serotonergic neurons of the raphe. Up to 80% of nigral dopamine neurons can be lost before significant motor deficits are manifest. TGF α was shown, when infused into rat brains, to be useful for the treatment of neurodegenerative disorders. Intracerebroventricular (ICV) or intrastriatal infusions of TGF α induced neuronal stem cell proliferation, but degenerating or damaged or otherwise abnormal cells needed to be present to facilitate migration of the neuronal stem cells to a site of injury on a scale sufficient to

impact recovery from an associated neurological deficit. Forebrain neural stem cells, that give rise to migrating progenitor cells that affect treatment and recovery from a neurological deficit disorder, are the migrating cells that affect treatment recovery from a neural deficit disorder (*e.g.*, Parkinson's Disease, Huntington's Disease, Alzheimer's Disease and the like).

Neural stem cells have been found in subependyma throughout the adult rodent CNS (Ray *et al. Soc. Neurosci.* 22:394.5, 1996) and in the subependyma of adult human forebrain (Kirschenbaum *et al., Cerebral Cortex* 4:576-589, 1994). Thus, the discovery that TGF α stimulates proliferation of neural stem cells and promotes migration to a site of injury or deficit has led to its investigation for the treatment of a neurodegenerative disorder (Alzheimer's Disease, Huntington's Disease and Parkinson's Disease) or CNS traumatic injury (*e.g.*, spinal chord injury), demyelinating disease, CNS inflammatory disease, CNS autoimmune disease (*e.g.*, multiple sclerosis) and CNS ischemic disease (*e.g.*, stroke or brain attack).

A CNS stem cell has the potential to differentiate into neurons and astrocytes as well as self replication and thus self renewal. Both neuronal and glial cells are derived from a common precursor cell. In the vertebrate CNS, pluripotent cells have been identified *in vitro* and *in vivo*. Certain mitogens, such as TGF- α , can cause proliferation of CNS pluripotent cells *in vitro*. Thus, it is possible to harvest such cell from a subject, treat them *ex vivo* to stimulate proliferation in culture and then readminister the cells back to a subject. Immunohistochemical analysis in the human brain supports the notion that TGF- α and its 35 kD precursor are widely distributed in neurons and glial cells both during development and during adulthood. In TGF- α knockout mice genetically altered to lack expression of functioning TGF- α , there was a decrease in neural progenitor cell proliferation in forebrain subependyma, providing evidence for TGF- α as a proliferative factor for neural progenitor cells.

TGF- α is found mainly in various neurons of the CNS during development and in the adult brain in the cerebral neocortex, hippocampus and striatum. It is also

found in glial cells, primarily in the cerebral and cerebellar cortex areas. Northern blot analyses showed that TGF α but not EGF (epidermal growth factor) is the most abundant ligand that binds to one or more of the EGF receptor family in the brain. TGF α mRNA levels were 15-170 times higher than EGF in cerebellum and cerebral cortex. TGF α also appears in germinal centers of the brain during neurogenesis and gliogenesis in the developing brain. In the midbrain, the distribution of TGF α overlaps with tyrosine hydroxylase mRNA and fetal dopaminergic neurons. In culture, TGF α enhanced survival and neurite outgrowth of neonatal rat dorsal ganglion neurons (EGF did not) and survival and differentiation of CNS neurons.

TGF α induced proliferation of neural precursor cells of the murine embryonic mesencephalon and further induced a significant increase in the number of astroglia and microglia in fetal rat medial septal cells. TGF α increased glutamic acid decarboxylase activity and decreased choline acetyltransferase activity. Thus, TGF α acted as a general neuronal survival factor affecting both cholinergic and GABAergic neurons. In addition, TGF α is a mitogen for pluripotent brain stem cells. Forebrain subependyma contains nestin positive neural stem cells and their progeny, which are constitutively proliferating progenitor epithelial cells. A "knockout" mouse that was genetically engineered to delete the gene for TGF α showed a reduction in neuronal progenitor cells in the subependyma and a reduction in neuronal progenitors that migrate to the olfactory bulb. *In vitro*, TGF α promoted dopamine uptake in fetal rat dopaminergic neurons in a dose-dependent and time-dependent manner. TGF α selectively promoted dopaminergic cell survival, enhanced neurite length, branch number and the soma area of tyrosine hydroxylase immunopositive cells. The levels of TGF α were elevated in ventricular cerebrospinal fluid in juvenile parkinsonism and Parkinson's Disease and may represent a compensatory response to neurodegeneration. Further, TGF α prevented a striatal neuronal degeneration in an animal model of Huntington's Disease.

Nucleic Acids and Vectors

Polynucleotide or nucleic acid sequence refers to a polymeric form of nucleotides. In some instances a polynucleotide refers to a sequence that is not immediately contiguous with either of the coding sequences with which it is immediately contiguous (one on the 5' end and one on the 3' end) in the naturally occurring genome of the organism from which it is derived. The term therefore includes, for example, a recombinant DNA which is incorporated into a vector; into an autonomously replicating plasmid or virus; or into the genomic DNA of a prokaryote or eukaryote, or which exists as a separate molecule (*e.g.*, a cDNA) independent of other sequences. The nucleotides of the invention can be ribonucleotides, deoxyribonucleotides, or modified forms of either nucleotide. In addition, the polynucleotide sequence involved in producing a polypeptide chain can include regions preceding and following the coding region (leader and trailer) as well as intervening sequences (introns) between individual coding segments (exons) depending upon the source of the polynucleotide sequence.

The term polynucleotide(s) generally refers to any polyribonucleotide or polydeoxyribonucleotide, which may be unmodified RNA or DNA or modified RNA or DNA. Thus, for instance, polynucleotides as used herein refers to, among others, single- and double-stranded DNA, DNA that is a mixture of single- and double-stranded regions, single- and double-stranded RNA, and RNA that is mixture of single- and double-stranded regions, hybrid molecules comprising DNA and RNA that may be single-stranded or, more typically, double-stranded or a mixture of single- and double-stranded regions.

In addition, the polynucleotides or nucleic acid sequences may contain one or more modified bases. Thus, DNAs or RNAs with backbones modified for stability or for other reasons are "polynucleotides" as that term is intended herein. Moreover, DNAs or RNAs comprising unusual bases, such as inosine, or modified bases, such as tritylated bases, to name just two examples, are polynucleotides as the term is used herein.

Nucleic acid sequences can be created which encode a fusion protein (*e.g.*, a TGF- α polypeptide and another polypeptide, such as a targeting sequence) and can be

operatively linked to expression control sequences. "Operatively linked" refers to a juxtaposition wherein the components so described are in a relationship permitting them to function in their intended manner. For example, a coding sequence is "operably linked" to another coding sequence when RNA polymerase will transcribe the two coding sequences into a single mRNA, which is then translated into a single polypeptide having amino acids derived from both coding sequences. The coding sequences need not be contiguous to one another so long as the expressed sequences ultimately process to produce the desired protein. An expression control sequence operatively linked to a coding sequence is ligated such that expression of the coding sequence is achieved under conditions compatible with the expression control sequences. As used herein, the term "expression control sequences" refers to nucleic acid sequences that regulate the expression of a nucleic acid sequence to which it is operatively linked. Expression control sequences are operatively linked to a nucleic acid sequence when the expression control sequences control and regulate the transcription and, as appropriate, translation of the nucleic acid sequence. Thus, expression control sequences can include appropriate promoters, enhancers, transcription terminators, a start codon (*i.e.*, ATG) in front of a protein-encoding gene, splicing signals for introns, maintenance of the correct reading frame of that gene to permit proper translation of the mRNA, and stop codons. The term "control sequences" is intended to include, at a minimum, components whose presence can influence expression, and can also include additional components whose presence is advantageous, for example, leader sequences and fusion partner sequences. Expression control sequences can include a promoter.

By "promoter" is meant minimal sequence sufficient to direct transcription. Also included in the invention are those promoter elements which are sufficient to render promoter-dependent gene expression controllable for cell-type specific, tissue-specific, or inducible by external signals or agents; such elements may be located in the 5' or 3' regions of the of a polynucleotide sequence. Both constitutive and inducible promoters, are included in the invention (see *e.g.*, Bitter *et al.*, Methods in Enzymology 153:516-544, 1987). For example, when cloning in bacterial systems, inducible promoters such as pL of bacteriophage, plac, ptrp, ptac (ptrp-lac hybrid promoter) and the like may be used. When cloning in mammalian cell systems, promoters derived from the genome of

mammalian cells (*e.g.*, metallothionein promoter) or from mammalian viruses (*e.g.*, the retrovirus long terminal repeat; the adenovirus late promoter; the vaccinia virus 7.5K promoter) may be used. Promoters produced by recombinant DNA or synthetic techniques may also be used to provide for transcription of the nucleic acid sequences of the invention.

A nucleic acid sequence of the invention including, for example, a polynucleotide encoding a fusion protein, may be inserted into a recombinant expression vector. A recombinant expression vector generally refers to a plasmid, virus or other vehicle known in the art that has been manipulated by insertion or incorporation of a nucleic acid sequences. For example, a recombinant expression vector of the invention includes a polynucleotide sequence encoding a TGF- α polypeptide having a sequence as set forth in SEQ ID NO:1, 2, 3, 4 or 6 or fragment thereof (as described more fully below). The expression vector typically contains an origin of replication, a promoter, as well as specific genes which allow phenotypic selection of the transformed cells.

Vectors suitable for use in the invention include, but are not limited to the T7-based expression vector for expression in bacteria (Rosenberg, *et al.*, Gene 56:125, 1987), the pMSXND expression vector for expression in mammalian cells (Lee and Nathans, J. Biol. Chem. 263:3521, 1988), baculovirus-derived vectors for expression in insect cells, cauliflower mosaic virus, CaMV; tobacco mosaic virus, TMV. The nucleic acid sequences of the invention can also include a localization sequence to direct the indicator to particular cellular sites by fusion to appropriate organellar targeting signals or localized host proteins. For example, a polynucleotide encoding a localization sequence, or signal sequence, can be used as a repressor and thus can be ligated or fused at the 5' terminus of a polynucleotide encoding a polypeptide or a polypeptide fragment of the invention such that the localization or signal peptide is located at the amino terminal end of a resulting polypeptide. The construction of expression vectors and the expression of genes in transfected cells involves the use of molecular cloning techniques also well known in the art. (See, for example, Sambrook *et al.*, Molecular Cloning --A Laboratory Manual, Cold Spring Harbor Laboratory, Cold Spring Harbor, NY, 1989, and Current Protocols in Molecular Biology, M. Ausubel *et al.*, eds., (Current Protocols, a joint venture between Greene Publishing Associates, Inc. and John Wiley & Sons, Inc., most

recent Supplement)). These methods include *in vitro* recombinant DNA techniques, synthetic techniques and *in vivo* recombination/genetic recombination. (See also, Maniatis, *et al.*, Molecular Cloning A Laboratory Manual, Cold Spring Harbor Laboratory, N.Y., 1989).

5 In yeast, a number of vectors containing constitutive or inducible promoters may be used. For a review see, Current Protocols in Molecular Biology, Vol. 2, Ed. Ausubel, *et al.*, Greene Publish. Assoc. & Wiley Interscience, Ch. 13, 1988; Grant, *et al.*, "Expression and Secretion Vectors for Yeast," in Methods in Enzymology, Eds. Wu & Grossman, 1987, Acad. Press, N.Y., Vol. 153, pp.516-544, 1987; Glover, DNA Cloning,
10 Vol. II, IRL Press, Wash., D.C., Ch. 3, 1986; and Bitter, "Heterologous Gene Expression in Yeast," Methods in Enzymology, Eds. Berger & Kimmel, Acad. Press, N.Y., Vol. 152, pp. 673-684, 1987; and The Molecular Biology of the Yeast *Saccharomyces*, Eds. Strathern *et al.*, Cold Spring Harbor Press, Vols. I and II, 1982. A constitutive yeast promoter such as ADH or LEU2 or an inducible promoter such as GAL may be used
15 ("Cloning in Yeast," Ch. 3, R. Rothstein In: DNA Cloning Vol.11, A Practical Approach, Ed. DM Glover, IRL Press, Wash., D.C., 1986). Alternatively, vectors may be used which promote integration of foreign DNA sequences into the yeast chromosome.

 An alternative expression system which could be used to express a TGF- α
20 polypeptide or function fragment of the invention is an insect system. In one such system, *Autographa californica* nuclear polyhedrosis virus (AcNPV) is used as a vector to express foreign or mutated polynucleotide sequences. The virus grows in *Spodoptera frugiperda* cells. The sequence encoding a polypeptide of the invention may be cloned into non-essential regions (for example, the polyhedrin gene) of the virus and placed
25 under control of an AcNPV promoter (for example the polyhedrin promoter). Successful insertion of the sequences coding for a polypeptide of the invention will result in inactivation of the polyhedrin gene and production of non-occluded recombinant virus (*i.e.*, virus lacking the proteinaceous coat coded for by the polyhedrin gene). These recombinant viruses are then used to infect *S. frugiperda* cells in which
30 the inserted gene is expressed, see Smith, *et al.*, J. Virol. 46:584, 1983; Smith, U.S. Patent No. 4,215,051.

The vectors of the invention can be used to transform a host cell. By transform or transformation is meant a permanent or transient genetic change induced in a cell following incorporation of new DNA (*i.e.*, DNA exogenous to the cell). Where the cell is a mammalian cell, a permanent genetic change is generally achieved by introduction of the DNA into the genome of the cell.

A transformed cell or host cell generally refers to a cell (*e.g.*, prokaryotic or eukaryotic) into which (or into an ancestor of which) has been introduced, by means of recombinant DNA techniques, a polynucleotide molecule encoding a TGF- α polypeptide or functional fragments thereof (*e.g.*, a functional fragment as set forth in SEQ ID NO:4, as described below).

Transformation of a host cell with recombinant DNA may be carried out by conventional techniques as are well known to those skilled in the art. Where the host is prokaryotic, such as *E. coli*, competent cells which are capable of DNA uptake can be prepared from cells harvested after exponential growth phase and subsequently treated by the CaCl_2 method by procedures well known in the art. Alternatively, MgCl_2 or RbCl can be used. Transformation can also be performed after forming a protoplast of the host cell or by electroporation.

When the host is a eukaryote, methods of transfection or transformation with DNA include calcium phosphate co-precipitates, conventional mechanical procedures such as microinjection, electroporation, insertion of a plasmid encased in liposomes, or virus vectors, as well as others known in the art, may be used. Eukaryotic cells can also be cotransfected with DNA sequences encoding a TGF- α polypeptide or fragment and a second foreign DNA molecule encoding a selectable marker, such as the herpes simplex thymidine kinase gene. Another method is to use a eukaryotic viral vector, such as simian virus 40 (SV40) or bovine papilloma virus, to transiently infect or transform eukaryotic cells and express the protein. (Eukaryotic Viral Vectors, Cold Spring Harbor Laboratory, Gluzman ed., 1982). Typically, a eukaryotic host will be utilized as the host cell. The eukaryotic cell may be a yeast cell (*e.g.*, *Saccharomyces cerevisiae*), an insect cell (*e.g.*, *Drosophila sp.*) or may be a mammalian cell, including a human cell.

Eukaryotic systems, and mammalian expression systems, allow for post-translational modifications of expressed mammalian proteins to occur. Eukaryotic cells which possess the cellular machinery for processing of the primary transcript, glycosylation, phosphorylation, and, advantageously secretion of the gene product
5 should be used. Such host cell lines may include, but are not limited to, CHO, VERO, BHK, HeLa, COS, MDCK, Jurkat, HEK-293, and WI38.

Mammalian cell systems which utilize recombinant viruses or viral elements to direct expression may be engineered. For example, when using adenovirus expression vectors, a polynucleotide encoding a TGF- α polypeptide or fragment thereof may be
10 ligated to an adenovirus transcription/ translation control complex, *e.g.*, the late promoter and tripartite leader sequence. This chimeric sequence may then be inserted in the adenovirus genome by *in vitro* or *in vivo* recombination. Insertion in a non-essential region of the viral genome (*e.g.*, region E1 or E3) will result in a recombinant virus that is viable and capable of expressing a TGF- α polypeptide or fragment thereof in infected
15 hosts (*e.g.*, see Logan & Shenk, Proc. Natl. Acad. Sci. USA, 81:3655-3659, 1984). Alternatively, the vaccinia virus 7.5K promoter may be used. (*e.g.*, see, Mackett, *et al.*, Proc. Natl. Acad. Sci. USA, 79:7415-7419, 1982; Mackett, *et al.*, J. Virol. 49:857-864, 1984; Panicali, *et al.*, Proc. Natl. Acad. Sci. USA 79:4927-4931, 1982). Of particular interest are vectors based on bovine papilloma virus which have the ability to replicate as
20 extrachromosomal elements (Sarver, *et al.*, Mol. Cell. Biol. 1:486, 1981). Shortly after entry of this DNA into mouse cells, the plasmid replicates to about 100 to 200 copies per cell. Transcription of the inserted cDNA does not require integration of the plasmid into the host's chromosome, thereby yielding a high level of expression. These vectors can be used for stable expression by including a selectable marker in the plasmid, such as the
25 *neo* gene. High level expression may also be achieved using inducible promoters, including, but not limited to, the metallothionine IIA promoter and heat shock promoters.

For long-term, high-yield production of recombinant proteins, stable expression is preferred. Rather than using expression vectors which contain viral origins of
30 replication, host cells can be transformed with the cDNA encoding a TGF- α polypeptide or functional fragment controlled by appropriate expression control elements (*e.g.*,

promoter, enhancer, sequences, transcription terminators, polyadenylation sites, etc.), and a selectable marker. The selectable marker in the recombinant vector confers resistance to the selection and allows cells to stably integrate the plasmid into their chromosomes and grow to form foci which in turn can be cloned and expanded into cell lines. For example, following the introduction of foreign DNA, engineered cells may be allowed to grow for 1-2 days in an enriched media, and then are switched to a selective media. A number of selection systems may be used, including, but not limited to, the herpes simplex virus thymidine kinase (Wigler, *et al.*, Cell, 11:223, 1977), hypoxanthine-guanine phosphoribosyltransferase (Szybalska & Szybalski, Proc. Natl. Acad. Sci. USA, 48:2026, 1962), and adenine phosphoribosyltransferase (Lowy, *et al.*, Cell, 22:817, 1980) genes can be employed in tk-, hgp^rt- or ap^rt- cells respectively. Also, anti-metabolite resistance can be used as the basis of selection for dhfr, which confers resistance to methotrexate (Wigler, *et al.*, Proc. Natl. Acad. Sci. USA, 77:3567, 1980; O'Hare, *et al.*, Proc. Natl. Acad. Sci. USA, 8:1527, 1981); gpt, which confers resistance to mycophenolic acid (Mulligan & Berg, Proc. Natl. Acad. Sci. USA, 78:2072, 1981); neo, which confers resistance to the aminoglycoside G-418 (Colberre-Garapin, *et al.*, J. Mol. Biol. 150:1, 1981); and hyg^ro, which confers resistance to hygromycin (Santerre, *et al.*, Gene 30:147, 1984) genes. Recently, additional selectable genes have been described, namely trpB, which allows cells to utilize indole in place of tryptophan; hisD, which allows cells to utilize histinol in place of histidine (Hartman & Mulligan, Proc. Natl. Acad. Sci. USA 85:8047, 1988); and ODC (ornithine decarboxylase) which confers resistance to the ornithine decarboxylase inhibitor, 2-(difluoromethyl)-DL-ornithine, DFMO (McConlogue L., In: Current Communications in Molecular Biology, Cold Spring Harbor Laboratory, ed., 1987).

The term "primer" as used herein refers to an oligonucleotide, whether natural or synthetic, which is capable of acting as a point of initiation of synthesis when placed under conditions in which primer extension is initiated or possible. Synthesis of a primer extension product which is complementary to a nucleic acid strand is initiated in the presence of nucleoside triphosphates and a polymerase in an appropriate buffer at a suitable temperature.

Proteins and Polypeptides

A polypeptide or protein refers to a polymer in which the monomers are amino acid residues which are joined together through amide bonds. When the amino acids are alpha-amino acids, either the L-optical isomer or the D-optical isomer can be used, the L-isomers being typical. A TGF- α polypeptide or TGF- α related polypeptide is intended to encompass an amino acid sequence, including modified sequences such as glycoproteins, which exhibit TGF- α activity. The polypeptides of the invention encompass amino acid sequences of human TGF- α as shown in SEQ ID NO:1 as well as polypeptides that have structural and/or functional characteristics of TGF- α . For example, a polypeptide or a TGF- α related polypeptide of the invention may include a polypeptide that shares a cysteine disulfide bond structure similar to TGF- α such as a related family of proteins including vaccinia growth factor, amphiregulin precursor, betacellulin precursor, heparin binding EGF-like growth factor, epiregulin (rodent only), HUS 19878, myxomavirus growth factor (MGF), Shope fibroma virus growth factor (SFGF), and schwannoma derived growth factor. In addition, a polypeptide of the invention will have one or more functional characteristics related to TGF- α including, for example, the ability to interact with an EGF family receptor member, stimulate proliferation or migration of stem cells, or to treat or prevent cachexia.

The polypeptides of the invention are intended to cover naturally occurring proteins, as well as those which are recombinantly or synthetically synthesized. In addition, a TGF- α or related polypeptide can occur in at least two different conformations wherein both conformations have the same or substantially the same amino acid sequence but have different three dimensional structures so long as the have a biological activity related to TGF- α . Polypeptide or protein fragments of TGF- α are also encompassed by the invention such as those described by formulas I, II, and III (see below). Fragments can have the same or substantially the same amino acid sequence as the naturally occurring protein. A polypeptide or peptide having substantially the same sequence means that an amino acid sequence is largely, but not entirely, the same, but retains a functional activity of the sequence to which it is related. In general polypeptides of the present invention include peptides, or full length protein, that contains

substitutions, deletions, or insertions into the protein backbone, that would still have an approximately 50%-70% homology to the original protein over the corresponding portion. A yet greater degree of departure from homology is allowed if like-amino acids, *i.e.* conservative amino acid substitutions, do not count as a change in the sequence.

- 5 Polypeptide fragments of the invention retain a biological activity associated with TGF- α as described above.

Homology to TGF- α polypeptide can be measured using standard sequence analysis software (*e.g.*, Sequence Analysis Software Package of the Genetics Computer Group, University of Wisconsin Biotechnology Center, 1710 University
10 Avenue, Madison, WI 53705; also see Ausubel, *et al.*, *supra*). Such procedures and algorithms include, for example, a BLAST program (Basic Local Alignment Search Tool at the National Center for Biological Information), ALIGN, AMAS (Analysis of Multiply Aligned Sequences), AMPS (Protein Multiple Sequence Alignment), ASSET (Aligned Segment Statistical Evaluation Tool), BANDS, BESTSCOR,
15 BIOSCAN (Biological Sequence Comparative Analysis Node), BLIMPS (BLOCKS IMPROVED SEARCHER), FASTA, INTERVALS & POINTS, BMB, CLUSTAL V, CLUSTAL W, CONSENSUS, LCONSENSUS, WCONSENSUS, Smith-Waterman algorithm, DARWIN, Las Vegas algorithm, FNAT (Forced Nucleotide Alignment Tool), Framealign, Framesearch, DYNAMIC, FILTER, FSAP (Fristensky Sequence
20 Analysis Package), GAP (Global Alignment Program), GENAL, GIBBS, GenQuest, ISSC (Sensitive Sequence Comparison), LALIGN (Local Sequence Alignment), LCP (Local Content Program), MACAW (Multiple Alignment Construction & Analysis Workbench), MAP (Multiple Alignment Program), MBLKP, MBLKN, PIMA (Pattern-Induced Multi-sequence Alignment), SAGA (Sequence Alignment by
25 Genetic Algorithm) and WHAT-IF.

A polypeptide may be substantially related but for a conservative variation, such polypeptides being encompassed by the invention. A conservative variation denotes the replacement of an amino acid residue by another, biologically similar residue. Examples
30 of conservative variations include the substitution of one hydrophobic residue such as isoleucine, valine, leucine or methionine for another, or the substitution of one polar

residue for another, such as the substitution of arginine for lysine, glutamic for aspartic acids, or glutamine for asparagine, and the like. Other illustrative examples of conservative substitutions include the changes of: alanine to serine; arginine to lysine; asparagine to glutamine or histidine; aspartate to glutamate; cysteine to serine; glutamine
5 to asparagine; glutamate to aspartate; glycine to proline; histidine to asparagine or glutamine; isoleucine to leucine or valine; leucine to valine or isoleucine; lysine to arginine, glutamine, or glutamate; methionine to leucine or isoleucine; phenylalanine to tyrosine, leucine or methionine; serine to threonine; threonine to serine; tryptophan to tyrosine; tyrosine to tryptophan or phenylalanine; valine to isoleucine to leucine. The
10 term "conservative variation" also includes the use of a substituted amino acid in place of an unsubstituted parent amino acid provided that antibodies raised to the substituted polypeptide also immunoreact with the unsubstituted polypeptide.

Modifications and substitutions are not limited to replacement of amino acids.
15 For a variety of purposes, such as increased stability, solubility, or configuration concerns, one skilled in the art will recognize the need to introduce, (by deletion, replacement, or addition) other modifications. Examples of such other modifications include incorporation of rare amino acids, dextra-amino acids, glycosylation sites, cytosine for specific disulfide bridge formation. The modified peptides can be
20 chemically synthesized, or the isolated gene can be site-directed mutagenized, or a synthetic gene can be synthesized and expressed in bacteria, yeast, baculovirus, tissue culture and so on.

Solid-phase chemical peptide synthesis methods can also be used to synthesize the polypeptide or fragments of the invention. Such method have been known in the art
25 since the early 1960's (Merrifield, R. B., *J. Am. Chem. Soc.*, 85, 2149-2154 (1963) (See also Stewart, J. M. and Young, J. D., *Solid Phase Peptide Synthesis*, 2 ed., Pierce Chemical Co., Rockford, Ill., pp. 11-12)) and have recently been employed in commercially available laboratory peptide design and synthesis kits (Cambridge Research Biochemicals). Such commercially available laboratory kits have generally
30 utilized the teachings of H. M. Geysen *et al*, *Proc. Natl. Acad. Sci., USA*, 81, 3998 (1984) and provide for synthesizing peptides upon the tips of a multitude of "rods" or

“pins” all of which are connected to a single plate. When such a system is utilized, a plate of rods or pins is inverted and inserted into a second plate of corresponding wells or reservoirs, which contain solutions for attaching or anchoring an appropriate amino acid to the pin's or rod's tips. By repeating such a process step, *i.e.*, inverting and inserting the rod's and pin's tips into appropriate solutions, amino acids are built into desired peptides. In addition, a number of available Fmoc peptide synthesis systems are available. For example, assembly of a polypeptide or fragment can be carried out on a solid support using an Applied Biosystems, Inc. Model 431A automated peptide synthesizer. For example, if the peptide is from formula I or formula II (see below), a preferred means for synthesizing peptides of 10-18 amino acids in length is by direct peptide synthesis generally starting with the N-terminal amino acid and adding amino acids in the C terminal direction. TGF α has been made using recombinant techniques and is available as a laboratory reagent commercially. The bifunctional compounds of formula III are best synthesized with each loop peptide moiety synthesized and then added to the heterocyclic nitrogen atom using standard heterocyclic addition synthesis.

TGF- α Peptide Mimics

The functional peptides of the invention are based upon the discovery that a loop peptide of TGF- α exhibits TGF- α biological activity and can therefore stimulate CNS multipotent precursor cells to divide and migrate through the brain. This activity indicates that the loop peptide is effective to treat neurological deficits caused by a wide variety of diseases and injuries that each result in a neurological deficit in some specific area of the brain or specific kind of neuron. These include degenerative diseases, including the more common Alzheimer's Disease (AD), Parkinson's Disease (PD), and Huntington's Disease (HD), and the less common Pick's disease, progressive supranuclear palsy, striatonigral degeneration, cortico-basal degeneration, olivopontocerebellar atrophy, Leigh's disease, infantile necrotizing encephalomyelopathy, Hunter's disease, mucopolysaccharidosis, various leukodystrophies (such as Krabbe's disease, Pelizaeus-Merzbacher disease and the like), amaurotic (familial) idiocy, Kuf's disease, Spielmayer-Vogt disease, Tay Sachs disease, Batten disease, Jansky-Bielschowsky disease, Reye's disease, cerebral ataxia,

chronic alcoholism, beriberi, Hallervorden-Spatz syndrome, cerebellar degeneration, and the like.


Further, injuries (traumatic or neurotoxic) that cause a loss of neuronal
5 function can be treated by the functional peptides. Such injuries include, for example, gunshot wounds, injuries caused by blunt force, penetration injuries, injuries caused by surgical procedure (*e.g.*, tumor removal, abscess removal, epilepsy lesion removal) poisoning (*e.g.*, carbon monoxide), shaken baby syndrome, adverse reactions to medications, drug overdoses, and post-traumatic encephalopathy. Ischemia can
10 further cause CNS injury due to disruption of blood flow or oxygen delivery that can kill or injure neurons and glial cells (*e.g.*, TGF- α confers protection from ischemia in a porcine gastrointestinal model and a family member, Heparin-binding EGF, confers protection from ischemia in a rat stroke model). Such injuries can be treated by administration of the functional peptides and include, for example, injuries caused by
15 stroke, anoxia, hypoxia, partial drowning, myoclonus, severe smoke inhalation, dystonias, and acquired hydrocephalus. Developmental disorders that can be treated by the functional peptides include, for example, schizophrenia, certain forms of severe mental retardation, cerebral palsy, congenital hydrocephalus, severe autism, Downs Syndrome, LHRH/hypothalamic disorder, and spina bifida. The functional peptides
20 can be further used to treat disorders affecting vision caused by the loss or failure of retinal cells and include, for example, diabetic retinopathy, serious retinal detachment (associated with glaucoma), traumatic injury to the retina, retinal vascular occlusion, macular degeneration, optic nerve atrophy and other retinal degenerative diseases. Injuries to the spinal cord can be treated by the functional peptides. Examples of
25 spinal cord injuries are post-polio syndrome, amyotrophic lateral sclerosis, traumatic injury, surgical injury, and paralytic diseases. Demyelinating autoimmune disorders can be treated by administration of the functional peptides and include, for example, multiple sclerosis. Lastly, the functional peptides can be used to treat neurological deficits caused by infection of inflammatory diseases, including, for example,
30 Creutzfeldt-Jacob disease and other slow virus infectious diseases of the CNS, AIDS encephalopathy, post-encephalitic Parkinsonism, viral encephalitis, bacterial meningitis and other CNS effects of infectious diseases.

By “functional” as used in connection with the peptides or peptide fragments of the invention is meant that the peptides or fragments have TGF α activity. This biological activity is associated with the peptides of formula I, formula II and formula
5 III and the data available for TGF α .

Generally, the terms “treating”, “treatment” and the like are used herein to mean affecting a subject, tissue or cell to obtain a desired pharmacologic and/or physiologic effect. The effect may be prophylactic in terms of completely or partially preventing a disease or disorder or sign or symptom thereof, and/or may be therapeutic in terms of a
10 partial or complete cure for a disorder or disease and/or adverse effect attributable to the disorder or disease. “Treating” as used herein covers any treatment of, or prevention of, or inhibition of a disorder or disease in a subject. The subject can be an invertebrate, a vertebrate, a mammal, and particularly a human, and includes by way of example: (a) preventing the disease or disorder from occurring in a subject that may be predisposed to
15 the disease or disorder, but has not yet been diagnosed as having it; (b) inhibiting the disease or disorder, *i.e.*, arresting its progression; or (c) relieving or ameliorating the disease or disorder, *i.e.*, causing regression.

The invention also provides methods of modulating weight-loss associated with disease and disorders of the gastrointestinal tract, for example, those associated
20 with viral infections and chemotherapy by administering TGF- α or related polypeptides or fragments thereof which retain TGF- α biological activity (*e.g.*, SEQ ID NO:1, 2, or 3, and the peptides of formula I, II, or III).

The invention provides a peptide having TGF α biological activity, comprising
25 at least an 11-membered peptide compound of formula I (SEQ ID NO:4):



wherein X₁ is independently Val, Gly or Ala, wherein X₂ is Tyr or Phe, wherein X₃ is
30 Arg or Lys, and wherein the two Cys moieties form a disulfide bond to create an 11-

amino acid functional peptide having a 10 member loop structure. In addition, at least one or more of the following amino acids of formula II (SEQ ID NO:5) may be added to the C terminus Cys moiety of formula I (SEQ ID NO:4):

$$5 \quad -X_4 - \text{His} - X_{1c} - X_4 - X_5 - X_6 - X_{1c} \quad (\text{II})$$

wherein X₄ is Glu or Asp, wherein X₅ is Leu or Ile, and wherein X₆ is Asp or Glu. Preferably, X_{1a} is Val, X_{1b} is Gly and X_{1c} is Ala thereby producing an 11, 12, 13, 14, 15, 16, 17 or 18 amino acid peptide. Preferably, X₂ is Tyr, and X₃ is Arg.


10 Accordingly, in one embodiment the functional peptide of the invention has a
sequence:

NH₂-X_{1a}-Cys-His-Ser-X_{1b}-X₂-X_{1a}-X_{1b}-X_{1a}-X₃-Cys-X₄-His-X_{1c}-X₄-X₅-X₆-X_{1c}-COOH
(SEQ ID NO:6)


SEQ ID NO:6 forms a 10 member loop structure with a 7 member tail that can be varied in length. In addition, SEQ ID NO:6 can form dimers comprising, for example, a 34-mer peptide. Accordingly, the functional peptide can be from about 10 to 18 amino acids in length (*e.g.*, 10, 11, 12, 13, 14, 15, 16, 17, or 18 amino acids) wherein X_{1a} is Val, X_{1b} is Gly, X_{1c} is Ala and X₄ is Gly and may also comprise hetero- or homo-dimers of various TGF- α peptides described herein. Such dimers may have greater or reduced activities as compared to monomers.

The invention further provides a pharmaceutical composition comprising a peptide in a pharmaceutically acceptable carrier, wherein the peptide compound comprises at least about a 10 to 18-membered peptide compound of formula I (SEQ ID NO:4, including members of SEQ ID NO:5 attached to SEQ ID NO:4 and including SEQ ID NO:6). Preferably, at least one or more of the seven amino acids of formula II are added to the C terminus Cys moiety. Most preferably, the functional peptide is 18 amino acids in length wherein X_{1a} is Val, X_{1b} is Gly, X_{1c} is Ala and X₄ is Gly. The peptides described herein are all useful in the methods of the invention.

The invention further provides a method for treating a neurodegenerative disease with a pharmaceutically active TGF- α polypeptide, functional fragment peptide thereof or a pharmaceutically active TGF- α 57 polypeptide, wherein the peptide comprises at least an 11-membered peptide compound of formula I or a
 5 polypeptide of formula III, wherein formula I (SEQ ID NO:4) is:




wherein X_1 is independently Val, Gly or Ala, wherein X_2 is Try or Phe, wherein X_3 is
 10 Arg or Lys, and wherein the two Cys moieties form a disulfide bond to create an 11-amino acid functional peptide; and wherein formula III is:



15 wherein the linker moiety is designed to link the N-terminus of the Loop peptide to a nitrogen atom of the ring $\text{C}_4\text{H}_8\text{N}_2$ and wherein the "loop peptide" comprises at least an 11-membered peptide compound of formula I (SEQ ID NO:4); wherein X_1 is independently Val, Gly or Ala, wherein X_2 is Try or Phe, wherein X_3 is Arg or Lys,
 20 and wherein the two Cys moieties form a disulfide bond to create an 11-amino acid functional peptide having TGF- α activity. Furthermore, the functional peptides of the invention, as described above (*e.g.*, SEQ ID Nos: 4, 5, and 6), having from about 10 to 18 amino acids in length (*e.g.*, 10, 11, 12, 13, 14, 15, 16, 17, or 18 amino acids) wherein X_{1a} is Val, X_{1b} is Gly, X_{1c} is Ala and X_4 is Gly and hetero- or homo-dimers
 25 of the various TGF- α peptides described herein can be used in the methods of the invention.


The invention further provides a method for treating a neurodegenerative disease with an pharmaceutically active TGF- α 57 polypeptide (SEQ ID NO:3),
 30 wherein TGF- α 57 is a 57 amino acid polypeptide having the formula IV:




wherein human TGF α is a 50 amino acid polypeptide having a sequence as set forth in SEQ ID NO:1.

5 The invention further provides a method for treating a CNS disease or disorder, wherein the CNS disease or disorder includes CNS ischemia, spinal cord injury, MS, and retinal injury, with a pharmaceutically active TGF α peptide or a TGF α 57 polypeptide, wherein the peptide comprises at least an 11-membered peptide compound of formula I (SEQ ID NO:4):


10



wherein X₁ is independently Val, Gly or Ala, wherein X₂ is Try or Phe, wherein X₃ is Arg or Lys, and wherein the two Cys moieties form a disulfide bond to create an 11-
15 amino acid functional TGF- α peptide; and wherein TGF- α 57 is a 57 amino acid polypeptide having the formula IV:



20 wherein human TGF α is a 50 amino acid polypeptide having the formula of SEQ ID NO:1. Preferably, at least one or more of the following amino acids from formula II are added to the C terminus Cys moiety of formula I:




25

wherein X₄ is Glu or Asp, wherein X₅ is Leu or Ile, and wherein X₆ is Asp or Glu. Preferably, X_{1a} is Val, X_{1b} is Gly and X_{1c} is Ala. Preferably, X₂ is Tyr, and X₃ is Arg. Most preferably, the functional peptide is 18 amino acids in length wherein X_{1a} is Val,
30 X_{1b} is Gly, X_{1c} is Ala and X₄ is Gly. Furthermore, the functional peptides of the invention, as described above (*e.g.*, SEQ ID Nos: 4, 5, and 6), having from about 10


to 18 amino acids in length (*e.g.*, 10, 11, 12, 13, 14, 15, 16, 17, or 18 amino acids) wherein X_{1a} is Val, X_{1b} is Gly, X_{1c} is Ala and X_4 is Gly and hetero- or homo-dimers of the various TGF- α peptides described herein can be used in the methods for treating a CNS disease or disorder.

5

The invention further provides a method for enhancing hematopoiesis and myelopoiesis during cytotoxic or immune-suppressing therapy, comprising administering a TGF α polypeptide (SEQ ID NO:1), a TGF α 57 polypeptide (*i.e.*, formula IV), a functional TGF- α peptide thereof, or a combination thereof, wherein
10 the peptide comprises at least an 11-membered peptide compound of formula I (SEQ ID NO:4):



wherein X_1 is independently Val, Gly or Ala, wherein X_2 is Try or Phe, wherein X_3 is
15 Arg or Lys, and wherein the two Cys moieties form a disulfide bond to create an 11-amino acid functional TGF- α peptide. Preferably, at least one or more of the following amino acids of formula II are added to the C terminus Cys moiety of formula I:




wherein X_4 is Glu or Asp, wherein X_5 is Leu or Ile, and wherein X_6 is Asp or Glu. Preferably, X_{1a} is Val, X_{1b} is Gly and X_{1c} is Ala. Preferably, X_2 is Tyr, and X_3 is Arg.
25 Most preferably, the functional peptide is 18 amino acids in length wherein X_{1a} is Val, X_{1b} is Gly, X_{1c} is Ala and X_4 is Gly. Furthermore, the functional peptides of the invention, as described above (*e.g.*, SEQ ID Nos: 4, 5, and 6), having from about 10 to 18 amino acids in length (*e.g.*, 10, 11, 12, 13, 14, 15, 16, 17, or 18 amino acids) wherein X_{1a} is Val, X_{1b} is Gly, X_{1c} is Ala and X_4 is Gly and hetero- or homo-dimers
30 of the various TGF- α peptides described herein can be used in the methods for enhancing hematopoiesis or myelopoiesis. Preferably, the invention further comprises administering a second hematopoietic growth factor agent to stimulate

more mature hematopoietic precursor cells, wherein the second hematopoietic growth factor includes erythropoietin, thrombopoietin, G-CSF (granulocyte colony stimulating factor), and GM-CSF (granulocyte macrophage colony stimulating factor).

5


The invention further provides a method for treating or preventing mucositis of the gastrointestinal tract caused by cytotoxic or immune-suppressing therapy, comprising administering a TGF- α polypeptide (SEQ ID NO:1), a TGF- α 57 polypeptide (*i.e.*, formula IV), a functional TGF- α peptide thereof, or combinations thereof, wherein the peptide comprises at least an 11-membered peptide compound of formula I (SEQ ID NO:4):

10



wherein X_{1a} and X_{1b} are independently Val, Gly or Ala; X_2 is Tyr or Phe; X_3 is Arg or Lys; and the two Cys moieties are linked via a disulfide bond to form an at least 11-amino acid functional peptide having TGF- α activity. Preferably, at least one or more of the following amino acids are added to the C terminus Cys moiety from formula II:

20



(II)

wherein X_4 is Glu or Asp, wherein X_5 is Leu or Ile, and wherein X_6 is Asp or Glu.

Preferably, X_{1a} is Val, X_{1b} is Gly and X_{1c} is Ala. Preferably, X_2 is Tyr, and X_3 is Arg.

Most preferably, the functional peptide is 18 amino acids in length wherein X_{1a} is Val, X_{1b} is Gly, X_{1c} is Ala and X_4 is Gly. Furthermore, the functional peptides of the invention, as described above (*e.g.*, SEQ ID Nos: 4, 5, and 6), having from about 10 to 18 amino acids in length (*e.g.*, 10, 11, 12, 13, 14, 15, 16, 17, or 18 amino acids) wherein X_{1a} is Val, X_{1b} is Gly, X_{1c} is Ala and X_4 is Gly and hetero- or homo-dimers of the various TGF- α peptides described herein can be used in the methods for treating or preventing mucositis.

30

The invention further provides a bifunctional compound that acts as a TGF α mimetic, comprising a compound of formula III:

Loop peptide N-terminus -linker- cyclic C₄H₈N₂ -linker- Loop peptide N-terminus
 5 (III)

wherein the linker moiety is designed to link the N-terminus of the Loop peptide to a nitrogen atom of the ring C₄H₈N₂ and wherein the "loop peptide" comprises at least an 11-membered peptide compound of formula I:

10 NH₂- X_{1a} - Cys - His - Ser - X_{1b} - X₂ - X_{1a} - X_{1b} - X_{1a} - X₃ - Cys COOH (I)


wherein X_{1a} and X_{1b} are independently Val, Gly or Ala; X₂ is Tyr or Phe; X₃ is Arg or Lys; and the two Cys moieties are linked via a disulfide bond to form an at least 11-
 15 amino acid functional peptide having TGF- α activity. Preferably, at least one or more of the following amino acids are added to the C terminus Cys moiety from formula II:

- X₄ - His - X_{1c} - X₄ - X₅ - X₆ - X_{1c}
 (II)

20 wherein X₄ is Glu or Asp, wherein X₅ is Leu or Ile, and wherein X₆ is Asp or Glu. Preferably, X_{1a} is Val, X_{1b} is Gly and X_{1c} is Ala. Preferably, the linker group is independently selected from the group consisting of substituted or unsubstituted C₁₋₆ alkyl, substituted or unsubstituted C₂₋₆ alkenyl, substituted or unsubstituted C₁₋₆
 25 alkoxy, xylenyl, wherein the substitutions are selected from the group consisting of oxo, epoxyl, hydroxyl, chloryl, bromyl, fluoryl, and amino. Preferably, X₂ is Tyr, and X₃ is Arg. Most preferably, the functional peptide is 18 amino acids in length wherein X_{1a} is Val, X_{1b} is Gly, X_{1c} is Ala and X₄ is Gly.

30 The invention further provides a method for treating inflammatory bowel disease, colitis, and Chron's Disease of the gastrointestinal tract, comprising administering a TGF- α polypeptide (SEQ ID NO:1), a TGF- α 57 polypeptide (formula


IV), a functional TGF- α peptide thereof, or combinations thereof, wherein the peptide comprises at least an 11-membered peptide compound of formula I:



5

wherein X_1 is independently Val, Gly or Ala, wherein X_2 is Try or Phe, wherein X_3 is Arg or Lys, and wherein the two Cys moieties form a disulfide bond to create an 11-amino acid functional TGF- α peptide. Preferably, at least one or more of the following amino acids are added to the C terminus Cys moiety from formula II:

10




wherein X_4 is Glu or Asp, wherein X_5 is Leu or Ile, and wherein X_6 is Asp or Glu.

Preferably, X_{1a} is Val, X_{1b} is Gly and X_{1c} is Ala. Preferably, X_2 is Tyr, and X_3 is Arg.

15 Most preferably, the functional peptide is 18 amino acids in length wherein X_{1a} is Val, X_{1b} is Gly, X_{1c} is Ala and X_4 is Gly. Furthermore, the functional peptides of the invention, as described above (*e.g.*, SEQ ID Nos: 4, 5, and 6), having from about 10 to 18 amino acids in length (*e.g.*, 10, 11, 12, 13, 14, 15, 16, 17, or 18 amino acids) wherein X_{1a} is Val, X_{1b} is Gly, X_{1c} is Ala and X_4 is Gly and hetero- or homo-dimers
20 of the various TGF- α peptides described herein can be used in the methods for treating a inflammatory bowel disease, colitis, Chron's Disease and the like.


The invention further provides a method for treating an inflammatory reaction or autoimmune diseases resulting in weight-loss, comprising administering a TGF α polypeptide (SEQ ID NO:1), a TGF α 57 polypeptide (formula IV), a functional TGF- α peptide thereof, or combinations thereof, wherein the peptide comprises at least an 11-membered peptide compound of formula I:



30

wherein X_1 is independently Val, Gly or Ala, wherein X_2 is Try or Phe, wherein X_3 is Arg or Lys, and wherein the two Cys moieties form a disulfide bond to create an 11-

amino acid functional TGF- α peptide. Preferably, at least one or more of the following amino acids are added to the C terminus Cys moiety from formula II (SEQ ID NO:5):



wherein X₄ is Glu or Asp, wherein X₅ is Leu or Ile, and wherein X₆ is Asp or Glu. Preferably, X_{1a} is Val, X_{1b} is Gly and X_{1c} is Ala. Preferably, X₂ is Tyr, and X₃ is Arg. Most preferably, the functional peptide is 18 amino acids in length wherein X_{1a} is Val, X_{1b} is Gly, X_{1c} is Ala and X₄ is Gly. Furthermore, the functional peptides of the invention, as described above (*e.g.*, SEQ ID Nos: 4, 5, and 6), having from about 10 to 18 amino acids in length (*e.g.*, 10, 11, 12, 13, 14, 15, 16, 17, or 18 amino acids) wherein X_{1a} is Val, X_{1b} is Gly, X_{1c} is Ala and X₄ is Gly and hetero- or homo-dimers of the various TGF- α peptides described herein can be used in the methods for treating an autoimmune disease or inflammatory disorder. Preferably, the autoimmune diseases includes Type II (Juvenile) Diabetes, rheumatoid arthritis, lupus, HIV-associated disorders (*e.g.*, AIDS) and multiple sclerosis.

Gene Therapy and Gene Delivery

The TGF- α polypeptides (e.g., SEQ ID NO:1), TGF- α 57 polypeptide, and functional TGF- α peptides thereof are particularly suited for delivery to a subject by means of a nucleic acid gene expression system *ex vivo* or *in vivo*. A variety of transfection techniques are currently available and used to transfer DNA *in vitro* into cells; including calcium phosphate-DNA precipitation, DEAE-Dextran transfection, electroporation, liposome mediated DNA transfer or transduction with recombinant viral vectors. Such *ex vivo* treatment protocols have been used to transfer DNA into a variety of different cell types including epithelial cells (U.S. Pat. No. 4,868,116; Morgan and Mulligan WO87/00201; Morgan *et al.*, 1987, *Science* 237:1476-1479; Morgan and Mulligan, U.S. Pat. No. 4,980,286), endothelial cells (WO89/05345), hepatocytes (WO89/07136; Wolff *et al.*, 1987, *Proc. Natl. Acad. Sci. USA* 84:3344-3348; Ledley *et al.*, 1987 *Proc. Natl. Acad. Sci.* 84:5335-5339; Wilson and Mulligan,

WO89/07136; Wilson *et al.*, 1990, *Proc. Natl. Acad. Sci.* 87:8437-8441) fibroblasts (Palmer *et al.*, 1987, *Proc. Natl. Acad. Sci. USA* 84:1055-1059; Anson *et al.*, 1987, *Mol. Biol. Med.* 4:11-20; Rosenberg *et al.*, 1988, *Science* 242:1575-1578; Naughton & Naughton, U.S. Pat. No. 4,963,489), lymphocytes (Anderson *et al.*, U.S. Pat. No. 5,399,346; Blaese, R. M. *et al.*, 1995, *Science* 270:475-480) and hematopoietic stem cells (Lim, B. *et al.* 1989, *Proc. Natl. Acad. Sci. USA* 86:8892-8896; Anderson *et al.*, U.S. Pat. No. 5,399,346). A summary of typical protocols, methodology, and vectors is provided in "The Development of Human Gene Therapy," Ed. Theodore Friedmann, Cold Spring Harbor Laboratory Press, New York, 1999, the disclosure of which is incorporated herein.

Direct *in vivo* gene transfer has recently been attempted with formulations of DNA trapped in liposomes (Ledley *et al.*, 1987, *J. Pediatrics* 110:1); or in proteoliposomes that contain viral envelope receptor proteins (Nicolau *et al.*, 1983, *Proc. Natl. Acad. Sci. U.S.A.* 80:1068); and DNA coupled to a polylysine-glycoprotein carrier complex. In addition, "gene guns" have been used for gene delivery into cells (Australian Patent No. 9068389). Naked DNA, or DNA associated with liposomes, can be formulated in liquid carrier solutions for injection into interstitial spaces for transfer of DNA into cells (Felgner, WO90/11092).

As described above, polynucleotide sequences encoding a TGF- α polypeptide or function peptide fragment, can be cloned into vectors suitable for delivery to host cells for expression. In particular retroviral vectors containing the polypeptides of the invention are particularly suitable for delivering polynucleotides to cells for gene therapy. Current strategies for gene therapy are reviewed in "The Development of Human Gene Therapy," Ed. Theodore Friedmann, Cold Spring Harbor Laboratory Press, New York, 1999, the disclosure of which is incorporated herein.

Delivery of a polynucleotide of interest may be accomplished *in vivo* by administration of the vectors to an individual subject, typically by systemic administration (*e.g.*, intravenous, intraperitoneal, intramuscular, subdermal, or intracranial infusion). Alternatively, the vectors may be used to deliver polynucleotides to cells *ex vivo* such as cells explanted from an individual patient

(e.g., tumor-infiltrating lymphocytes, bone marrow aspirates, tissue biopsy) or universal donor hematopoietic stem cells, followed by reimplantation of the cells into a patient, usually after selection for cells which have incorporated the polynucleotide.

5 The vectors may be used for gene therapy to reduce the incidence of weight-loss and associated disorders resulting from particular diseases (e.g., cancer), or viral diseases (e.g., AIDS, mononucleosis, herpesvirus infection, cytomegalovirus infection, papillomavirus infection) or to modify the genome of selected types of cells of a patient for any therapeutic benefit.

10 The vectors of the invention can be used to introduce polynucleotides into a variety of cells and tissues including myeloid cells, bone marrow cells, lymphocytes, hepatocytes, fibroblasts, lung cells, epithelial cells and muscle cells. For example, polynucleotides encoding a TGF- α polypeptide may be transferred to stem cells.

Pharmaceutical Composition and Formulations

15 The invention includes various pharmaceutical compositions useful for delivery or administration of the peptides of the invention. In one embodiment the pharmaceutical composition are useful in treating or preventing weight-loss associated with a disorder or disease. Such disorders or diseases include weight-loss attributable to, for example, chemotherapy or a viral infection (e.g., HIV). The pharmaceutical compositions according to the invention are prepared by bringing a polypeptide or
20 peptide derivative of TGF- α , a TGF- α mimetic into a form suitable for administration to a subject using carriers, excipients and additives or auxiliaries. Frequently used carriers or auxiliaries include magnesium carbonate, titanium dioxide, lactose, mannitol and other sugars, talc, milk protein, gelatin, starch, vitamins, cellulose and its derivatives, animal and vegetable oils, polyethylene glycols and solvents, such as sterile water,
25 alcohols, glycerol and polyhydric alcohols. Intravenous vehicles include fluid and nutrient replenishers. Preservatives include antimicrobial, anti-oxidants, chelating agents and inert gases. Other pharmaceutically acceptable carriers include aqueous solutions, non-toxic excipients, including salts, preservatives, buffers and the like, as described, for instance, in Remington's Pharmaceutical Sciences, 15th ed. Easton: Mack Publishing
30 Co., 1405-1412, 1461-1487 (1975) and The National Formulary XIV., 14th ed.

Washington: American Pharmaceutical Association (1975), the contents of which are hereby incorporated by reference. The pH and exact concentration of the various components of the pharmaceutical composition are adjusted according to routine skills in the art. See Goodman and Gilman's The Pharmacological Basis for Therapeutics (7th ed.).

The pharmaceutical compositions are preferably prepared and administered in dose units. Solid dose units are tablets, capsules and suppositories and including, for example, alginate based pH dependent release gel caps. For treatment of a subject, depending on activity of the compound, manner of administration, nature and severity of the disorder, age and body weight of the subject, different daily doses are necessary. Under certain circumstances, however, higher or lower daily doses may be appropriate. The administration of the daily dose can be carried out both by single administration in the form of an individual dose unit or by several smaller dose units and also by multiple administration of subdivided doses at specific intervals.

The pharmaceutical compositions according to the invention may be administered locally or systemically in a therapeutically effective dose. Amounts effective for this use will, of course, depend on the severity of the disease and the weight and general state of the subject. Typically, dosages used *in vitro* may provide useful guidance in the amounts useful for *in situ* administration of the pharmaceutical composition, and animal models may be used to determine effective dosages for treatment of particular disorders. Various considerations are described, *e.g.*, in Langer, Science, 249: 1527, (1990); Gilman *et al.* (eds.) (1990), each of which is herein incorporated by reference.

In one embodiment, the invention provides a pharmaceutical composition useful for administering a TGF- α polypeptide or functional fragment, or a nucleic acid encoding a TGF- α polypeptide or functional fragment, to a subject in need of such treatment. "Administering" the pharmaceutical composition of the invention may be accomplished by any means known to the skilled artisan. Preferably a "subject" refers to a mammal, most preferably a human.

The TGF- α polypeptide or functional fragment can be administered parenterally, enterically, by injection, rapid infusion, nasopharyngeal absorption, dermal absorption, rectally and orally. Pharmaceutically acceptable carrier preparations for parenteral administration include sterile or aqueous or non-aqueous solutions, suspensions, and emulsions. Examples of non-aqueous solvents are propylene glycol, polyethylene glycol, vegetable oils such as olive oil, and injectable organic esters such as ethyl oleate. Carriers for occlusive dressings can be used to increase skin permeability and enhance antigen absorption. Liquid dosage forms for oral administration may generally comprise a liposome solution containing the liquid dosage form. Suitable solid or liquid pharmaceutical preparation forms are, for example, granules, powders, tablets, coated tablets, (micro)capsules, suppositories, syrups, emulsions, suspensions, creams, aerosols, drops or injectable solution in ampule form and also preparations with protracted release of active compounds, in whose preparation excipients and additives and/or auxiliaries such as disintegrants, binders, coating agents, swelling agents, lubricants, flavorings, sweeteners and elixirs containing inert diluents commonly used in the art, such as purified water. Where the disease or disorder is a gastrointestinal disorder oral formulations or suppository formulations are preferred.

Sterile injectable solutions can be prepared by incorporating the active agent (see formula I, formula II, or formula III and TGF α) in the required amount (*e.g.*, about 10 μ g to about 10 mg/kg) in an appropriate solvent and then sterilizing, such as by sterile filtration. Further, powders can be prepared by standard techniques such as freeze drying or vacuum drying.

In another embodiment, the active agent is prepared with a biodegradable carrier for sustained release characteristics for either sustained release in the GI tract or for target organ implantation with long term active agent release characteristics to the intended site of activity. Biodegradable polymers include, for example, ethylene vinyl acetate, polyanhydrides, polyglycolic acids, polylactic acids, collagen, polyorthoesters, and poly acetic acid. Liposomal formulation can also be used.

30

The invention will now be described in greater detail by reference to the following non-limiting examples.

EXAMPLE 1

5 Each of the three loop regions in human TGF α was investigated for TGF α -like biological activity, such as stimulation of cellular proliferation as measured by ^3H thymidine incorporation of stem cells. As shown in Figure 2, only the Loop C peptide (corresponding to amino acids 33-50) showed significant TGF- α biological activity as compared to data obtained with TGF- α 50 amino acid polypeptide or even the altered
10 splice 57 amino acid polypeptide and is therefore a TGF- α mimetic peptide. Accordingly, data from TGF α or TGF- α 57 show what can be called "TGF- α activity" and that these are predictive of activity of the functional TGF- α peptide and similar functional TGF- α peptides embodied in the genus of formula I with or without the addition of a "tail" region of formula II. These data predict activity for the functional
15 TGF- α peptides when activity is also shown for TGF- α or for TGF- α 57.

EXAMPLE 2

Hematopoiesis

TGF- α and related polypeptides, such as TGF- α 57, showed surprising
20 enhancing activity in an *in vivo* model of general hematopoiesis when administered in conjunction with a potent cytotoxic agent Cis Platinum (CP). Figure 3 shows a graph of mouse spleen weights that were treated with CP at either 5 $\mu\text{g/g}$ or 10 $\mu\text{g/g}$ and with TGF- α 57 at concentrations of 10 ng/g or 50 ng/g. These data show that TGF- α 57 treatment caused a return to normal spleen weights despite CP treatment that
25 reduced spleen weights significantly. This *in vivo* experiment is a predictive model for hematopoiesis in humans as CP is a cytotoxic agent commonly used for cancer chemotherapy that is known to significantly reduce trilineage hematopoietic cells. Hematopoietic and myeloid cells are red blood cell precursors, platelet precursors (megakaryocytes), and immune (white) blood cell precursors of various forms of T
30 cells, B cells and macrophages. Moreover, platelet counts were higher in those mice injected with TGF- α 57 (and CP) as opposed to CP alone were such counts were

significantly reduced from normal. It should be noted that references to TGF- α as a human 50 amino acid polypeptide further include reference to human TGF α 57 as an alternative variant.

5 The experiment procedure dosed those animals to be treated with TGF α 57 4 hours prior to challenge with CP. A single dose of CP was administered. Additional doses (as indicated) of TGF α 57 were made at 24 hours, 48 hours, 72 hours and 96 hours after the CP dose. All doses were made by IP injection. Controls were dosed with saline instead of either or both of CP and TGF- α 57.

10

 The animals were sacrificed about 4 hours after the last TGF- α 57 (or saline) dose. Key organs were removed and spleens were immediately weighed after a clean incision. All the relevant organs were placed in formalin, transported for histopathological analysis, mounted, sectioned, stained and observed. The results of this histological analysis of the spleens for hematopoietic effect and the GI tract (below) provided surprising and unexpected data of the effect of TGF- α 57 activity.

15

 H&E-stained spleens of a CP-treated mouse spleen (10 μ g/g) showed apoptotic cells (densely stained with fragments of nuclei) in the germinal center (GC). T cells in the central arterial area showed the absence of a marginal zone and much fewer erythrocytes and T cells in the perifollicular area. A normal mouse spleen (no CP and no TGF- α 57) fixed in formalin showed an arteriole enriched for T cell progenitors. There was erythrocytes in the perifollicular zone surrounding both the T cell and B cell compartments of white pulp. A mouse spleen treated with CP (10 μ g/g) and TGF- α 57 (50 ng/g) showed an increased number of T cells and erythrocytes in the perifollicular zone. The T cells stained for the T-cell receptor but were negative for CD4 and CD8 markers. Accordingly, the T-cells are double null T-cell progenitors induced by TGF- α administration.

20

25

 These *in vivo* data in a predictive model of hematopoiesis and confirmed by blinded histological analysis (the histologist/pathologist was blinded as to the treatment history of the coded tissues received) providing surprising evidence of the

30

utility of peptides having TGF- α activity to augment hematopoiesis and genesis of immune cells following cytotoxic exposure. These data predict and provide a reasonable correlation that TGF- α and the peptides of formula I, formula II and formula III are useful therapeutic agents for enhancing hematopoiesis following or during cytotoxic therapy, such as cancer treatment. Therefore, a useful method for improving cancer chemotherapy is to combine either TGF- α or a peptide from formula I, formula II, formula III, of formula IV or combinations thereof with cytotoxic treatment regimens to reduce dose-limiting side effects of cytotoxic agents.

10 An additional experiment investigated TGF- α activity (using TGF- α 57) on human bone-marrow enriched CD34 cells. FACS-sorted human CD34 positive and CD38 negative cells were cultured in liquid primary cultures in Iscove's modified Dulbecco's media with supplements. TGF α (57) was added alone (10 ng/ml) and exhibited a 35% increase in CD34 positive progenitor cells. Stem Cell Factor (SCF) was used as a positive control (500 ng/ml) and provided a three-fold increase in CD34 positive cells. When a combination of SCF (500 ng/ml) and TGF α (10 ng/ml) was added, a synergistic 12-fold increase in CD34 positive cells was observed. An unexpected result was the stimulation of the proliferation of dendritic precursor cells in the TGF- α treated cultures.

20

EXAMPLE 3

Mucositis and Gastrointestinal Diseases

The small intestine comprises the duodenum, jejunum and ileum. It is the principal site for absorption of digestive products from the GI tract. Digestion begins in the stomach and is completed in the small intestine in association with the absorptive process. The intestinal mucosa surface is made up of numerous finger-like projections called villi. In addition, mucosal epithelium between the basis of the villi is formed into the crypts which contain stem cells.

30 TGF α or a peptide from formula I, formula II, formula III, or formula IV having TGF α activity or combinations thereof are also useful for treating mucositis

associated intestinal bleeding, dyspepsia caused by with cytotoxic therapy and for improving the barrier function of the GI tract compromised by cytotoxic therapy. The *in vivo* experiment with seven groups of mice described above for hematopoietic effects noted in spleens also examined the GI tract of these treated mice. Histological examination of mouse intestines showed the following: CP (single ip dose of 10 µg/g) treated intestine, when cross-sectioned, showed significant injury to the villi. Specifically, the villi are necrotic, the crypts are in irregular shapes, and the tips of the crypts were exhibiting loss of cellular integrity. A cross section of a normal mouse GI tract (no CP and no TGFα57) showed a normal intestinal surface with villi having long and slender mucosal projections with a core of lamina propria covered by a luminal epithelial layer. A single row of intestinal crypt is found at the base of the mucosa. These crypts that lie between adjacent villi are surrounded by the same lamina propria that form the villous cores. Both columnar absorptive cells and goblet cells cover the villous surfaces. The goblet cells contain apical clear vacuoles. A cross section of a mouse intestine exposed to both the CP (10 µg/g) and TGFα57 (50 ng/g) showed that the intestinal structure was very similar to the normal intestinal structure. Specifically, the villus was long and slender. Both absorptive cells and goblet cells were visible at the surface of the villi, and there was an abundant amount of goblet cells on the surface.

A 160X magnification of the intestines of a CP-treated mouse, a normal mouse and a CP treated and TGFα57 treated mouse at the same doses as described above. The CP-treated mouse showed injured villi with degenerating and necrotic tips. Red blood cells were observed in the damaged villi. The crypts were irregularly shaped and in had various heights. The normal mouse showed smooth villi tips of the villi and nuclei of enterocytes were observed throughout the villus. The crypts were similar in height and had a regular shape. The CP treated and TGF-α treated mouse had normal appearing villi as described for the normal mouse. The crypts also appeared normal.

Further CP (10 µg/g) treated without TGF-α57 mice and CP (10 µg/g) and 50 ng/g of TGF-α57 treated mice intestines when examined under higher magnification showed severely injured crypt surfaces in the CP treated mice due to cell death and necrosis. Red cells were visible at the damaged surface indicating intestinal bleeding.

5 In addition, the CP-treated mouse showed a loss of brush borders and very little of a glycocalyx or fuzzy coat. Goblet cells appeared interspersed, necrotic and fewer in number than normal. The effect of TGF-α treatment showed protection of the villi surface. Specifically, the epithelial cells appeared normal with extended brush borders. The nuclei were very densely stained and elongated.

10

The histological data is summarized in Figure 4 that measured average crypt height of the three groups of mice. TGFα57 and TGF-α (50 a.a.) treatment (50 ng/g) was able to more-than-restore crypt height loss from CP treatment.

15 An alcian blue staining method permitted differentiation of absorptive cells and goblet cells. Goblet cell mucus is stained a blue color while the absorptive cells remain less stained. Stains of intestine from normal mice, CP only treated (10 µg/g) and both CP (10 µg/g) and TGFα57 (50 ng/g) treated mice showed significant differences. In the normal intestine each villus extended from the luminal surface to
20 the basal muscularis mucosal surface. Goblet cells were scattered and predominated in the base of the villus whereas columnar absorptive cells lined the luminal surface. In the CP treated mouse, the alcian blue staining showed villi that contained fewer number of goblet cells (than normal). The injured absorptive and goblet cells were degenerating at the tip of the villi and abundant secretory mucus material was stained
25 in the luminal surface. In the CP/TGF-α mouse, there were an increased number of goblet cells scattered throughout the villi. The intestinal villi appeared normal with elongation. The majority of enterocytes did not appear to be alcian blue stained positive. The luminal plasma membranes of the villi were well protected by TGF-α treatment. The number of goblet cells was counted on the average unit length of
30 intestine. TGFα treatment not only increased the number of goblet cells but also increased the number from CP treatment to a higher level than normal intestine.

Accordingly, these data show the effects of TGF α , and the functional peptides having TGF- α activity from formula I, formula II, formula III, and formula IV having therapeutic activity to treat or prevent mucositis associated with cytotoxic drug therapy and for inflammatory bowel diseases. Moreover, the histological effect showing that there was a prevention of mast cell degranulation, provides additional data supporting the gastrointestinal applications for TGF α , and the functional peptides having TGF- α activity of formula I, formula II, formula III, and formula IV.

EXAMPLE 4

10 **Immune Related Diseases**

In addition, TGF- α activity resulted in stimulation of proliferation of select immune cells (particularly of the T cell lineage) after administration to mice after immune-suppression of CP administration. The stimulated immune cells were phenotypically identified as CD4 positive T cells and double null CD4 negative CD8 negative T cell progenitors. Thus, TGF- α activity (*e.g.*, from TGF α 57 administration) resulted in generation of T-cells with characteristics that regulated immune functions. Therefore, these data predict that TGF α activity and the functional peptides of formula I, formula II, formula III, and formula IV will be effective in treating autoimmune diseases by mitigating over-inflammatory reactions. The *in vivo* activity of TGF α (and the functional peptides of formula I, formula II, formula III, and formula IV) to stimulate early T cell progenitors in the release of TH-1 and TH-2 cytokines and this regulation of immune phenomena. The stimulation of select immune cells, in particular cells of a T cell lineage, was seen consistently in the mice who received CP and TGF- α 57 in lymphoid tissue, Peyer's Patches and the spleen. Further, recruitment of help via CD4 cells in some cases boosts immune system function in general.

TGF- α administration prevented mast cell degranulation and subsequent histamine release. In addition TGF- α has effects in downregulating TNF- α receptors *in vivo* and downregulating IL-6 and MIP *in vivo*, including blockign

neutrophil trafficking. This is a parallel activity that is in addition to the gastrointestinal anti-inflammatory activity and prevention of mucositis of TGF α (and the functional peptides of formula I, formula II, formula III, and formula IV) described herein.

5

EXAMPLE 5

In order to determine the effects of TGF- α polypeptides on weight-loss four groups of rats were tested. The experiment was designed to compare two of the peptides of TGF- α (SEQ ID NO:1 and SEQ ID NO:3) on weight-loss in the presence of a chemotherapeutic drug, cisplatin.

10 All animals were dosed over a period of 5 days. Group 1 animals received cisplatin at 10 μ g/g, Group 2 animals received cisplatin at 10 μ g/g plus TGF- α (SEQ ID NO:1) at 50 ng/g; Group 3 animals received cisplatin at 10 μ g/g plus TGF- α 57 (SEQ ID NO:3) at 50 ng/g; and Group 4 animals received TGF- α (SEQ ID NO:1) at 50 ng/g. Following completion of the dosing protocols animals from each group were measure
15 and organs/tissues were harvested and placed in buffered formalin. The tissues measured included lungs, spleens, kidneys, pancreas, intestines and tongues.

In the 9 animals in group 1 (cisplatin treatment), the average weight loss was 18.3%; in the 13 animals in groups 2 and 3 (cisplatin+TGF) the average weight loss was 12.1%; and in the 6 animals in group 4 (TGF alone) the average weight loss was 0.9%
20 (Figure 5).

In addition, studies of TGF- α for the treatment of diarrhea in non-human primates was also performed. A 6-year old non-human primate exhibiting chronic inflammatory-like gastrointestinal symptoms was treated with TGF- α at 300 ng/g intraperitoneally once and subsequently 50 ng/g S.C. for 6 days. The primate showed a
25 steady increase in stool consistency and the monkey showed steady weight gain through the treatment period (see Table 1 and 2). This weight gain was maintained at least for several weeks post treatment. In addition, the reduction of SEGs (see column 6, Table 1) neutrophils correlates with reduction in inflammation associated with neutrophil influx

and concomitant pro-inflammatory cytokines. No adverse effects were noted in hematology or serum chemistries, or in the primates attitude, behavior or appetite.

TABLE I

Time	wt.	hemo- globin	pcv %	wbc	Seg	Bands	Lymph	Monos	Eos	Basos	Abn. Cells	Platelets	CD4 ⁺	CD8 ⁺	Dual CD8 ⁺ CD4 ⁺
1	5.80	12.6	40.3	16.6	76%	0%	19%	5%	0%	0%	0%	543	28.4%	56.3%	6.7%
2	6.33	11.1	38.0	20.2	69%	0%	20%	10%	1%	0%	0%	567			
3	6.74	9.2	32.1	10.3	61%	0%	34%	4%	1%	0%	0%	456	36.7%	53.1%	6.3%
4	8.21	10.3	34.2	8.4	48%	0%	42%	9%	1%	0%	0%	534	31.3%	54.0%	9.1%
5	8.93	10.8	37.1	11.2	46%	0%	45%	8%	0%	1%	0%	425	33.4%	49.8%	8.1%
6	9.42	11.5	38.1	15.5	56%	1%	31%	11%	1%	0%	0%	434	35.1%	50.3%	7.7%

TABLE 2

Time	Na ⁺	K ⁺	Cl ⁻	Glu	BUN	Creatine	Total Protein	Albumin	Albumin corrected	Total Bilirubin	Ca ²⁺	Alk Phos	ALT (GPT)	AST (GOT)	GGT
1	133	3.3	87	73	45	0.6	8.6	4.9	5.9	1.2	11.6	103	8	26	57
2	144	4.8	95	51	19	0.5	7.4	3.7	4.4						
3	146	4.6	107	68	16	0.5	7.2	2.9	3.5	0.3	9.8	116	17	45	89
4	150	4.4	107	50	19	0.7	7.1	2.9	3.5	0.3	9.7	130	25	34	91
5	148	4.0	108	25	18	0.6	6.6	2.5	3.0	0.2	9.1	107	19	37	64
6	145	3.8	108	21	22	0.5	7.0	2.5	3.0	0.3	9.3	113	15	34	58

Note: Blood glucose levels are generally well below the normal reference range. This is not an abnormality. Albumin results require a correction factor for non-human primates, which is calculated into the second "Albumin corrected" column.

While the invention has been described in detail with reference to certain preferred embodiments thereof, it will be understood that modifications and variations are within the spirit and scope of that which is described and claimed.

WHAT IS CLAIMED IS:

1. A polypeptide comprising a peptide having a sequence NH₂- X_{1a} - Cys
- His - Ser - X_{1b} - X₂ - X_{1a} - X_{1b} - X_{1a} - X₃ - Cys - COOH (SEQ ID
5 NO:4) wherein X_{1a} and X_{1b} are independently Val, Gly or Ala; X₂ is
Tyr or Phe; X₃ is Arg or Lys; and the two Cys moieties are linked via a
disulfide bond to form an at least 11-amino acid functional peptide
having TGF- α activity.
2. The polypeptide of claim 1, wherein at least one or more of the
10 following amino acids are linked to the C-terminal Cys moiety of SEQ
ID NO:4:
- X₄ - His - X_{1c} - X₄ - X₅ - X₆ - X_{1c} (SEQ ID NO:5) wherein X₄ is
Glu or Asp; X₅ is Leu or Ile; and X₆ is Asp or Glu.
3. The polypeptide of claim 2, wherein X_{1a} is Val, X_{1b} is Gly and X_{1c} is
15 Ala.
4. The polypeptide of claim 2, wherein X₂ is Tyr and X₃ is Arg.
5. The polypeptide of claim 2, wherein the functional peptide is 18 amino
20 acids in length and X_{1a} is Val, X_{1b} is Gly, X_{1c} is Ala and X₄ is Gly.
6. A method of treating a subject having or at risk of exhibiting weight-
loss comprising administering to the subject a transforming growth
25 factor-alpha (TGF- α) polypeptide in an effective amount to inhibit or
reduce weight-loss in the subject.
7. The method of claim 6, wherein the polypeptide has an amino acid
30 sequence as set forth in SEQ ID NO:1.

8. The method of claim 6, wherein the polypeptide has an amino acid sequence as set forth in SEQ ID NO:3.
- 5 9. The method of claim 6, wherein the polypeptide comprises a peptide having a sequence NH₂- X_{1a} - Cys - His - Ser - X_{1b} - X₂ - X_{1a} - X_{1b} - X_{1a} - X₃ - Cys COOH (SEQ ID NO:4) wherein X_{1a} and X_{1b} are independently Val, Gly or Ala; X₂ is Tyr or Phe; X₃ is Arg or Lys; and the two Cys moieties are linked via a disulfide bond to form an at least 11-amino acid functional peptide having TGF- α activity.
- 10 10. The method of claim 9, wherein at least one or more of the following amino acids are linked to the C-terminal Cys moiety of SEQ ID NO:4: - X₄ - His - X_{1c} - X₄ - X₅ - X₆ - X_{1c} (SEQ ID NO:5) wherein X₄ is Glu or Asp; X₅ is Leu or Ile; and X₆ is Asp or Glu.
- 15 11. The method of claim 10, wherein X_{1a} is Val, X_{1b} is Gly and X_{1c} is Ala.
12. The method of claim 10, wherein X₂ is Tyr and X₃ is Arg.
- 20 13. The method of claim 10, wherein the functional peptide is 18 amino acids in length and X_{1a} is Val, X_{1b} is Gly, X_{1c} is Ala and X₄ is Gly.
14. The method of claim 6, wherein the weight-loss is the result of a disease or disorder.
- 25 15. The method of claim 6, wherein the weight-loss is associated with treatment with of the subject with a chemotherapeutic agent.

16. The method of claim 15, wherein the chemotherapeutic agent is selected from the group consisting of carmustine (BCNU), chlorambucil (Leukeran), cisplatin (Platinol), Cytarabine, doxorubicin (Adriamycin), fluorouracil (5-FU), methoxetrate (Mexate), taxol, CPT111, etoposide, and plicamycin (Mithracin).
17. The method of claim 15, wherein the disease or disorder is ARC or AIDS.
18. The method of claim 6, wherein the subject is a mammal.
19. The method of claim 18, wherein the mammal is a human.
20. A method of increasing the body weight of a subject comprising administering to the subject prior to, simultaneously with, or substantially following weight-loss a transforming growth factor-alpha (TGF- α) polypeptide in an effective amount to increase or maintain the weight of the subject.
21. The method of claim 20, wherein the polypeptide has an amino acid sequence as set forth in SEQ ID NO:1.
22. The method of claim 20, wherein the polypeptide has an amino acid sequence as set forth in SEQ ID NO:3.
23. The method of claim 20, wherein the polypeptide comprises a peptide having a sequence NH₂- X_{1a} - Cys - His - Ser - X_{1b} - X₂ - X_{1a} - X_{1b} - X_{1a} - X₃ - Cys COOH (SEQ ID NO:4) wherein X_{1a} and X_{1b} are independently Val, Gly or Ala; X₂ is Tyr or Phe; X₃ is Arg or Lys; and the two Cys moieties are linked via a disulfide bond to form an at least 11-amino acid functional peptide having TGF- α activity.

24. The method of claim 23, wherein at least one or more of the following amino acids are linked to the C-terminal Cys moiety of SEQ ID NO:4:
- X₄ - His - X_{1c} - X₄ - X₅ - X₆ - X_{1c} (SEQ ID NO:5) wherein X₄ is Glu or Asp; X₅ is Leu or Ile; and X₆ is Asp or Glu.
- 5
25. The method of claim 24, wherein X_{1a} is Val, X_{1b} is Gly and X_{1c} is Ala.
26. The method of claim 24, wherein X₂ is Tyr and X₃ is Arg.
- 10
27. The method of claim 24, wherein the functional peptide is 18 amino acids in length and X_{1a} is Val, X_{1b} is Gly, X_{1c} is Ala and X₄ is Gly.
28. The method of claim 20, wherein the weight-loss is the result of a disease or disorder.
- 15
29. The method of claim 20, wherein the weight-loss is associated with treatment of the subject with a chemotherapeutic agent.
- 20
30. The method of claim 29, wherein the chemotherapeutic agent is selected from the group consisting of carmustine (BCNU), chlorambucil (Leukeran), cisplatin (Platinol), Cytarabine, doxorubicin (Adriamycin), fluorouracil (5-FU), methoxetrate (Mexate), taxol, CPT111, etoposide, and plicamycin (Mithracin).
- 25
31. The method of claim 28, wherein the disease or disorder is ARC or AIDS.
32. The method of claim 20, wherein the subject is a mammal.
- 30
33. The method of claim 32, wherein the mammal is a human.

34. A pharmaceutical composition comprising a polypeptide having a sequence $\text{NH}_2\text{-X}_{1a}\text{-Cys-His-Ser-X}_{1b}\text{-X}_2\text{-X}_{1a}\text{-X}_{1b}\text{-X}_{1a}\text{-X}_3\text{-Cys COOH}$ (SEQ ID NO:4) wherein X_{1a} and X_{1b} are independently Val, Gly or Ala; X_2 is Tyr or Phe; X_3 is Arg or Lys; and the two Cys moieties are linked via a disulfide bond to form an at least 11-amino acid functional peptide having TGF- α activity, and a pharmaceutically acceptable carrier.
35. The pharmaceutical composition of claim 34, wherein at least one or more of the following amino acids are linked to the C-terminal Cys moiety of SEQ ID NO:4: $\text{-X}_4\text{-His-X}_{1c}\text{-X}_4\text{-X}_5\text{-X}_6\text{-X}_{1c}$ (SEQ ID NO:5) wherein X_4 is Glu or Asp; X_5 is Leu or Ile; and X_6 is Asp or Glu.
36. The pharmaceutical composition of claim 34, wherein X_{1a} is Val, X_{1b} is Gly and X_{1c} is Ala.
37. The pharmaceutical composition of claim 35, wherein X_2 is Tyr and X_3 is Arg.
38. The pharmaceutical composition of claim 35, wherein the functional peptide is 18 amino acids in length and X_{1a} is Val, X_{1b} is Gly, X_{1c} is Ala and X_4 is Gly.
39. A method for treating a neurodegenerative disease in a subject comprising administering to the subject a transforming growth factor- α (TGF- α) polypeptide in an effective amount to modulate the neurodegenerative disease.
40. The method of claim 39, wherein the polypeptide has an amino acid sequence as set forth in SEQ ID NO:1.

41. The method of claim 39, wherein the polypeptide has an amino acid sequence as set forth in SEQ ID NO:3.
42. The method of claim 39, wherein the polypeptide has a sequence NH₂-X_{1a} - Cys - His - Ser - X_{1b} - X₂ - X_{1a} - X_{1b} - X_{1a} - X₃ - Cys COOH (SEQ ID NO:4) wherein X_{1a} and X_{1b} are independently Val, Gly or Ala; X₂ is Tyr or Phe; X₃ is Arg or Lys; and the two Cys moieties are linked via a disulfide bond to form an at least 11-amino acid functional peptide having TGF- α activity.
43. The method of claim 42, wherein at least one or more of the following amino acids are linked to the C-terminal Cys moiety of SEQ ID NO:4: - X₄ - His - X_{1c} - X₄ - X₅ - X₆ - X_{1c} (SEQ ID NO:5) wherein X₄ is Glu or Asp; X₅ is Leu or Ile; and X₆ is Asp or Glu.
44. The method of claim 43, wherein X_{1a} is Val, X_{1b} is Gly and X_{1c} is Ala.
45. The method of claim 43, wherein X₂ is Tyr and X₃ is Arg.
46. The method of claim 43, wherein the functional peptide is 18 amino acids in length wherein X_{1a} is Val, X_{1b} is Gly, X_{1c} is Ala and X₄ is Gly.
47. A method for treating a CNS disease or disorder comprising administering to a subject a polypeptide having a sequence as set forth in SEQ ID NO:3, or a polypeptide having a sequence NH₂- X_{1a} - Cys - His - Ser - X_{1b} - X₂ - X_{1a} - X_{1b} - X_{1a} - X₃ - Cys COOH (SEQ ID NO:4) wherein X_{1a} and X_{1b} are independently Val, Gly or Ala; X₂ is Tyr or Phe; X₃ is Arg or Lys; and the two Cys moieties are linked via a disulfide bond to form an at least 11-amino acid functional peptide having TGF- α activity.

48. The method of claim 47, wherein the CNS disease or disorder is selected from the group consisting of CNS ischemia, spinal cord injury, MS, and retinal injury.
- 5 49. The method of claim 47, wherein at least one or more of the following amino acids are linked to the C-terminal Cys moiety of SEQ ID NO:4: - X₄ - His - X_{1c} - X₄ - X₅ - X₆ - X_{1c} (SEQ ID NO:5) wherein X₄ is Glu or Asp; X₅ is Leu or Ile; and X₆ is Asp or Glu.
- 10 50. The method of claim 49, wherein X_{1a} is Val, X_{1b} is Gly and X_{1c} is Ala.
51. The method of claim 49, wherein X₂ is Tyr and X₃ is Arg.
- 15 52. The method of claim 49, wherein the functional peptide is 18 amino acids in length and wherein X_{1a} is Val, X_{1b} is Gly, X_{1c} is Ala and X₄ is Gly.
- 20 53. A method for enhancing hematopoiesis during cytotoxic or immune-suppressing therapy, comprising administering a TGF α polypeptide in an effective amount to enhance hematopoeisis.
54. The method of claim 53, wherein the polypeptide has an amino acid sequence as set forth in SEQ ID NO:1.
- 25 55. The method of claim 53, wherein the polypeptide has an amino acid sequence as set forth in SEQ ID NO:3.

56. The method of claim 53, wherein the polypeptide has a sequence
NH₂- X_{1a} - Cys - His - Ser - X_{1b} - X₂ - X_{1a} - X_{1b} - X_{1a} - X₃ - Cys-
COOH (SEQ ID NO:4) wherein X_{1a} and X_{1b} are independently Val,
5 Gly or Ala; X₂ is Tyr or Phe; X₃ is Arg or Lys; and the two Cys
moieties are linked via a disulfide bond to form an at least 11-amino
acid functional peptide having TGF- α activity.
- 10 57. The method of claim 56, wherein at least one or more of the following
amino acids are linked to the C-terminal Cys moiety of SEQ ID NO:4:
- X₄ - His - X_{1c} - X₄ - X₅ - X₆ - X_{1c} (SEQ ID NO:5) wherein X₄ is Glu
or Asp; X₅ is Leu or Ile; and X₆ is Asp or Glu.
- 15 58. The method of claim 57, wherein X_{1a} is Val, X_{1b} is Gly and X_{1c} is
Ala.
59. The method of claim 57, wherein X₂ is Tyr and X₃ is Arg.
- 20 60. The method of claim 57, wherein the functional peptide is 18 amino
acids in length wherein X_{1a} is Val, X_{1b} is Gly, X_{1c} is Ala and X₄ is
Gly.
- 25 61. The method of claim 53, further comprising administering a second
hematopoietic growth factor agent to stimulate the generation of more
mature hematopoietic precursor cells, wherein the second
hematopoietic growth factor is selected from the group consisting of
erythropoietin, thrombopoietin, G-CSF (granulocyte colony
stimulating factor), and GM-CSF (granulocyte macrophage colony
30 stimulating factor).


- 5
62. A method for treating or preventing mucositis of the gastrointestinal tract in a subject comprising administering a TGF α polypeptide in an amount effective to inhibit or prevent oral or intestinal mucositis in the subject.
63. The method of claim 62, wherein the polypeptide has an amino acid sequence as set forth in SEQ ID NO:1.
- 10 64. The method of claim 62, wherein the polypeptide has an amino acid sequence as set forth in SEQ ID NO:3.
- 15 65. The method of claim 62, wherein the polypeptide has a sequence NH₂- X_{1a} - Cys - His - Ser - X_{1b} - X₂ - X_{1a} - X_{1b} - X_{1a} - X₃ - Cys COOH (SEQ ID NO:4) wherein X_{1a} and X_{1b} are independently Val, Gly or Ala; X₂ is Tyr or Phe; X₃ is Arg or Lys; and the two Cys moieties are linked via a disulfide bond to form an at least 11-amino acid functional peptide having TGF- α activity.
- 20 66. The method of claim 65, wherein at least one or more of the following amino acids are linked to the C-terminal Cys moiety of SEQ ID NO:4: - X₄ - His - X_{1c} - X₄ - X₅ - X₆ - X_{1c} (SEQ ID NO:5) wherein X₄ is Glu or Asp; X₅ is Leu or Ile; and X₆ is Asp or Glu.
- 25 67. The method of claim 66, wherein X_{1a} is Val, X_{1b} is Gly and X_{1c} is Ala.
68. The method of claim 66, wherein X₂ is Tyr and X₃ is Arg.
- 30 69. The method of claim 66, wherein the functional peptide is 18 amino acids in length wherein X_{1a} is Val, X_{1b} is Gly, X_{1c} is Ala and X₄ is Gly.

70. The method of claim 62, wherein the oral or intestinal mucositis results from cytotoxic or immune-suppressing therapy.
- 5 71. The method of claim 62, wherein the mucositis results from ARC or AIDS.
72. The method of claim 62, wherein the subject is a mammal.
- 10 73. The method of claim 72, wherein the mammal is a human.
74. A compound as shown in formula III:
- 15 loop peptide N-terminus -linker-cyclic $C_4H_8N_2$ -linker- loop peptide N-terminus (III)
- wherein the linker moiety is designed to link the N-terminus of the loop peptide to a nitrogen atom of the ring $C_4H_8N_2$ and wherein the loop peptide has a sequence NH_2 - X_{1a} - Cys - His - Ser - X_{1b} - X_2 - X_{1a} - X_{1b} - X_{1a} - X_3 - Cys $COOH$ (SEQ ID NO:4) wherein X_{1a} and X_{1b} are independently Val, Gly or Ala; X_2 is Tyr or Phe; X_3 is Arg or Lys; and the two Cys moieties are linked via a disulfide bond to form an at least 11-amino acid functional peptide having TGF- α activity, wherein said compound functions as a TGF- α mimetic.
- 20 75. The compound of claim 74, wherein at least one or more of the following amino acids are linked to the C-terminal Cys moiety of SEQ ID NO:4: - X_4 - His - X_{1c} - X_4 - X_5 - X_6 - X_{1c} (SEQ ID NO:5) wherein X_4 is Glu or Asp; X_5 is Leu or Ile; and X_6 is Asp or Glu.
- 25 76. The compound of claim 75, wherein X_{1a} is Val, X_{1b} is Gly and X_{1c} is Ala.
- 30

77. The compound of claim 75, wherein X₂ is Tyr and X₃ is Arg.
- 5 78. The compound of claim 75, wherein the functional peptide is 18 amino acids in length wherein X_{1a} is Val, X_{1b} is Gly, X_{1c} is Ala and X₄ is Gly.
- 10 79. The compound of claim 74, wherein the linker group is independently selected from the group consisting of substituted or unsubstituted C₁₋₆ alkyl, substituted or unsubstituted C₂₋₆ alkenyl, substituted or unsubstituted C₁₋₆ alkoxy, xylene, wherein the substitutions are selected from the group consisting of oxo, epoxy, hydroxy, chloro, bromo, fluoro, and amino.
- 15 80. A method for treating inflammatory bowel disease, colitis, and Chron's Disease of the gastrointestinal tract, comprising administering a TGF α polypeptide in an effective amount to inhibit or ameliorate the disease.
- 20 81. The method of claim 80, wherein the polypeptide has an amino acid sequence as set forth in SEQ ID NO:1.
82. The method of claim 80, wherein the polypeptide has an amino acid sequence as set forth in SEQ ID NO:3.
- 25 83. The method of claim 80, wherein the polypeptide has a sequence NH₂-X_{1a}-Cys-His-Ser-X_{1b}-X₂-X_{1a}-X_{1b}-X_{1a}-X₃-Cys COOH (SEQ ID NO:4) wherein X_{1a} and X_{1b} are independently Val, Gly or Ala; X₂ is Tyr or Phe; X₃ is Arg or Lys; and the two Cys moieties are linked via a disulfide bond to form an at least 11-amino acid functional peptide having TGF- α activity.

84. The method of claim 83, wherein at least one or more of the following amino acids are linked to the C-terminal Cys moiety of SEQ ID NO:4:
- X₄ - His - X_{1c} - X₄ - X₅ - X₆ - X_{1c} (SEQ ID NO:5) wherein X₄ is Glu or Asp; X₅ is Leu or Ile; and X₆ is Asp or Glu.
85. The method of claim 84, wherein X_{1a} is Val, X_{1b} is Gly and X_{1c} is Ala.
86. The method of claim 84, wherein X₂ is Tyr and X₃ is Arg.
87. The method of claim 84, wherein the functional peptide is 18 amino acids in length and wherein X_{1a} is Val, X_{1b} is Gly, X_{1c} is Ala, and X₄ is Gly.
88. A method for treating or preventing an inflammatory reaction of an autoimmune disease in a subject comprising administering a TGF α polypeptide to the subject in an effective amount to inhibit or ameliorate the inflammatory reaction.
89. The method of claim 88, wherein the polypeptide has an amino acid sequence as set forth in SEQ ID NO:1.
90. The method of claim 88, wherein the polypeptide has an amino acid sequence as set forth in SEQ ID NO:3.
91. The method of claim 88, wherein the polypeptide has a sequence NH₂-X_{1a} - Cys - His - Ser - X_{1b} - X₂ - X_{1a} - X_{1b} - X_{1a} - X₃ - Cys COOH (SEQ ID NO:4) wherein X_{1a} and X_{1b} are independently Val, Gly or Ala; X₂ is Tyr or Phe; X₃ is Arg or Lys; and the two Cys moieties are linked via a disulfide bond to form an at least 11-amino acid functional peptide having TGF- α activity.

- 5 92. The method of claim 91, wherein at least one or more of the following amino acids are linked to the C-terminal Cys moiety of SEQ ID NO:4: - X₄ - His - X_{1c} - X₄ - X₅ - X₆ - X_{1c} (SEQ ID NO:5) wherein X₄ is Glu or Asp; X₅ is Leu or Ile; and X₆ is Asp or Glu.
93. The method The method of claim 92, wherein X_{1a} is Val, X_{1b} is Gly and X_{1c} is Ala.
- 10 94. The method of claim 92, wherein X₂ is Tyr and X₃ is Arg.
95. The method of claim 92, wherein the functional peptide is 18 amino acids in length wherein X_{1a} is Val, X_{1b} is Gly, X_{1c} is Ala and X₄ is Gly.
- 15 96. The method of claim 88, wherein the autoimmune diseases are selected from the group consisting of Type II (Juvenile) Diabetes, rheumatoid arthritis, lupus, glomerular nephritis, and multiple sclerosis.
97. The method of claim 88, wherein the subject is a mammal.
- 20 98. The method of claim 97, wherein the mammal is a human.



TGFα

Fig. 1

2/6




Fig. 2

3/6




Fig. 3

The Measurement of Crypt Height in Different Treatments




Fig. 4

Five-day chemotherapy in mouse model - percent of original weight lost following treatment




FIG. 5

Weight loss in mice following cisplatin administration with and without concurrent
GFA treatment (5 day experiment)




FIG. 6

SEQUENCE LISTING

<110> Stem Cell Pharmaceuticals, Inc.

<120> TGF-alpha POLYPEPTIDES, FUNCTIONAL FRAGMENTS AND
METHODS OF USE THEREFOR

<130> Stem1100

<140> Not Yet Known

<141> 2000-04-26

<150> 09/299,473

<151> 1999-04-26

<150> 09/459,813

<151> 1999-12-13

<160> 6

<170> PatentIn Ver. 2.1

<210> 1

<211> 50

<212> PRT

<213> Homo sapiens

<400> 1

Val Val Ser His Phe Asn Asp Cys Pro Asp Ser His Thr Gln Phe Cys
1 5 10 15

Phe His Gly Thr Cys Arg Phe Leu Val Gln Glu Asp Lys Pro Ala Cys
20 25 30

Val Cys His Ser Gly Tyr Val Gly Ala Arg Cys Glu His Ala Asp Leu
35 40 45

Leu Ala
50

<210> 2

<211> 50

<212> PRT

<213> Rattus norvegicus

<400> 2

Val Val Ser His Phe Asn Lys Cys Pro Asp Ser His Thr Gln Tyr Cys
1 5 10 15

Phe His Gly Thr Cys Arg Phe Leu Val Gln Glu Glu Lys Pro Ala Cys
20 25 30

Val Cys His Ser Gly Tyr Val Gly Val Arg Cys Glu His Ala Asp Leu
35 40 45

Asp Ala
50

<210> 3
<211> 57
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: A modified
human TGF-alpha sequence

<400> 3
Ser Leu Ser Leu Pro Ala Met Val Val Ser His Phe Asn Asp Cys Pro
1 5 10 15

Asp Ser His Thr Gln Phe Cys Phe His Gly Thr Cys Arg Phe Leu Val
20 25 30

Gln Glu Asp Lys Pro Ala Cys Val Cys His Ser Gly Tyr Val Gly Ala
35 40 45

Arg Cys Glu His Ala Asp Leu Leu Ala
50 55

<210> 4
<211> 11
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: An artificial
peptide sequence

<220>
<221> UNSURE
<222> ()
<223> X at residue 1, 5, 7 to 9 are independently V G or
A; X at residue 6 is Y or F; and X at residue 10
is R or K.

<400> 4
Xaa Cys His Ser Xaa Xaa Xaa Xaa Xaa Xaa Cys
1 5 10

<210> 5
<211> 7
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Artificial
peptide sequence

<220>

<221> UNSURE

<222> (1)..(7)

<223> X at residue 1 and 4 are E or D; X at residue 3
and 7 are V, G, or A; X at residue 5 is L or I;
and X at residue 6 is D or E.

<400> 5

Xaa His Xaa Xaa Xaa Xaa Xaa
1 5

<210> 6

<211> 18

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Artificial
Peptide Sequence

<220>

<221> UNSURE

<222> (1)..(18)

<223> X at residues 1, 5, 7-9, 14, 18 are indep. V, G or
A; X at residues 6 is Y or F; X at residue 10 is R
or K; X at residue 12, 15 is indep. E or D; X at
residue 16 is L or I; X at residue 17 is D or E

<400> 6

Xaa Cys His Ser Xaa Xaa Xaa Xaa Xaa Xaa Cys Xaa His Xaa Xaa Xaa
1 5 10 15

Xaa Xaa

1

3

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
2 November 2000 (02.11.2000)

PCT

(10) International Publication Number
WO 00/65028 A3

- (51) **International Patent Classification⁷:** **A01N 37/18**,
A61K 38/00, C07K 14/00, 16/00, 17/00, 2/00, 4/00, 5/00,
7/00, 1/00
- (21) **International Application Number:** PCT/US00/11564
- (22) **International Filing Date:** 26 April 2000 (26.04.2000)
- (25) **Filing Language:** English
- (26) **Publication Language:** English
- (30) **Priority Data:**
09/299,473 26 April 1999 (26.04.1999) US
09/459,813 13 December 1999 (13.12.1999) US
- (71) **Applicant:** **STEM CELL PHARMACEUTICALS, INC.**, [US/US]; Suite 700, 562 First Avenue South, Seattle, WA 98104 (US).
- (72) **Inventors:** **TWARDZIK, Daniel, R.**; 10195 South Beach Drive, Bainbridge Island, WA 98110 (US). **PASKELL, Stefan**; 6075 NE Tolo Road, Bainbridge Island, WA 98110 (US). **FELKER, Thomas, S.**; 11344 SW McCormick Place, Vashon, WA 98070 (US).
- (74) **Agent:** **HAILE, Lisa, A.**; Gray Cary Ware & Friedenrich LLP, Suite 1600, 4365 Executive Drive, San Diego, CA 92121-2189 (US).
- (81) **Designated States (national):** AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW.
- (84) **Designated States (regional):** ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).
- Published:**
— With international search report.
- (88) **Date of publication of the international search report:**
3 May 2001
- For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.*

(54) **Title:** TGF- α POLYPEPTIDES, FUNCTIONAL FRAGMENTS AND METHODS OF USE THEREFOR

(57) **Abstract:** Disclosed are peptides related to human TGF- α , having TGF- α biological activity, which are useful for many of the indications that full-length TGF- α polypeptide is useful. Also provided are methods of use of such peptides, as well as human TGF- α and biologically related polypeptides. For example, methods for treating or preventing cachexia in subjects are provided as well as methods for stimulating hematopoiesis in patients undergoing cytotoxic chemotherapy. In addition, the use of TGF- α related peptides to related neurodegenerative diseases is also provided. Methods of the invention also provide protection for patients undergoing cytotoxic therapy from side effects such as gastrointestinal (GI) mucositis.



WO 00/65028 A3

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US00/11564**A. CLASSIFICATION OF SUBJECT MATTER**

IPC(7) : Please See Extra Sheet.

US CL : 514/2; 530/300, 350

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 514/2; 530/300, 350

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

Issues_AA, a-geneseq36, swiss-prot38, sptrembl112, a-issued, pir64

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X --- Y --- A	US 5,633,147 A (MEISSNER et al) 27 May 1997, Abstract, column 2, line 20, column 10, lines 63-66, column 11, lines 26-30, SEQ ID NO:7 and Sequence Comparison A.	1,34 --- 9,23 --- 2 - 5 , 3 5 - 38,42,47,56,83, 74-79

☒ Further documents are listed in the continuation of Box C. ☐ See patent family annex.

* Special categories of cited documents:	"T"	later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
"A" document defining the general state of the art which is not considered to be of particular relevance	"X"	document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
"E" earlier document published on or after the international filing date	"Y"	document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	"&"	document member of the same patent family
"O" document referring to an oral disclosure, use, exhibition or other means		
"P" document published prior to the international filing date but later than the priority date claimed		

Date of the actual completion of the international search

19 OCTOBER 2000

Date of mailing of the international search report

27 NOV 2000

Name and mailing address of the ISA/US
Commissioner of Patents and Trademarks
Box PCT
Washington, D.C. 20231

Facsimile No. (703) 305-3230

Authorized officer

ROBERT LANDSMAN

Telephone No. (703) 308-0196

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US00/11564

C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X --- Y --- A	WO 91/01141 (TAM) 07 February 1991, see page 1, line 7, page 5, lines 5-6, page 15, lines 7-8 and Sequence Comparison B.	6,7,14,18 -21,28,32,33 ----- 9,23 ----- 8,10-13,15- 17,22,24-27,29- 31,39-61,80-87

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US00/11564

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This international report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:

2. ☐ Claims Nos.:
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:

3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

Please See Extra Sheet.

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☒ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
1-61, 74-87
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
☐ No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US00/11564

A. CLASSIFICATION OF SUBJECT MATTER:
IPC (7):

A01N 37/18; A61K 38/00; C07K 14/00, 16/00, 17/00, 2/00, 4/00, 5/00, 7/00, 1/00

BOX II. OBSERVATIONS WHERE UNITY OF INVENTION WAS LACKING
This ISA found multiple inventions as follows:

This application contains the following inventions or groups of inventions which are not so linked as to form a single inventive concept under PCT Rule 13.1. In order for all inventions to be searched, the appropriate additional search fees must be paid.

Group I, claims 1-38, drawn to a polypeptide and a method of treating weight loss, or increase body weight.

Group II, claims 39-52, drawn to a method of treating a neurological and CNS disease.

Group III, claims 53-61, drawn to a method of enhancing hematopoiesis.

Group IV, claims 62-73, drawn to a method of treating or preventing mucositis.

Group V, claims 74-79, drawn to a compound.

Group VI, claims 80-87, drawn to a method of treating inflammatory bowel disease.

Group VII, claims 88-98, drawn to a method of treating an autoimmune disease.

The inventions listed as Groups I-VII do not relate to a single inventive concept under PCT Rule 13.1 because, under PCT Rule 13.2, they lack the same or corresponding special technical features for the following reasons: the special technical feature of Group I is a method of treating weight loss. The special technical feature of Group II is a method of treating neurological and CNS diseases. The special technical feature of Group III is a method of enhancing hematopoiesis. The special technical feature of Group IV is a method of treating or preventing mucositis. The special technical feature of Group V is a compound. The special technical feature of Group VI is a method of treating inflammatory bowel disease. The special technical feature of Group VII is a method of treating an autoimmune disease. The methods of Groups I-VII require different method steps and reagents for achieving different goals. The Groups are not so linked by a special technical feature within the meaning of PCT Rule 13.2 so as to form a single inventive concept.

CORRECTED VERSION

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
2 November 2000 (02.11.2000)

PCT

(10) International Publication Number
WO 00/65028 A3

(51) International Patent Classification⁷: A01N 37/18,
A61K 38/00, C07K 14/00, 16/00, 17/00, 2/00, 4/00, 5/00,
7/00, 1/00

(21) International Application Number: PCT/US00/11564

(22) International Filing Date: 26 April 2000 (26.04.2000)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
09/299,473 26 April 1999 (26.04.1999) US
09/459,813 13 December 1999 (13.12.1999) US

(71) Applicant: STEM CELL PHARMACEUTICALS,
INC. [US/US]; Suite 700, 562 First Avenue South, Seattle,
WA 98104 (US).

(72) Inventors: TWARDZIK, Daniel, R.; 10195 South Beach
Drive, Bainbridge Island, WA 98110 (US). PASKELL,
Stefan; 6075 NE Tolo Road, Bainbridge Island, WA 98110
(US). FELKER, Thomas, S.; 11344 SW McCormick
Place, Vashon, WA 98070 (US).

(74) Agent: HAILE, Lisa, A.; Gray Cary Ware & Friedenrich
LLP, Suite 1600, 4365 Executive Drive, San Diego, CA
92121-2189 (US).

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU,
AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE,
DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU,
ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS,
LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ,
PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT,
TZ, UA, UG, UZ, VN, YU, ZA, ZW.

(84) Designated States (*regional*): ARIPO patent (GH, GM,
KE, LS, MW, SD, SL, SZ, TZ, UG, ZW), Eurasian patent
(AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent
(AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU,
MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM,
GA, GN, GW, ML, MR, NE, SN, TD, TG).

Published:
— with international search report

(88) Date of publication of the international search report:
3 May 2001

(48) Date of publication of this corrected version:
14 March 2002

(15) Information about Correction:
see PCT Gazette No. 11/2002 of 14 March 2002, Section
II

For two-letter codes and other abbreviations, refer to the "Guid-
ance Notes on Codes and Abbreviations" appearing at the begin-
ning of each regular issue of the PCT Gazette.

(54) Title: TGF- α POLYPEPTIDES, FUNCTIONAL FRAGMENTS AND METHODS OF USE THEREFOR

(57) Abstract: Disclosed are peptides related to human TGF- α , having TGF- α biological activity, which are useful for many of the indications that full-length TGF- α polypeptide is useful. Also provided are methods of use of such peptides, as well as human TGF- α and biologically related polypeptides. For example, methods for treating or preventing cachexia in subjects are provided as well as methods for stimulating hematopoiesis in patients undergoing cytotoxic chemotherapy. In addition, the use of TGF- α related peptides to related neurodegenerative diseases is also provided. Methods of the invention also provide protection for patients undergoing cytotoxic therapy from side effects such as gastrointestinal (GI) mucositis.



WO 00/65028 A3

TGF- α POLYPEPTIDES, FUNCTIONAL FRAGMENTS AND METHODS OF USE THEREFOR

FIELD OF THE INVENTION

The invention relates generally to transforming growth factor alpha (α) and
5 more specifically to methods of using TGF- α for stimulating hematopoiesis, for
suppressing immune function associated with autoimmune diseases, for suppressing
inflammatory responses mediated by excessive histamine release and by expression
of TNF-receptors and associated pro-inflammatory cytokines, and for treating
cachexia or for treating or preventing mucositis and gastrointestinal-associated
10 disorders.

BACKGROUND

There are several disease treatments that could significantly benefit by having
cells regenerate after injury or lesion formation, particularly in the CNS, in the
immune system and in the gastrointestinal tract. In some instances, a particular
15 treatment for a disease often detrimentally affects the subject being treated. For
example, administration of chemotherapeutic agents to subjects results in destruction
of healthy cells, for example, cells of the gastrointestinal tract. A number treatment-
related disorders are related to the choice of chemotherapeutic agent. Such agents
include carmustine (BCNU), chlorambucil (Leukeran), cisplatin (Platinol),
20 Cytarabine, doxorubicin (Adriamycin), fluorouracil (5-FU), methoxetrate (Mexate),
taxol, CPT111, etoposide, and plicamycin (Mithracin) which are known for their
direct stomatotoxic potential (Sonis, 1993, "Oral Complications in Cancer Therapy,"
In: Principles and Practice of Oncology, pp. 2385-2394, DeVitta *et al.*, Eds., J. B.
Lippincott, Philadelphia) and hence incidence of mucositis.

25 Oral mucositis can be initiated by the cytotoxic effects of chemotherapy
and/or radiotherapy on the rapidly dividing epithelial cells of the oropharyngeal
mucosa, and is exacerbated by infection with both endogenous oral flora and
opportunistic bacterial and fungal pathogens. Complications related to oral mucositis
30 vary in the different patient populations affected, but typically include pain, poor oral

intake with consequent dehydration and weight loss, and systemic infection with organisms originating in the oral cavity. The pain associated with oral mucositis may be severe requiring narcotic analgesics, and the difficulty in eating can result in patients receiving total parenteral nutrition.

5

Current therapies have been directed at decreasing oral flora and the extent of infection of oral ulcerations. Systemic treatment with G- and GM-CSF has been shown to result in a decreased incidence of oral mucositis, presumably by allowing for more rapid neutrophil recovery and thus an improved ability to combat infection, although it has been postulated that the CSFs may have a more direct effect on the oral mucosa (Chi *et al.*, 1995, J. Clin. Oncol. 13:2620-2628). In one study, GM-CSF was reported to exacerbate mucositis. (Cartee *et al.*, 1994, Cytokine 7:471-477). Benzydamine hydrochloride, a nonsteroidal drug with analgesic and antimicrobial properties, has been studied both in patients undergoing radiation therapy and in patients receiving intra-arterial chemotherapy.

In addition, diseases associated with epithelial cell depletion in the gastrointestinal tract often increase the risk of related disorders. Such related disorders include infection by opportunistic pathogens as well as weight loss associated with the loss in nutrient uptake in the gastrointestinal tract.

20

SUMMARY OF THE INVENTION

The present invention is based on the seminal discovery that TGF- α and functionally related polypeptides, TGF- α mimetics, functional TGF- α peptides, and polynucleotides encoding such polypeptides and peptide fragments are effective for treating or preventing weight-loss in subjects having disorders or diseases associated with weight-loss (*e.g.*, cachexia). In addition, the polypeptides of the invention have mitogenic and barrier function (*e.g.*, protective) effects on stem cells and their differentiated progeny from a variety of tissues including the gastrointestinal system, the nervous system and the hematopoietic system.

30

In a first embodiment, the invention provides a method of treating a subject having or at risk of having cachexia comprising administering to the subject a transforming growth factor-alpha (TGF- α) polypeptide in an amount effective to prevent or reduce weight-loss. In one aspect, the invention provides a method of
5 increasing the body weight of a subject comprising administering to the subject, prior to, simultaneously with, or substantially following chemotherapy, a transforming growth factor-alpha (TGF- α) polypeptide in an amount effective to increase the weight of the subject. In one aspect the subject has AIDS related complex (ARC) or AIDS and cachexia associated with such diseases.

10

In another embodiment, the invention provides a method for treating or preventing mucositis of the gastrointestinal tract in a subject, comprising administering a TGF α or related polypeptide in an amount effective to treat or prevent mucositis in the subject. For example, a subject undergoing chemotherapy can be
15 treated by the method of the invention.

The invention also provides a polypeptide comprising a peptide having a sequence NH₂- X_{1a} - Cys - His - Ser - X_{1b} - X₂ - X_{1a} - X_{1b} - X_{1a} - X₃ - Cys - COOH (SEQ ID NO:4) wherein X_{1a} and X_{1b} are independently Val, Gly or Ala; X₂ is Tyr or
20 Phe; X₃ is Arg or Lys; and the two Cys moieties are linked via a disulfide bond to form an at least 11-amino acid functional peptide having TGF- α activity.

In another embodiment, the invention provides a polypeptide comprising a peptide having a sequence NH₂- X_{1a} - Cys - His - Ser - X_{1b} - X₂ - X_{1a} - X_{1b} - X_{1a} - X₃ -
25 Cys - COOH (SEQ ID NO:4) wherein X_{1a} and X_{1b} are independently Val, Gly or Ala; X₂ is Tyr or Phe; X₃ is Arg or Lys; and the two Cys moieties are linked via a disulfide bond to form an at least 11-amino acid functional peptide having TGF- α activity and wherein at least one or more of the following amino acids are linked to the C-terminal Cys moiety of SEQ ID NO:4: - X₄ - His - X_{1c} - X₄ - X₅ - X₆ - X_{1c} (SEQ ID NO:5)
30 wherein X₄ is Glu or Asp; X₅ is Leu or Ile; and X₆ is Asp or Glu.

In yet another embodiment, the invention provides a pharmaceutical composition comprising a polypeptide having a sequence NH₂- X_{1a} - Cys - His - Ser - X_{1b} - X₂ - X_{1a} - X_{1b} - X_{1a} - X₃ - Cys COOH (SEQ ID NO:4) wherein X_{1a} and X_{1b} are independently Val, Gly or Ala; X₂ is Tyr or Phe; X₃ is Arg or Lys; and the two Cys moieties are linked via a disulfide bond to form an at least 11-amino acid functional peptide having TGF- α activity, and a pharmaceutically acceptable carrier. In addition, at least one or more of the following amino acids are linked to the C-terminal Cys moiety of SEQ ID NO:4: - X₄ - His - X_{1c} - X₄ - X₅ - X₆ - X_{1c} (SEQ ID NO:5) wherein X₄ is Glu or Asp; X₅ is Leu or Ile; and X₆ is Asp or Glu.

The invention also provides a compound that acts as a TGF- α mimetic, comprising a compound of formula: loop peptide N-terminus-linker-cyclic C₄H₈N₂-linker-loop peptide N-terminus wherein the linker moiety is designed to link the N-terminus of the loop peptide to a nitrogen atom of the ring C₄H₈N₂ and wherein the loop peptide has a sequence NH₂- X_{1a} - Cys - His - Ser - X_{1b} - X₂ - X_{1a} - X_{1b} - X_{1a} - X₃ - Cys COOH (SEQ ID NO:4) wherein X_{1a} and X_{1b} are independently Val, Gly or Ala; X₂ is Tyr or Phe; X₃ is Arg or Lys; and the two Cys moieties are linked via a disulfide bond to form an at least 11-amino acid functional peptide having TGF- α activity.

BRIEF DESCRIPTION OF THE FIGURE

Figure 1 shows the structure of rat TGF α polypeptide and its 50 amino acids arranged into three loops (SEQ ID NO:2). The human TGF α sequence is provided in SEQ ID NO:1 with a similar tertiary structure and a close sequence homology.

Figure 2 shows a graph comparing TGF α biological activity of the three loop peptide regions of TGF α (see Figure 1) wherein Loop A is amino acids 1-21 (starting at the N terminus), Loop B is amino acids 16 to 32 and Loop C is amino acids 33 to 50. Only Loop C showed significant TGF α activity as determined by cell proliferation and in a dose response fashion.

Figure 3 shows a graph of mouse spleen weights that were treated with Cis Platinum (CP) at either 5 µg/g or 10 µg/g and with TGFα at concentrations of 10 ng/g or 50 ng/g. These data show that TGFα treatment caused a return to normal spleen weights despite CP treatment that reduced spleen weights significantly.

5

Figure 4 depicts a summary of histological data that measured average crypt height of the three groups of mice. TGFα 57 treatment (50 ng/g) was able to more-than-restore crypt height loss from CP treatment.

10 **Figure 5** shows a graph depicting the effects of cisplatin-alone, cisplatin and a TGF-α polypeptide, and a TGF-α alone on weight loss of mice.

Figure 6 shows weight loss in mice following cisplatin administration with and without concurrent TGF-α treatment. The graph shows (from left to right) the proportion of weight-loss in the presence of PBS alone, TGF-α alone, cisplatin alone, and cisplatin+TGF-α.

15

DETAILED DESCRIPTION OF THE INVENTION

The present invention provides compositions of TGF-α polypeptides, TGF-α mimetics, TGF-α related polypeptides and functional fragments thereof as well as polynucleotides encoding the polypeptides and fragments thereof. In addition, the invention provides methods of using the polypeptides and polynucleotides of the invention for treating or preventing a number of diseases and disorders.

20

Transforming Growth Factor-α

TGF-α is a member of the epidermal growth factor (EGF) family and interacts with one or more receptors in the EGF-family of receptors. TGF-α stimulates the receptor's endogenous tyrosine kinase activity which results in activating various cellular functions, such as stimulating a mitogenic or migration response in a wide variety of cell types. TGF-α and EGF mRNAs reach their highest levels and relative abundance (compared to total RNA) in the early postnatal period and decrease thereafter, suggesting a role in embryonic development. From a histological

25

perspective, TGF- α is found in numerous cell types and tissues throughout the body. The active form of TGF- α is derived from a larger 30-35 kD precursor and contains 50 amino acids. Human TGF- α shares only a 30% structural homology with the 53-amino acid form of EGF, but includes conservation and spacing of all six cysteine residues. TGF α is highly conserved among species. For example, the rat and human polypeptides share about 90% homology compared to a 70% homology as between the rat and human EGF polypeptide. The amino acid sequence of human TGF α is shown in SEQ ID NO:1. TGF α shares cysteine disulfide bond structures with a family of proteins including vaccinia growth factor, amphiregulin precursor, betacellulin precursor, heparin binding EGF-like growth factor, epiregulin (rodent only), HUS 19878, myxomavirus growth factor (MGF), Shope fibroma virus growth factor (SFGE), and schwannoma derived growth factor. Such TGF- α related polypeptides are also useful in the methods of the invention.

TGF- α is an acid and heat stable polypeptide of about 5.6 kDa molecular weight. It is synthesized as a larger 30-35 kDa molecular weight glycosylated and membrane-bound precursor protein wherein the soluble 5.6 kDa active form is released following specific cleavage by an elastase-like protease. TGF- α binds with high affinity in the nanomolar range and induces autophosphorylation of one or more members of EGF receptor family (*e.g.*, ErbB1 through 4) to transduce subsequent signal pathways with the EGF receptors. TGF- α is 50 amino acids in length and has three disulfide bonds to form its tertiary configuration. All three disulfide bonds are required for activity. TGF- α is stored in precursor form in alpha granules of some secretory cells. Moreover, the primary amino acid sequence is highly conserved among various species examined, such as more than 92% homology at the amino acid level as between human and rat TGF α polypeptides.

Human TGF α is a polypeptide of 50 amino acids. The corresponding rat sequence is shown in Figure 1. The human or rat TGF α polypeptide can be divided roughly into three loop regions corresponding roughly (starting at the N terminus) to amino acids 1-21, to amino acids 16-32, and to amino acids 33-50. As discussed

more fully below, the invention provides functional fragments of TGF- α that retain TGF- α biological activity. "Functional fragment" as used herein means a TGF- α peptide that is a fragment or a modified fragment of a full length TGF- α polypeptide or related polypeptide so long as the fragment retains some TGF- α related biological activity (*e.g.*, interacts with an EGF family receptor, stimulates proliferation or migration of stem cells, useful for treating or preventing cachexia). Other biological activities associated with the polypeptides of the invention include, for example, mitogenic effects on stem cells and their more differentiated progeny of various tissues (*e.g.*, epithelial stem cells, hematopoietic stem cells, neural stem cells, liver stem cells, keratinocyte stem cells, and pancreatic derived stem cells).

The mucosal epithelium of the intestine is in a continually dynamic state known as "epithelial renewal" in which undifferentiated stem cells from a proliferative crypt zone divide, differentiate and migrate to the luminal surface. Once terminally differentiated, mucosal epithelial cells are sloughed from the tips of the villi. The turnover of the crypt-villus cell population is rapid and occurs every 24-72 hours. Continuous exfoliation of the cells at the villus tip is counterbalanced by ongoing proliferation in the crypt so that net intestinal epithelial mass remains relatively constant. The rapidly-proliferating epithelium of the gastrointestinal tract is extremely sensitive to cytotoxic drugs that are widely used in cancer chemotherapy. By "gastrointestinal tract" is meant, for example, the tissues of the mouth, esophagus, stomach, small intestine, large intestine, rectum and anus. This "side effect" reduces the tolerated dose of such drugs as it can cause a breakdown of the GI barrier function and septic propagate a septic condition in a patient already immuno-compromised. This can also lead to life-threatening hemorrhage. Therefore, there is a need in the art for the development of products and delivery systems that stimulate the repair and rejuvenation of mucosal epithelium in the gastrointestinal tract to provide benefit to subjects having, for example, weight-loss disorders associated with chemotherapy and radiation therapy for cancer as well as disorders or diseases associated with pathogens such as HIV.

Accordingly, the invention provides a class of peptides, including TGF- α and those smaller than the 50 amino acid human TGF- α , yet retaining TGF- α biological activity, which are useful as pharmacologic and therapeutic agents. Other polypeptides or fragments thereof include TGF-related polypeptides that have the biological activity of TGF- α (e.g., amphiregulin, vaccinia growth factor, myxomavirus growth factor (MGF), Shope fibroma virus growth factor (SFGF), heparin-binding EGF-like growth factor (HB-EGF)).

The invention also provides methods of using TGF- α , related polypeptides and peptide fragments thereof as disclosed herein to stimulate hematopoiesis in subjects undergoing cytotoxic cancer chemotherapy and to act as a cytoprotective agents and in treatments for subjects at risk of or having weight-loss disorders associated with cancer cytotoxic therapy. Such disorders include for example, gastrointestinal (GI) mucositis, which can be the result of cytotoxic therapy. While not wanting to be bound to a particular theory, it is believed TGF- α may alleviate GI mucositis, in part, through its mitogenic activity for GI epithelial stem cells.

TGF α has been investigated extensively and has recently been identified as useful for treating subjects with neurological deficits. This mechanism is thought to stimulate proliferation and migration of stem cells of neural origin to those sites or lesions in a deficit. For example, Parkinson's Disease is characterized by resting tremor, rigidity, inability to initiate movement (akinesia) and slowness of movement (bradykinesia). The motor deficits are associated with progressive degeneration of the dopaminergic innervation to the nucleus accumbens and degeneration of noradrenergic cells of the locus ceruleus and serotonergic neurons of the raphe. Up to 80% of nigral dopamine neurons can be lost before significant motor deficits are manifest. TGF α was shown, when infused into rat brains, to be useful for the treatment of neurodegenerative disorders. Intracerebroventricular (ICV) or intrastriatal infusions of TGF α induced neuronal stem cell proliferation, but degenerating or damaged or otherwise abnormal cells needed to be present to facilitate migration of the neuronal stem cells to a site of injury on a scale sufficient to

impact recovery from an associated neurological deficit. Forebrain neural stem cells, that give rise to migrating progenitor cells that affect treatment and recovery from a neurological deficit disorder, are the migrating cells that affect treatment recovery from a neural deficit disorder (*e.g.*, Parkinson's Disease, Huntington's Disease,
5 Alzheimer's Disease and the like).

Neural stem cells have been found in subependyma throughout the adult rodent CNS (Ray *et al. Soc. Neurosci.* 22:394.5, 1996) and in the subependyma of adult human forebrain (Kirschenbaum *et al., Cerebral Cortex* 4:576-589, 1994).
10 Thus, the discovery that TGF α stimulates proliferation of neural stem cells and promotes migration to a site of injury or deficit has led to its investigation for the treatment of a neurodegenerative disorder (Alzheimer's Disease, Huntington's Disease and Parkinson's Disease) or CNS traumatic injury (*e.g.*, spinal chord injury), demyelinating disease, CNS inflammatory disease, CNS autoimmune disease (*e.g.*,
15 multiple sclerosis) and CNS ischemic disease (*e.g.*, stroke or brain attack).

A CNS stem cell has the potential to differentiate into neurons and astrocytes as well as self replication and thus self renewal. Both neuronal and glial cells are derived from a common precursor cell. In the vertebrate CNS, pluripotential cells
20 have been identified *in vitro* and *in vivo*. Certain mitogens, such as TGF- α , can cause proliferation of CNS pluripotential cells *in vitro*. Thus, it is possible to harvest such cell from a subject, treat them *ex vivo* to stimulate proliferation in culture and then readminister the cells back to a subject. Immunohistochemical analysis in the human brain supports the notion that TGF- α and its 35 kD precursor are widely distributed in
25 neurons and glial cells both during development and during adulthood. In TGF- α knockout mice genetically altered to lack expression of functioning TGF- α , there was a decrease in neural progenitor cell proliferation in forebrain subependyma, providing evidence for TGF- α as a proliferative factor for neural progenitor cells.

30 TGF- α is found mainly in various neurons of the CNS during development and in the adult brain in the cerebral neocortex, hippocampus and striatum. It is also

found in glial cells, primarily in the cerebral and cerebellar cortex areas. Northern blot analyses showed that TGF α but not EGF (epidermal growth factor) is the most abundant ligand that binds to one or more of the EGF receptor family in the brain. TGF α mRNA levels were 15-170 times higher than EGF in cerebellum and cerebral cortex. TGF α also appears in germinal centers of the brain during neurogenesis and gliogenesis in the developing brain. In the midbrain, the distribution of TGF α overlaps with tyrosine hydroxylase mRNA and fetal dopaminergic neurons. In culture, TGF α enhanced survival and neurite outgrowth of neonatal rat dorsal ganglion neurons (EGF did not) and survival and differentiation of CNS neurons.

10 TGF α induced proliferation of neural precursor cells of the murine embryonic mesencephalon and further induced a significant increase in the number of astroglia and microglia in fetal rat medial septal cells. TGF α increased glutamic acid decarboxylase activity and decreased choline acetyltransferase activity. Thus, TGF α acted as a general neuronal survival factor affecting both cholinergic and GABAergic

15 neurons. In addition, TGF α is a mitogen for pluripotent brain stem cells. Forebrain subependyma contains nestin positive neural stem cells and their progeny, which are constitutively proliferating progenitor epithelial cells. A "knockout" mouse that was genetically engineered to delete the gene for TGF α showed a reduction in neuronal progenitor cells in the subependyma and a reduction in neuronal progenitors that

20 migrate to the olfactory bulb. *In vitro*, TGF α promoted dopamine uptake in fetal rat dopaminergic neurons in a dose-dependent and time-dependent manner. TGF α selectively promoted dopaminergic cell survival, enhanced neurite length, branch number and the soma area of tyrosine hydroxylase immunopositive cells. The levels of TGF α were elevated in ventricular cerebrospinal fluid in juvenile parkinsonism and

25 Parkinson's Disease and may represent a compensatory response to neurodegeneration. Further, TGF α prevented a striatal neuronal degeneration in an animal model of Huntington's Disease.

Nucleic Acids and Vectors

Polynucleotide or nucleic acid sequence refers to a polymeric form of nucleotides. In some instances a polynucleotide refers to a sequence that is not immediately contiguous with either of the coding sequences with which it is
5 immediately contiguous (one on the 5' end and one on the 3' end) in the naturally occurring genome of the organism from which it is derived. The term therefore includes, for example, a recombinant DNA which is incorporated into a vector; into an autonomously replicating plasmid or virus; or into the genomic DNA of a prokaryote or eukaryote, or which exists as a separate molecule (*e.g.*, a cDNA) independent of other
10 sequences. The nucleotides of the invention can be ribonucleotides, deoxyribonucleotides, or modified forms of either nucleotide. In addition, the polynucleotide sequence involved in producing a polypeptide chain can include regions preceding and following the coding region (leader and trailer) as well as intervening sequences (introns) between individual coding segments (exons) depending upon the
15 source of the polynucleotide sequence.

The term polynucleotide(s) generally refers to any polyribonucleotide or polydeoxyribonucleotide, which may be unmodified RNA or DNA or modified RNA or DNA. Thus, for instance, polynucleotides as used herein refers to, among others, single- and double-stranded DNA, DNA that is a mixture of single- and double-stranded
20 regions, single- and double-stranded RNA, and RNA that is mixture of single- and double-stranded regions, hybrid molecules comprising DNA and RNA that may be single-stranded or, more typically, double-stranded or a mixture of single- and double-stranded regions.

In addition, the polynucleotides or nucleic acid sequences may contain one or
25 more modified bases. Thus, DNAs or RNAs with backbones modified for stability or for other reasons are "polynucleotides" as that term is intended herein. Moreover, DNAs or RNAs comprising unusual bases, such as inosine, or modified bases, such as tritylated bases, to name just two examples, are polynucleotides as the term is used herein.

Nucleic acid sequences can be created which encode a fusion protein (*e.g.*, a
30 TGF- α polypeptide and another polypeptide, such as a targeting sequence) and can be

operatively linked to expression control sequences. "Operatively linked" refers to a juxtaposition wherein the components so described are in a relationship permitting them to function in their intended manner. For example, a coding sequence is "operably linked" to another coding sequence when RNA polymerase will transcribe the two
5 coding sequences into a single mRNA, which is then translated into a single polypeptide having amino acids derived from both coding sequences. The coding sequences need not be contiguous to one another so long as the expressed sequences ultimately process to produce the desired protein. An expression control sequence operatively linked to a coding sequence is ligated such that expression of the coding sequence is achieved under
10 conditions compatible with the expression control sequences. As used herein, the term "expression control sequences" refers to nucleic acid sequences that regulate the expression of a nucleic acid sequence to which it is operatively linked. Expression control sequences are operatively linked to a nucleic acid sequence when the expression control sequences control and regulate the transcription and, as appropriate, translation
15 of the nucleic acid sequence. Thus, expression control sequences can include appropriate promoters, enhancers, transcription terminators, a start codon (*i.e.*, ATG) in front of a protein-encoding gene, splicing signals for introns, maintenance of the correct reading frame of that gene to permit proper translation of the mRNA, and stop codons. The term "control sequences" is intended to include, at a minimum, components whose
20 presence can influence expression, and can also include additional components whose presence is advantageous, for example, leader sequences and fusion partner sequences. Expression control sequences can include a promoter.

By "promoter" is meant minimal sequence sufficient to direct transcription. Also included in the invention are those promoter elements which are sufficient to render
25 promoter-dependent gene expression controllable for cell-type specific, tissue-specific, or inducible by external signals or agents; such elements may be located in the 5' or 3' regions of the of a polynucleotide sequence. Both constitutive and inducible promoters, are included in the invention (see *e.g.*, Bitter *et al.*, Methods in Enzymology 153:516-544, 1987). For example, when cloning in bacterial systems, inducible promoters such
30 as pL of bacteriophage, plac, ptrp, ptac (ptrp-lac hybrid promoter) and the like may be used. When cloning in mammalian cell systems, promoters derived from the genome of

mammalian cells (*e.g.*, metallothionein promoter) or from mammalian viruses (*e.g.*, the retrovirus long terminal repeat; the adenovirus late promoter; the vaccinia virus 7.5K promoter) may be used. Promoters produced by recombinant DNA or synthetic techniques may also be used to provide for transcription of the nucleic acid sequences of
5 the invention.

A nucleic acid sequence of the invention including, for example, a polynucleotide encoding a fusion protein, may be inserted into a recombinant expression vector. A recombinant expression vector generally refers to a plasmid, virus or other vehicle known in the art that has been manipulated by insertion or incorporation of a
10 nucleic acid sequences. For example, a recombinant expression vector of the invention includes a polynucleotide sequence encoding a TGF- α polypeptide having a sequence as set forth in SEQ ID NO:1, 2, 3, 4 or 6 or fragment thereof (as described more fully below). The expression vector typically contains an origin of replication, a promoter, as well as specific genes which allow phenotypic selection of the transformed cells.

15 Vectors suitable for use in the invention include, but are not limited to the T7-based expression vector for expression in bacteria (Rosenberg, *et al.*, Gene 56:125, 1987), the pMSXND expression vector for expression in mammalian cells (Lee and Nathans, J. Biol. Chem. 263:3521, 1988), baculovirus-derived vectors for expression in insect cells, cauliflower mosaic virus, CaMV; tobacco mosaic virus, TMV. The nucleic acid
20 sequences of the invention can also include a localization sequence to direct the indicator to particular cellular sites by fusion to appropriate organellar targeting signals or localized host proteins. For example, a polynucleotide encoding a localization sequence, or signal sequence, can be used as a repressor and thus can be ligated or fused at the 5' terminus of a polynucleotide encoding a polypeptide or a polypeptide fragment of the
25 invention such that the localization or signal peptide is located at the amino terminal end of a resulting polypeptide. The construction of expression vectors and the expression of genes in transfected cells involves the use of molecular cloning techniques also well known in the art. (See, for example, Sambrook *et al.*, Molecular Cloning --A Laboratory Manual, Cold Spring Harbor Laboratory, Cold Spring Harbor, NY, 1989, and Current
30 Protocols in Molecular Biology, M. Ausubel *et al.*, eds., (Current Protocols, a joint venture between Greene Publishing Associates, Inc. and John Wiley & Sons, Inc., most

recent Supplement)). These methods include *in vitro* recombinant DNA techniques, synthetic techniques and *in vivo* recombination/genetic recombination. (See also, Maniatis, *et al.*, Molecular Cloning A Laboratory Manual, Cold Spring Harbor Laboratory, N.Y., 1989).

5 In yeast, a number of vectors containing constitutive or inducible promoters may be used. For a review see, Current Protocols in Molecular Biology, Vol. 2, Ed. Ausubel, *et al.*, Greene Publish. Assoc. & Wiley Interscience, Ch. 13, 1988; Grant, *et al.*, "Expression and Secretion Vectors for Yeast," in Methods in Enzymology, Eds. Wu & Grossman, 1987, Acad. Press, N.Y., Vol. 153, pp.516-544, 1987; Glover, DNA Cloning,
10 Vol. II, IRL Press, Wash., D.C., Ch. 3, 1986; and Bitter, "Heterologous Gene Expression in Yeast," Methods in Enzymology, Eds. Berger & Kimmel, Acad. Press, N.Y., Vol. 152, pp. 673-684, 1987; and The Molecular Biology of the Yeast *Saccharomyces*, Eds. Strathern *et al.*, Cold Spring Harbor Press, Vols. I and II, 1982. A constitutive yeast promoter such as ADH or LEU2 or an inducible promoter such as GAL may be used
15 ("Cloning in Yeast," Ch. 3, R. Rothstein In: DNA Cloning Vol.11, A Practical Approach, Ed. DM Glover, IRL Press, Wash., D.C., 1986). Alternatively, vectors may be used which promote integration of foreign DNA sequences into the yeast chromosome.

20 An alternative expression system which could be used to express a TGF- α polypeptide or function fragment of the invention is an insect system. In one such system, *Autographa californica* nuclear polyhedrosis virus (AcNPV) is used as a vector to express foreign or mutated polynucleotide sequences. The virus grows in *Spodoptera frugiperda* cells. The sequence encoding a polypeptide of the invention may be cloned into non-essential regions (for example, the polyhedrin gene) of the virus and placed
25 under control of an AcNPV promoter (for example the polyhedrin promoter). Successful insertion of the sequences coding for a polypeptide of the invention will result in inactivation of the polyhedrin gene and production of non-occluded recombinant virus (*i.e.*, virus lacking the proteinaceous coat coded for by the polyhedrin gene). These recombinant viruses are then used to infect *S. frugiperda* cells in which
30 the inserted gene is expressed, see Smith, *et al.*, J. Virol. 46:584, 1983; Smith, U.S. Patent No. 4,215,051.

The vectors of the invention can be used to transform a host cell. By transform or transformation is meant a permanent or transient genetic change induced in a cell following incorporation of new DNA (*i.e.*, DNA exogenous to the cell). Where the cell is a mammalian cell, a permanent genetic change is generally achieved by introduction
5 of the DNA into the genome of the cell.

A transformed cell or host cell generally refers to a cell (*e.g.*, prokaryotic or eukaryotic) into which (or into an ancestor of which) has been introduced, by means of recombinant DNA techniques, a polynucleotide molecule encoding a TGF- α polypeptide or functional fragments thereof (*e.g.*, a functional fragment as set forth in SEQ ID NO:4,
10 as described below).

Transformation of a host cell with recombinant DNA may be carried out by conventional techniques as are well known to those skilled in the art. Where the host is prokaryotic, such as *E. coli*, competent cells which are capable of DNA uptake can be prepared from cells harvested after exponential growth phase and subsequently treated
15 by the CaCl_2 method by procedures well known in the art. Alternatively, MgCl_2 or RbCl can be used. Transformation can also be performed after forming a protoplast of the host cell or by electroporation.

When the host is a eukaryote, methods of transfection or transformation with DNA include calcium phosphate co-precipitates, conventional mechanical procedures
20 such as microinjection, electroporation, insertion of a plasmid encased in liposomes, or virus vectors, as well as others known in the art, may be used. Eukaryotic cells can also be cotransfected with DNA sequences encoding a TGF- α polypeptide or fragment and a second foreign DNA molecule encoding a selectable marker, such as the herpes simplex thymidine kinase gene. Another method is to use a eukaryotic viral vector, such as
25 simian virus 40 (SV40) or bovine papilloma virus, to transiently infect or transform eukaryotic cells and express the protein. (Eukaryotic Viral Vectors, Cold Spring Harbor Laboratory, Gluzman ed., 1982). Typically, a eukaryotic host will be utilized as the host cell. The eukaryotic cell may be a yeast cell (*e.g.*, *Saccharomyces cerevisiae*), an insect cell (*e.g.*, *Drosophila sp.*) or may be a mammalian cell, including a human cell.

Eukaryotic systems, and mammalian expression systems, allow for post-translational modifications of expressed mammalian proteins to occur. Eukaryotic cells which possess the cellular machinery for processing of the primary transcript, glycosylation, phosphorylation, and, advantageously secretion of the gene product
5 should be used. Such host cell lines may include, but are not limited to, CHO, VERO, BHK, HeLa, COS, MDCK, Jurkat, HEK-293, and WI38.

Mammalian cell systems which utilize recombinant viruses or viral elements to direct expression may be engineered. For example, when using adenovirus expression vectors, a polynucleotide encoding a TGF- α polypeptide or fragment thereof may be
10 ligated to an adenovirus transcription/ translation control complex, *e.g.*, the late promoter and tripartite leader sequence. This chimeric sequence may then be inserted in the adenovirus genome by *in vitro* or *in vivo* recombination. Insertion in a non-essential region of the viral genome (*e.g.*, region E1 or E3) will result in a recombinant virus that is viable and capable of expressing a TGF- α polypeptide or fragment thereof in infected
15 hosts (*e.g.*, see Logan & Shenk, Proc. Natl. Acad. Sci. USA, 81:3655-3659, 1984). Alternatively, the vaccinia virus 7.5K promoter may be used. (*e.g.*, see, Mackett, *et al.*, Proc. Natl. Acad. Sci. USA, 79:7415-7419, 1982; Mackett, *et al.*, J. Virol. 49:857-864, 1984; Panicali, *et al.*, Proc. Natl. Acad. Sci. USA 79:4927-4931, 1982). Of particular interest are vectors based on bovine papilloma virus which have the ability to replicate as
20 extrachromosomal elements (Sarver, *et al.*, Mol. Cell. Biol. 1:486, 1981). Shortly after entry of this DNA into mouse cells, the plasmid replicates to about 100 to 200 copies per cell. Transcription of the inserted cDNA does not require integration of the plasmid into the host's chromosome, thereby yielding a high level of expression. These vectors can be used for stable expression by including a selectable marker in the plasmid, such as the
25 *neo* gene. High level expression may also be achieved using inducible promoters, including, but not limited to, the metallothionine IIA promoter and heat shock promoters.

For long-term, high-yield production of recombinant proteins, stable expression is preferred. Rather than using expression vectors which contain viral origins of
30 replication, host cells can be transformed with the cDNA encoding a TGF- α polypeptide or functional fragment controlled by appropriate expression control elements (*e.g.*,

promoter, enhancer, sequences, transcription terminators, polyadenylation sites, etc.), and a selectable marker. The selectable marker in the recombinant vector confers resistance to the selection and allows cells to stably integrate the plasmid into their chromosomes and grow to form foci which in turn can be cloned and expanded into cell lines. For example, following the introduction of foreign DNA, engineered cells may be allowed to grow for 1-2 days in an enriched media, and then are switched to a selective media. A number of selection systems may be used, including, but not limited to, the herpes simplex virus thymidine kinase (Wigler, *et al.*, Cell, 11:223, 1977), hypoxanthine-guanine phosphoribosyltransferase (Szybalska & Szybalski, Proc. Natl. Acad. Sci. USA, 48:2026, 1962), and adenine phosphoribosyltransferase (Lowy, *et al.*, Cell, 22:817, 1980) genes can be employed in tk-, hgp^rt- or apr^rt- cells respectively. Also, anti-metabolite resistance can be used as the basis of selection for dhfr, which confers resistance to methotrexate (Wigler, *et al.*, Proc. Natl. Acad. Sci. USA, 77:3567, 1980; O'Hare, *et al.*, Proc. Natl. Acad. Sci. USA, 8:1527, 1981); gpt, which confers resistance to mycophenolic acid (Mulligan & Berg, Proc. Natl. Acad. Sci. USA, 78:2072, 1981); neo, which confers resistance to the aminoglycoside G-418 (Colberre-Garapin, *et al.*, J. Mol. Biol. 150:1, 1981); and hyg^r, which confers resistance to hygromycin (Santerre, *et al.*, Gene 30:147, 1984) genes. Recently, additional selectable genes have been described, namely trpB, which allows cells to utilize indole in place of tryptophan; hisD, which allows cells to utilize histinol in place of histidine (Hartman & Mulligan, Proc. Natl. Acad. Sci. USA 85:8047, 1988); and ODC (ornithine decarboxylase) which confers resistance to the ornithine decarboxylase inhibitor, 2-(difluoromethyl)-DL-ornithine, DFMO (McConlogue L., In: Current Communications in Molecular Biology, Cold Spring Harbor Laboratory, ed., 1987).

The term "primer" as used herein refers to an oligonucleotide, whether natural or synthetic, which is capable of acting as a point of initiation of synthesis when placed under conditions in which primer extension is initiated or possible. Synthesis of a primer extension product which is complementary to a nucleic acid strand is initiated in the presence of nucleoside triphosphates and a polymerase in an appropriate buffer at a suitable temperature.

Proteins and Polypeptides

A polypeptide or protein refers to a polymer in which the monomers are amino acid residues which are joined together through amide bonds. When the amino acids are alpha-amino acids, either the L-optical isomer or the D-optical isomer can be used, the L-isomers being typical. A TGF- α polypeptide or TGF- α related polypeptide is intended to encompass an amino acid sequence, including modified sequences such as glycoproteins, which exhibit TGF- α activity. The polypeptides of the invention encompass amino acid sequences of human TGF- α as shown in SEQ ID NO:1 as well as polypeptides that have structural and/or functional characteristics of TGF- α . For example, a polypeptide or a TGF- α related polypeptide of the invention may include a polypeptide that shares a cysteine disulfide bond structure similar to TGF- α such as a related family of proteins including vaccinia growth factor, amphiregulin precursor, betacellulin precursor, heparin binding EGF-like growth factor, epiregulin (rodent only), HUS 19878, myxomavirus growth factor (MGF), Shope fibroma virus growth factor (SFGE), and schwannoma derived growth factor. In addition, a polypeptide of the invention will have one or more functional characteristics related to TGF- α including, for example, the ability to interact with an EGF family receptor member, stimulate proliferation or migration of stem cells, or to treat or prevent cachexia.

The polypeptides of the invention are intended to cover naturally occurring proteins, as well as those which are recombinantly or synthetically synthesized. In addition, a TGF- α or related polypeptide can occur in at least two different conformations wherein both conformations have the same or substantially the same amino acid sequence but have different three dimensional structures so long as the have a biological activity related to TGF- α . Polypeptide or protein fragments of TGF- α are also encompassed by the invention such as those described by formulas I, II, and III (see below). Fragments can have the same or substantially the same amino acid sequence as the naturally occurring protein. A polypeptide or peptide having substantially the same sequence means that an amino acid sequence is largely, but not entirely, the same, but retains a functional activity of the sequence to which it is related. In general polypeptides of the present invention include peptides, or full length protein, that contains

substitutions, deletions, or insertions into the protein backbone, that would still have an approximately 50%-70% homology to the original protein over the corresponding portion. A yet greater degree of departure from homology is allowed if like-amino acids, *i.e.* conservative amino acid substitutions, do not count as a change in the sequence.

- 5 Polypeptide fragments of the invention retain a biological activity associated with TGF- α as described above.

Homology to TGF- α polypeptide can be measured using standard sequence analysis software (*e.g.*, Sequence Analysis Software Package of the Genetics Computer Group, University of Wisconsin Biotechnology Center, 1710 University Avenue, Madison, WI 53705; also see Ausubel, *et al.*, *supra*). Such procedures and algorithms include, for example, a BLAST program (Basic Local Alignment Search Tool at the National Center for Biological Information), ALIGN, AMAS (Analysis of Multiply Aligned Sequences), AMPS (Protein Multiple Sequence Alignment), ASSET (Aligned Segment Statistical Evaluation Tool), BANDS, BESTSCOR, BIOSCAN (Biological Sequence Comparative Analysis Node), BLIMPS (BLOCKS IMPROVED Searcher), FASTA, Intervals & Points, BMB, CLUSTAL V, CLUSTAL W, CONSENSUS, LCONSENSUS, WCONSENSUS, Smith-Waterman algorithm, DARWIN, Las Vegas algorithm, FNAT (Forced Nucleotide Alignment Tool), Framealign, Framesearch, DYNAMIC, FILTER, FSAP (Fristensky Sequence Analysis Package), GAP (Global Alignment Program), GENAL, GIBBS, GenQuest, ISSC (Sensitive Sequence Comparison), LALIGN (Local Sequence Alignment), LCP (Local Content Program), MACAW (Multiple Alignment Construction & Analysis Workbench), MAP (Multiple Alignment Program), MBLKP, MBLKN, PIMA (Pattern-Induced Multi-sequence Alignment), SAGA (Sequence Alignment by Genetic Algorithm) and WHAT-IF.

A polypeptide may be substantially related but for a conservative variation, such polypeptides being encompassed by the invention. A conservative variation denotes the replacement of an amino acid residue by another, biologically similar residue. Examples of conservative variations include the substitution of one hydrophobic residue such as isoleucine, valine, leucine or methionine for another, or the substitution of one polar

residue for another, such as the substitution of arginine for lysine, glutamic for aspartic acids, or glutamine for asparagine, and the like. Other illustrative examples of conservative substitutions include the changes of: alanine to serine; arginine to lysine; asparagine to glutamine or histidine; aspartate to glutamate; cysteine to serine; glutamine
5 to asparagine; glutamate to aspartate; glycine to proline; histidine to asparagine or glutamine; isoleucine to leucine or valine; leucine to valine or isoleucine; lysine to arginine, glutamine, or glutamate; methionine to leucine or isoleucine; phenylalanine to tyrosine, leucine or methionine; serine to threonine; threonine to serine; tryptophan to tyrosine; tyrosine to tryptophan or phenylalanine; valine to isoleucine to leucine. The
10 term "conservative variation" also includes the use of a substituted amino acid in place of an unsubstituted parent amino acid provided that antibodies raised to the substituted polypeptide also immunoreact with the unsubstituted polypeptide.

Modifications and substitutions are not limited to replacement of amino acids.
15 For a variety of purposes, such as increased stability, solubility, or configuration concerns, one skilled in the art will recognize the need to introduce, (by deletion, replacement, or addition) other modifications. Examples of such other modifications include incorporation of rare amino acids, dextra-amino acids, glycosylation sites, cytosine for specific disulfide bridge formation. The modified peptides can be
20 chemically synthesized, or the isolated gene can be site-directed mutagenized, or a synthetic gene can be synthesized and expressed in bacteria, yeast, baculovirus, tissue culture and so on.

Solid-phase chemical peptide synthesis methods can also be used to synthesize the polypeptide or fragments of the invention. Such method have been known in the art
25 since the early 1960's (Merrifield, R. B., *J. Am. Chem. Soc.*, 85, 2149-2154 (1963) (See also Stewart, J. M. and Young, J. D., *Solid Phase Peptide Synthesis*, 2 ed., Pierce Chemical Co., Rockford, Ill., pp. 11-12)) and have recently been employed in commercially available laboratory peptide design and synthesis kits (Cambridge Research Biochemicals). Such commercially available laboratory kits have generally
30 utilized the teachings of H. M. Geysen *et al*, *Proc. Natl. Acad. Sci., USA*, 81, 3998 (1984) and provide for synthesizing peptides upon the tips of a multitude of "rods" or

“pins” all of which are connected to a single plate. When such a system is utilized, a plate of rods or pins is inverted and inserted into a second plate of corresponding wells or reservoirs, which contain solutions for attaching or anchoring an appropriate amino acid to the pin's or rod's tips. By repeating such a process step, *i.e.*, inverting and inserting the rod's and pin's tips into appropriate solutions, amino acids are built into desired peptides. In addition, a number of available Fmoc peptide synthesis systems are available. For example, assembly of a polypeptide or fragment can be carried out on a solid support using an Applied Biosystems, Inc. Model 431A automated peptide synthesizer. For example, if the peptide is from formula I or formula II (see below), a preferred means for synthesizing peptides of 10-18 amino acids in length is by direct peptide synthesis generally starting with the N-terminal amino acid and adding amino acids in the C terminal direction. TGF α has been made using recombinant techniques and is available as a laboratory reagent commercially. The bifunctional compounds of formula III are best synthesized with each loop peptide moiety synthesized and then added to the heterocyclic nitrogen atom using standard heterocyclic addition synthesis.

TGF- α Peptide Mimics

The functional peptides of the invention are based upon the discovery that a loop peptide of TGF- α exhibits TGF- α biological activity and can therefore stimulate CNS multipotent precursor cells to divide and migrate through the brain. This activity indicates that the loop peptide is effective to treat neurological deficits caused by a wide variety of diseases and injuries that each result in a neurological deficit in some specific area of the brain or specific kind of neuron. These include degenerative diseases, including the more common Alzheimer's Disease (AD), Parkinson's Disease (PD), and Huntington's Disease (HD), and the less common Pick's disease, progressive supranuclear palsy, striatonigral degeneration, cortico-basal degeneration, olivopontocerebellar atrophy, Leigh's disease, infantile necrotizing encephalomyelopathy, Hunter's disease, mucopolysaccharidosis, various leukodystrophies (such as Krabbe's disease, Pelizaeus-Merzbacher disease and the like), amaurotic (familial) idiocy, Kuf's disease, Spielmayer-Vogt disease, Tay Sachs disease, Batten disease, Jansky-Bielschowsky disease, Reye's disease, cerebral ataxia,

chronic alcoholism, beriberi, Hallervorden-Spatz syndrome, cerebellar degeneration, and the like.


Further, injuries (traumatic or neurotoxic) that cause a loss of neuronal
5 function can be treated by the functional peptides. Such injuries include, for example, gunshot wounds, injuries caused by blunt force, penetration injuries, injuries caused by surgical procedure (*e.g.*, tumor removal, abscess removal, epilepsy lesion removal) poisoning (*e.g.*, carbon monoxide), shaken baby syndrome, adverse reactions to medications, drug overdoses, and post-traumatic encephalopathy. Ischemia can
10 further cause CNS injury due to disruption of blood flow or oxygen delivery that can kill or injure neurons and glial cells (*e.g.*, TGF- α confers protection from ischemia in a porcine gastrointestinal model and a family member, Heparin-binding EGF, confers protection from ischemia in a rat stroke model). Such injuries can be treated by administration of the functional peptides and include, for example, injuries caused by
15 stroke, anoxia, hypoxia, partial drowning, myoclonus, severe smoke inhalation, dystonias, and acquired hydrocephalus. Developmental disorders that can be treated by the functional peptides include, for example, schizophrenia, certain forms of severe mental retardation, cerebral palsy, congenital hydrocephalus, severe autism, Downs Syndrome, LHRH/hypothalamic disorder, and spina bifida. The functional peptides
20 can be further used to treat disorders affecting vision caused by the loss or failure of retinal cells and include, for example, diabetic retinopathy, serious retinal detachment (associated with glaucoma), traumatic injury to the retina, retinal vascular occlusion, macular degeneration, optic nerve atrophy and other retinal degenerative diseases. Injuries to the spinal cord can be treated by the functional peptides. Examples of
25 spinal cord injuries are post-polio syndrome, amyotrophic lateral sclerosis, traumatic injury, surgical injury, and paralytic diseases. Demyelinating autoimmune disorders can be treated by administration of the functional peptides and include, for example, multiple sclerosis. Lastly, the functional peptides can be used to treat neurological deficits caused by infection of inflammatory diseases, including, for example,
30 Creutzfeldt-Jacob disease and other slow virus infectious diseases of the CNS, AIDS encephalopathy, post-encephalitic Parkinsonism, viral encephalitis, bacterial meningitis and other CNS effects of infectious diseases.

By “functional” as used in connection with the peptides or peptide fragments of the invention is meant that the peptides or fragments have TGF α activity. This biological activity is associated with the peptides of formula I, formula II and formula
 5 III and the data available for TGF α .

Generally, the terms “treating”, “treatment” and the like are used herein to mean affecting a subject, tissue or cell to obtain a desired pharmacologic and/or physiologic effect. The effect may be prophylactic in terms of completely or partially preventing a disease or disorder or sign or symptom thereof, and/or may be therapeutic in terms of a
 10 partial or complete cure for a disorder or disease and/or adverse effect attributable to the disorder or disease. “Treating” as used herein covers any treatment of, or prevention of, or inhibition of a disorder or disease in a subject. The subject can be an invertebrate, a vertebrate, a mammal, and particularly a human, and includes by way of example: (a) preventing the disease or disorder from occurring in a subject that may be predisposed to
 15 the disease or disorder, but has not yet been diagnosed as having it; (b) inhibiting the disease or disorder, *i.e.*, arresting its progression; or (c) relieving or ameliorating the disease or disorder, *i.e.*, causing regression.

The invention also provides methods of modulating weight-loss associated with disease and disorders of the gastrointestinal tract, for example, those associated
 20 with viral infections and chemotherapy by administering TGF- α or related polypeptides or fragments thereof which retain TGF- α biological activity (*e.g.*, SEQ ID NO:1, 2, or 3, and the peptides of formula I, II, or III).

The invention provides a peptide having TGF α biological activity, comprising
 25 at least an 11-membered peptide compound of formula I (SEQ ID NO:4):



wherein X₁ is independently Val, Gly or Ala, wherein X₂ is Tyr or Phe, wherein X₃ is
 30 Arg or Lys, and wherein the two Cys moieties form a disulfide bond to create an 11-

amino acid functional peptide having a 10 member loop structure. In addition, at least one or more of the following amino acids of formula II (SEQ ID NO:5) may be added to the C terminus Cys moiety of formula I (SEQ ID NO:4):

$$5 \quad -X_4 - \text{His} - X_{1c} - X_4 - X_5 - X_6 - X_{1c} \quad (\text{II})$$

wherein X₄ is Glu or Asp, wherein X₅ is Leu or Ile, and wherein X₆ is Asp or Glu. Preferably, X_{1a} is Val, X_{1b} is Gly and X_{1c} is Ala thereby producing an 11, 12, 13, 14, 15, 16, 17 or 18 amino acid peptide. Preferably, X₂ is Tyr, and X₃ is Arg.


10 Accordingly, in one embodiment the functional peptide of the invention has a sequence:

NH₂-X_{1a}-Cys-His-Ser-X_{1b}-X₂-X_{1a}-X_{1b}-X_{1a}-X₃-Cys-X₄-His-X_{1c}-X₄-X₅-X₆-X_{1c}-COOH
(SEQ ID NO:6)


SEQ ID NO:6 forms a 10 member loop structure with a 7 member tail that can be varied in length. In addition, SEQ ID NO:6 can form dimers comprising, for example, a 34-mer peptide. Accordingly, the functional peptide can be from about 10 to 18 amino acids in length (*e.g.*, 10, 11, 12, 13, 14, 15, 16, 17, or 18 amino acids) wherein X_{1a} is Val, X_{1b} is Gly, X_{1c} is Ala and X₄ is Gly and may also comprise hetero- or homo-dimers of various TGF- α peptides described herein. Such dimers may have greater or reduced activities as compared to monomers.

The invention further provides a pharmaceutical composition comprising a peptide in a pharmaceutically acceptable carrier, wherein the peptide compound comprises at least about a 10 to 18-membered peptide compound of formula I (SEQ ID NO:4, including members of SEQ ID NO:5 attached to SEQ ID NO:4 and including SEQ ID NO:6). Preferably, at least one or more of the seven amino acids of formula II are added to the C terminus Cys moiety. Most preferably, the functional peptide is 18 amino acids in length wherein X_{1a} is Val, X_{1b} is Gly, X_{1c} is Ala and X₄ is Gly. The peptides described herein are all useful in the methods of the invention.

The invention further provides a method for treating a neurodegenerative disease with a pharmaceutically active TGF- α polypeptide, functional fragment peptide thereof or a pharmaceutically active TGF- α 57 polypeptide, wherein the peptide comprises at least an 11-membered peptide compound of formula I or a
 5 polypeptide of formula III, wherein formula I (SEQ ID NO:4) is:




wherein X_1 is independently Val, Gly or Ala, wherein X_2 is Try or Phe, wherein X_3 is
 10 Arg or Lys, and wherein the two Cys moieties form a disulfide bond to create an 11-amino acid functional peptide; and wherein formula III is:



15 wherein the linker moiety is designed to link the N-terminus of the Loop peptide to a nitrogen atom of the ring $\text{C}_4\text{H}_8\text{N}_2$ and wherein the "loop peptide" comprises at least an 11-membered peptide compound of formula I (SEQ ID NO:4); wherein X_1 is independently Val, Gly or Ala, wherein X_2 is Try or Phe, wherein X_3 is Arg or Lys,
 20 and wherein the two Cys moieties form a disulfide bond to create an 11-amino acid functional peptide having TGF- α activity. Furthermore, the functional peptides of the invention, as described above (*e.g.*, SEQ ID Nos: 4, 5, and 6), having from about 10 to 18 amino acids in length (*e.g.*, 10, 11, 12, 13, 14, 15, 16, 17, or 18 amino acids) wherein X_{1a} is Val, X_{1b} is Gly, X_{1c} is Ala and X_4 is Gly and hetero- or homo-dimers
 25 of the various TGF- α peptides described herein can be used in the methods of the invention.


The invention further provides a method for treating a neurodegenerative disease with an pharmaceutically active TGF- α 57 polypeptide (SEQ ID NO:3),
 30 wherein TGF- α 57 is a 57 amino acid polypeptide having the formula IV:




wherein human TGF α is a 50 amino acid polypeptide having a sequence as set forth in SEQ ID NO:1.

5 The invention further provides a method for treating a CNS disease or disorder, wherein the CNS disease or disorder includes CNS ischemia, spinal cord injury, MS, and retinal injury, with a pharmaceutically active TGF α peptide or a TGF α 57 polypeptide, wherein the peptide comprises at least an 11-membered peptide compound of formula I (SEQ ID NO:4):


10



wherein X₁ is independently Val, Gly or Ala, wherein X₂ is Try or Phe, wherein X₃ is Arg or Lys, and wherein the two Cys moieties form a disulfide bond to create an 11-
15 amino acid functional TGF- α peptide; and wherein TGF- α 57 is a 57 amino acid polypeptide having the formula IV:



20 wherein human TGF α is a 50 amino acid polypeptide having the formula of SEQ ID NO:1. Preferably, at least one or more of the following amino acids from formula II are added to the C terminus Cys moiety of formula I:




25

wherein X₄ is Glu or Asp, wherein X₅ is Leu or Ile, and wherein X₆ is Asp or Glu. Preferably, X_{1a} is Val, X_{1b} is Gly and X_{1c} is Ala. Preferably, X₂ is Tyr, and X₃ is Arg. Most preferably, the functional peptide is 18 amino acids in length wherein X_{1a} is Val,
30 X_{1b} is Gly, X_{1c} is Ala and X₄ is Gly. Furthermore, the functional peptides of the invention, as described above (*e.g.*, SEQ ID Nos: 4, 5, and 6), having from about 10


to 18 amino acids in length (*e.g.*, 10, 11, 12, 13, 14, 15, 16, 17, or 18 amino acids) wherein X_{1a} is Val, X_{1b} is Gly, X_{1c} is Ala and X₄ is Gly and hetero- or homo-dimers of the various TGF- α peptides described herein can be used in the methods for treating a CNS disease or disorder.

5

The invention further provides a method for enhancing hematopoiesis and myelopoiesis during cytotoxic or immune-suppressing therapy, comprising administering a TGF α polypeptide (SEQ ID NO:1), a TGF α 57 polypeptide (*i.e.*, formula IV), a functional TGF- α peptide thereof, or a combination thereof, wherein
10 the peptide comprises at least an 11-membered peptide compound of formula I (SEQ ID NO:4):



wherein X₁ is independently Val, Gly or Ala, wherein X₂ is Try or Phe, wherein X₃ is
15 Arg or Lys, and wherein the two Cys moieties form a disulfide bond to create an 11-amino acid functional TGF- α peptide. Preferably, at least one or more of the following amino acids of formula II are added to the C terminus Cys moiety of formula I:




wherein X₄ is Glu or Asp, wherein X₅ is Leu or Ile, and wherein X₆ is Asp or Glu. Preferably, X_{1a} is Val, X_{1b} is Gly and X_{1c} is Ala. Preferably, X₂ is Tyr, and X₃ is Arg.
25 Most preferably, the functional peptide is 18 amino acids in length wherein X_{1a} is Val, X_{1b} is Gly, X_{1c} is Ala and X₄ is Gly. Furthermore, the functional peptides of the invention, as described above (*e.g.*, SEQ ID Nos: 4, 5, and 6), having from about 10 to 18 amino acids in length (*e.g.*, 10, 11, 12, 13, 14, 15, 16, 17, or 18 amino acids) wherein X_{1a} is Val, X_{1b} is Gly, X_{1c} is Ala and X₄ is Gly and hetero- or homo-dimers
30 of the various TGF- α peptides described herein can be used in the methods for enhancing hematopoiesis or myelopoiesis. Preferably, the invention further comprises administering a second hematopoietic growth factor agent to stimulate


more mature hematopoietic precursor cells, wherein the second hematopoietic growth factor includes erythropoietin, thrombopoietin, G-CSF (granulocyte colony stimulating factor), and GM-CSF (granulocyte macrophage colony stimulating factor).

5

The invention further provides a method for treating or preventing mucositis of the gastrointestinal tract caused by cytotoxic or immune-suppressing therapy, comprising administering a TGF- α polypeptide (SEQ ID NO:1), a TGF- α 57 polypeptide (*i.e.*, formula IV), a functional TGF- α peptide thereof, or combinations thereof, wherein the peptide comprises at least an 11-membered peptide compound of formula I (SEQ ID NO:4):



wherein X_{1a} and X_{1b} are independently Val, Gly or Ala; X_2 is Tyr or Phe; X_3 is Arg or Lys; and the two Cys moieties are linked via a disulfide bond to form an at least 11-amino acid functional peptide having TGF- α activity. Preferably, at least one or more of the following amino acids are added to the C terminus Cys moiety from formula II:



wherein X_4 is Glu or Asp, wherein X_5 is Leu or Ile, and wherein X_6 is Asp or Glu. Preferably, X_{1a} is Val, X_{1b} is Gly and X_{1c} is Ala. Preferably, X_2 is Tyr, and X_3 is Arg. Most preferably, the functional peptide is 18 amino acids in length wherein X_{1a} is Val, X_{1b} is Gly, X_{1c} is Ala and X_4 is Gly. Furthermore, the functional peptides of the invention, as described above (*e.g.*, SEQ ID Nos: 4, 5, and 6), having from about 10 to 18 amino acids in length (*e.g.*, 10, 11, 12, 13, 14, 15, 16, 17, or 18 amino acids) wherein X_{1a} is Val, X_{1b} is Gly, X_{1c} is Ala and X_4 is Gly and hetero- or homo-dimers of the various TGF- α peptides described herein can be used in the methods for treating or preventing mucositis.

The invention further provides a bifunctional compound that acts as a TGF α mimetic, comprising a compound of formula III:

Loop peptide N-terminus -linker- cyclic C₄H₈N₂ -linker- Loop peptide N-terminus
(III)

wherein the linker moiety is designed to link the N-terminus of the Loop peptide to a nitrogen atom of the ring C₄H₈N₂ and wherein the "loop peptide" comprises at least an 11-membered peptide compound of formula I:

NH₂- X_{1a} - Cys - His - Ser - X_{1b} - X₂ - X_{1a} - X_{1b} - X_{1a} - X₃ - Cys COOH (I)


wherein X_{1a} and X_{1b} are independently Val, Gly or Ala; X₂ is Tyr or Phe; X₃ is Arg or Lys; and the two Cys moieties are linked via a disulfide bond to form an at least 11-amino acid functional peptide having TGF- α activity. Preferably, at least one or more of the following amino acids are added to the C terminus Cys moiety from formula II:

- X₄ - His - X_{1c} - X₄ - X₅ - X₆ - X_{1c}
(II)

wherein X₄ is Glu or Asp, wherein X₅ is Leu or Ile, and wherein X₆ is Asp or Glu. Preferably, X_{1a} is Val, X_{1b} is Gly and X_{1c} is Ala. Preferably, the linker group is independently selected from the group consisting of substituted or unsubstituted C₁₋₆ alkyl, substituted or unsubstituted C₂₋₆ alkenyl, substituted or unsubstituted C₁₋₆ alkoxy, xylenyl, wherein the substitutions are selected from the group consisting of oxo, epoxyl, hydroxyl, chloryl, bromyl, fluoryl, and amino. Preferably, X₂ is Tyr, and X₃ is Arg. Most preferably, the functional peptide is 18 amino acids in length wherein X_{1a} is Val, X_{1b} is Gly, X_{1c} is Ala and X₄ is Gly.

The invention further provides a method for treating inflammatory bowel disease, colitis, and Chron's Disease of the gastrointestinal tract, comprising administering a TGF- α polypeptide (SEQ ID NO:1), a TGF- α 57 polypeptide (formula


IV), a functional TGF- α peptide thereof, or combinations thereof, wherein the peptide comprises at least an 11-membered peptide compound of formula I:



5

wherein X_1 is independently Val, Gly or Ala, wherein X_2 is Try or Phe, wherein X_3 is Arg or Lys, and wherein the two Cys moieties form a disulfide bond to create an 11-amino acid functional TGF- α peptide. Preferably, at least one or more of the following amino acids are added to the C terminus Cys moiety from formula II:

10




wherein X_4 is Glu or Asp, wherein X_5 is Leu or Ile, and wherein X_6 is Asp or Glu.

Preferably, X_{1a} is Val, X_{1b} is Gly and X_{1c} is Ala. Preferably, X_2 is Tyr, and X_3 is Arg.

15 Most preferably, the functional peptide is 18 amino acids in length wherein X_{1a} is Val, X_{1b} is Gly, X_{1c} is Ala and X_4 is Gly. Furthermore, the functional peptides of the invention, as described above (*e.g.*, SEQ ID Nos: 4, 5, and 6), having from about 10 to 18 amino acids in length (*e.g.*, 10, 11, 12, 13, 14, 15, 16, 17, or 18 amino acids) wherein X_{1a} is Val, X_{1b} is Gly, X_{1c} is Ala and X_4 is Gly and hetero- or homo-dimers
20 of the various TGF- α peptides described herein can be used in the methods for treating a inflammatory bowel disease, colitis, Chron's Disease and the like.


The invention further provides a method for treating an inflammatory reaction or autoimmune diseases resulting in weight-loss, comprising administering a TGF α
25 polypeptide (SEQ ID NO:1), a TGF α 57 polypeptide (formula IV), a functional TGF- α peptide thereof, or combinations thereof, wherein the peptide comprises at least an 11-membered peptide compound of formula I:



30

wherein X_1 is independently Val, Gly or Ala, wherein X_2 is Try or Phe, wherein X_3 is Arg or Lys, and wherein the two Cys moieties form a disulfide bond to create an 11-

amino acid functional TGF- α peptide. Preferably, at least one or more of the following amino acids are added to the C terminus Cys moiety from formula II (SEQ ID NO:5):



wherein X₄ is Glu or Asp, wherein X₅ is Leu or Ile, and wherein X₆ is Asp or Glu. Preferably, X_{1a} is Val, X_{1b} is Gly and X_{1c} is Ala. Preferably, X₂ is Tyr, and X₃ is Arg. Most preferably, the functional peptide is 18 amino acids in length wherein X_{1a} is Val, X_{1b} is Gly, X_{1c} is Ala and X₄ is Gly. Furthermore, the functional peptides of the invention, as described above (*e.g.*, SEQ ID Nos: 4, 5, and 6), having from about 10 to 18 amino acids in length (*e.g.*, 10, 11, 12, 13, 14, 15, 16, 17, or 18 amino acids) wherein X_{1a} is Val, X_{1b} is Gly, X_{1c} is Ala and X₄ is Gly and hetero- or homo-dimers of the various TGF- α peptides described herein can be used in the methods for treating an autoimmune disease or inflammatory disorder. Preferably, the autoimmune diseases includes Type II (Juvenile) Diabetes, rheumatoid arthritis, lupus, HIV-associated disorders (*e.g.*, AIDS) and multiple sclerosis.

Gene Therapy and Gene Delivery

The TGF- α polypeptides (e.g., SEQ ID NO:1), TGF- α 57 polypeptide, and functional TGF- α peptides thereof are particularly suited for delivery to a subject by means of a nucleic acid gene expression system *ex vivo* or *in vivo*. A variety of transfection techniques are currently available and used to transfer DNA *in vitro* into cells; including calcium phosphate-DNA precipitation, DEAE-Dextran transfection, electroporation, liposome mediated DNA transfer or transduction with recombinant viral vectors. Such *ex vivo* treatment protocols have been used to transfer DNA into a variety of different cell types including epithelial cells (U.S. Pat. No. 4,868,116; Morgan and Mulligan WO87/00201; Morgan *et al.*, 1987, *Science* 237:1476-1479; Morgan and Mulligan, U.S. Pat. No. 4,980,286), endothelial cells (WO89/05345), hepatocytes (WO89/07136; Wolff *et al.*, 1987, *Proc. Natl. Acad. Sci. USA* 84:3344-3348; Ledley *et al.*, 1987 *Proc. Natl. Acad. Sci.* 84:5335-5339; Wilson and Mulligan,

WO89/07136; Wilson *et al.*, 1990, *Proc. Natl. Acad. Sci.* 87:8437-8441) fibroblasts (Palmer *et al.*, 1987, *Proc. Natl. Acad. Sci. USA* 84:1055-1059; Anson *et al.*, 1987, *Mol. Biol. Med.* 4:11-20; Rosenberg *et al.*, 1988, *Science* 242:1575-1578; Naughton & Naughton, U.S. Pat. No. 4,963,489), lymphocytes (Anderson *et al.*, U.S. Pat. No. 5,399,346; Blaese, R. M. *et al.*, 1995, *Science* 270:475-480) and hematopoietic stem cells (Lim, B. *et al.* 1989, *Proc. Natl. Acad. Sci. USA* 86:8892-8896; Anderson *et al.*, U.S. Pat. No. 5,399,346). A summary of typical protocols, methodology, and vectors is provided in "The Development of Human Gene Therapy," Ed. Theodore Friedmann, Cold Spring Harbor Laboratory Press, New York, 1999, the disclosure of which is incorporated herein.

Direct *in vivo* gene transfer has recently been attempted with formulations of DNA trapped in liposomes (Ledley *et al.*, 1987, *J. Pediatrics* 110:1); or in proteoliposomes that contain viral envelope receptor proteins (Nicolau *et al.*, 1983, *Proc. Natl. Acad. Sci. U.S.A.* 80:1068); and DNA coupled to a polylysine-glycoprotein carrier complex. In addition, "gene guns" have been used for gene delivery into cells (Australian Patent No. 9068389). Naked DNA, or DNA associated with liposomes, can be formulated in liquid carrier solutions for injection into interstitial spaces for transfer of DNA into cells (Felgner, WO90/11092).

As described above, polynucleotide sequences encoding a TGF- α polypeptide or function peptide fragment, can be cloned into vectors suitable for delivery to host cells for expression. In particular retroviral vectors containing the polypeptides of the invention are particularly suitable for delivering polynucleotides to cells for gene therapy. Current strategies for gene therapy are reviewed in "The Development of Human Gene Therapy," Ed. Theodore Friedmann, Cold Spring Harbor Laboratory Press, New York, 1999, the disclosure of which is incorporated herein.

Delivery of a polynucleotide of interest may be accomplished *in vivo* by administration of the vectors to an individual subject, typically by systemic administration (*e.g.*, intravenous, intraperitoneal, intramuscular, subdermal, or intracranial infusion). Alternatively, the vectors may be used to deliver polynucleotides to cells *ex vivo* such as cells explanted from an individual patient

(e.g., tumor-infiltrating lymphocytes, bone marrow aspirates, tissue biopsy) or universal donor hematopoietic stem cells, followed by reimplantation of the cells into a patient, usually after selection for cells which have incorporated the polynucleotide.

5 The vectors may be used for gene therapy to reduce the incidence of weight-loss and associated disorders resulting from particular diseases (e.g., cancer), or viral diseases (e.g., AIDS, mononucleosis, herpesvirus infection, cytomegalovirus infection, papillomavirus infection) or to modify the genome of selected types of cells of a patient for any therapeutic benefit.

10 The vectors of the invention can be used to introduce polynucleotides into a variety of cells and tissues including myeloid cells, bone marrow cells, lymphocytes, hepatocytes, fibroblasts, lung cells, epithelial cells and muscle cells. For example, polynucleotides encoding a TGF- α polypeptide may be transferred to stem cells.

Pharmaceutical Composition and Formulations

15 The invention includes various pharmaceutical compositions useful for delivery or administration of the peptides of the invention. In one embodiment the pharmaceutical composition are useful in treating or preventing weight-loss associated with a disorder or disease. Such disorders or diseases include weight-loss attributable to, for example, chemotherapy or a viral infection (e.g., HIV). The pharmaceutical compositions according to the invention are prepared by bringing a polypeptide or
20 peptide derivative of TGF- α , a TGF- α mimetic into a form suitable for administration to a subject using carriers, excipients and additives or auxiliaries. Frequently used carriers or auxiliaries include magnesium carbonate, titanium dioxide, lactose, mannitol and other sugars, talc, milk protein, gelatin, starch, vitamins, cellulose and its derivatives, animal and vegetable oils, polyethylene glycols and solvents, such as sterile water,
25 alcohols, glycerol and polyhydric alcohols. Intravenous vehicles include fluid and nutrient replenishers. Preservatives include antimicrobial, anti-oxidants, chelating agents and inert gases. Other pharmaceutically acceptable carriers include aqueous solutions, non-toxic excipients, including salts, preservatives, buffers and the like, as described, for instance, in Remington's Pharmaceutical Sciences, 15th ed. Easton: Mack Publishing
30 Co., 1405-1412, 1461-1487 (1975) and The National Formulary XIV., 14th ed.

Washington: American Pharmaceutical Association (1975), the contents of which are hereby incorporated by reference. The pH and exact concentration of the various components of the pharmaceutical composition are adjusted according to routine skills in the art. See Goodman and Gilman's The Pharmacological Basis for Therapeutics (7th ed.).

The pharmaceutical compositions are preferably prepared and administered in dose units. Solid dose units are tablets, capsules and suppositories and including, for example, alginate based pH dependent release gel caps. For treatment of a subject, depending on activity of the compound, manner of administration, nature and severity of the disorder, age and body weight of the subject, different daily doses are necessary. Under certain circumstances, however, higher or lower daily doses may be appropriate. The administration of the daily dose can be carried out both by single administration in the form of an individual dose unit or by several smaller dose units and also by multiple administration of subdivided doses at specific intervals.

The pharmaceutical compositions according to the invention may be administered locally or systemically in a therapeutically effective dose. Amounts effective for this use will, of course, depend on the severity of the disease and the weight and general state of the subject. Typically, dosages used *in vitro* may provide useful guidance in the amounts useful for *in situ* administration of the pharmaceutical composition, and animal models may be used to determine effective dosages for treatment of particular disorders. Various considerations are described, *e.g.*, in Langer, Science, 249: 1527, (1990); Gilman *et al.* (eds.) (1990), each of which is herein incorporated by reference.

In one embodiment, the invention provides a pharmaceutical composition useful for administering a TGF- α polypeptide or functional fragment, or a nucleic acid encoding a TGF- α polypeptide or functional fragment, to a subject in need of such treatment. "Administering" the pharmaceutical composition of the invention may be accomplished by any means known to the skilled artisan. Preferably a "subject" refers to a mammal, most preferably a human.

The TGF- α polypeptide or functional fragment can be administered parenterally, enterically, by injection, rapid infusion, nasopharyngeal absorption, dermal absorption, rectally and orally. Pharmaceutically acceptable carrier preparations for parenteral administration include sterile or aqueous or non-aqueous solutions, suspensions, and emulsions. Examples of non-aqueous solvents are propylene glycol, polyethylene glycol, vegetable oils such as olive oil, and injectable organic esters such as ethyl oleate. Carriers for occlusive dressings can be used to increase skin permeability and enhance antigen absorption. Liquid dosage forms for oral administration may generally comprise a liposome solution containing the liquid dosage form. Suitable solid or liquid pharmaceutical preparation forms are, for example, granules, powders, tablets, coated tablets, (micro)capsules, suppositories, syrups, emulsions, suspensions, creams, aerosols, drops or injectable solution in ampule form and also preparations with protracted release of active compounds, in whose preparation excipients and additives and/or auxiliaries such as disintegrants, binders, coating agents, swelling agents, lubricants, flavorings, sweeteners and elixirs containing inert diluents commonly used in the art, such as purified water. Where the disease or disorder is a gastrointestinal disorder oral formulations or suppository formulations are preferred.

Sterile injectable solutions can be prepared by incorporating the active agent (see formula I, formula II, or formula III and TGF α) in the required amount (*e.g.*, about 10 μ g to about 10 mg/kg) in an appropriate solvent and then sterilizing, such as by sterile filtration. Further, powders can be prepared by standard techniques such as freeze drying or vacuum drying.

In another embodiment, the active agent is prepared with a biodegradable carrier for sustained release characteristics for either sustained release in the GI tract or for target organ implantation with long term active agent release characteristics to the intended site of activity. Biodegradable polymers include, for example, ethylene vinyl acetate, polyanhydrides, polyglycolic acids, polylactic acids, collagen, polyorthoesters, and poly acetic acid. Liposomal formulation can also be used.

The invention will now be described in greater detail by reference to the following non-limiting examples.

EXAMPLE 1

5 Each of the three loop regions in human TGF α was investigated for TGF α -like biological activity, such as stimulation of cellular proliferation as measured by ^3H thymidine incorporation of stem cells. As shown in Figure 2, only the Loop C peptide (corresponding to amino acids 33-50) showed significant TGF- α biological activity as compared to data obtained with TGF- α 50 amino acid polypeptide or even the altered
10 splice 57 amino acid polypeptide and is therefore a TGF- α mimetic peptide. Accordingly, data from TGF α or TGF- α 57 show what can be called "TGF- α activity" and that these are predictive of activity of the functional TGF- α peptide and similar functional TGF- α peptides embodied in the genus of formula I with or without the addition of a "tail" region of formula II. These data predict activity for the functional
15 TGF- α peptides when activity is also shown for TGF- α or for TGF- α 57.

EXAMPLE 2

Hematopoiesis

 TGF- α and related polypeptides, such as TGF- α 57, showed surprising
20 enhancing activity in an *in vivo* model of general hematopoiesis when administered in conjunction with a potent cytotoxic agent Cis Platinum (CP). Figure 3 shows a graph of mouse spleen weights that were treated with CP at either 5 $\mu\text{g/g}$ or 10 $\mu\text{g/g}$ and with TGF- α 57 at concentrations of 10 ng/g or 50 ng/g. These data show that TGF- α 57 treatment caused a return to normal spleen weights despite CP treatment that
25 reduced spleen weights significantly. This *in vivo* experiment is a predictive model for hematopoiesis in humans as CP is a cytotoxic agent commonly used for cancer chemotherapy that is known to significantly reduce trilineage hematopoietic cells. Hematopoietic and myeloid cells are red blood cell precursors, platelet precursors (megakaryocytes), and immune (white) blood cell precursors of various forms of T
30 cells, B cells and macrophages. Moreover, platelet counts were higher in those mice injected with TGF- α 57 (and CP) as opposed to CP alone were such counts were

significantly reduced from normal. It should be noted that references to TGF- α as a human 50 amino acid polypeptide further include reference to human TGF α 57 as an alternative variant.

5 The experiment procedure dosed those animals to be treated with TGF α 57 4 hours prior to challenge with CP. A single dose of CP was administered. Additional doses (as indicated) of TGF α 57 were made at 24 hours, 48 hours, 72 hours and 96 hours after the CP dose. All doses were made by IP injection. Controls were dosed with saline instead of either or both of CP and TGF- α 57.

10

 The animals were sacrificed about 4 hours after the last TGF- α 57 (or saline) dose. Key organs were removed and spleens were immediately weighed after a clean incision. All the relevant organs were placed in formalin, transported for histopathological analysis, mounted, sectioned, stained and observed. The results of this histological analysis of the spleens for hematopoietic effect and the GI tract (below) provided surprising and unexpected data of the effect of TGF- α 57 activity.

 H&E-stained spleens of a CP-treated mouse spleen (10 μ g/g) showed apoptotic cells (densely stained with fragments of nuclei) in the germinal center (GC). T cells in the central arterial area showed the absence of a marginal zone and much fewer erythrocytes and T cells in the perifollicular area. A normal mouse spleen (no CP and no TGF- α 57) fixed in formalin showed an arteriole enriched for T cell progenitors. There was erythrocytes in the perifollicular zone surrounding both the T cell and B cell compartments of white pulp. A mouse spleen treated with CP (10 μ g/g) and TGF- α 57 (50 ng/g) showed an increased number of T cells and erythrocytes in the perifollicular zone. The T cells stained for the T-cell receptor but were negative for CD4 and CD8 markers. Accordingly, the T-cells are double null T-cell progenitors induced by TGF- α administration.

 These *in vivo* data in a predictive model of hematopoiesis and confirmed by blinded histological analysis (the histologist/pathologist was blinded as to the treatment history of the coded tissues received) providing surprising evidence of the

utility of peptides having TGF- α activity to augment hematopoiesis and genesis of immune cells following cytotoxic exposure. These data predict and provide a reasonable correlation that TGF- α and the peptides of formula I, formula II and formula III are useful therapeutic agents for enhancing hematopoiesis following or during cytotoxic therapy, such as cancer treatment. Therefore, a useful method for improving cancer chemotherapy is to combine either TGF- α or a peptide from formula I, formula II, formula III, of formula IV or combinations thereof with cytotoxic treatment regimens to reduce dose-limiting side effects of cytotoxic agents.

An additional experiment investigated TGF- α activity (using TGF- α 57) on human bone-marrow enriched CD34 cells. FACS-sorted human CD34 positive and CD38 negative cells were cultured in liquid primary cultures in Iscove's modified Dulbecco's media with supplements. TGF α (57) was added alone (10 ng/ml) and exhibited a 35% increase in CD34 positive progenitor cells. Stem Cell Factor (SCF) was used as a positive control (500 ng/ml) and provided a three-fold increase in CD34 positive cells. When a combination of SCF (500 ng/ml) and TGF α (10 ng/ml) was added, a synergistic 12-fold increase in CD34 positive cells was observed. An unexpected result was the stimulation of the proliferation of dendritic precursor cells in the TGF- α treated cultures.

EXAMPLE 3

Mucositis and Gastrointestinal Diseases

The small intestine comprises the duodenum, jejunum and ileum. It is the principal site for absorption of digestive products from the GI tract. Digestion begins in the stomach and is completed in the small intestine in association with the absorptive process. The intestinal mucosa surface is made up of numerous finger-like projections called villi. In addition, mucosal epithelium between the basis of the villi is formed into the crypts which contain stem cells.

TGF α or a peptide from formula I, formula II, formula III, or formula IV having TGF α activity or combinations thereof are also useful for treating mucositis

associated intestinal bleeding, dyspepsia caused by with cytotoxic therapy and for improving the barrier function of the GI tract compromised by cytotoxic therapy. The *in vivo* experiment with seven groups of mice described above for hematopoietic effects noted in spleens also examined the GI tract of these treated mice. Histological examination of mouse intestines showed the following: CP (single ip dose of 10 µg/g) treated intestine, when cross-sectioned, showed significant injury to the villi.

Specifically, the villi are necrotic, the crypts are in irregular shapes, and the tips of the crypts were exhibiting loss of cellular integrity. A cross section of a normal mouse GI tract (no CP and no TGFα57) showed a normal intestinal surface with villi having long and slender mucosal projections with a core of lamina propria covered by a luminal epithelial layer. A single row of intestinal crypt is found at the base of the mucosa. These crypts that lie between adjacent villi are surrounded by the same lamina propria that form the villous cores. Both columnar absorptive cells and goblet cells cover the villous surfaces. The goblet cells contain apical clear vacuoles. A cross section of a mouse intestine exposed to both the CP (10 µg/g) and TGFα57 (50 ng/g) showed that the intestinal structure was very similar to the normal intestinal structure. Specifically, the villus was long and slender. Both absorptive cells and goblet cells were visible at the surface of the villi, and there was an abundant amount of goblet cells on the surface.

A 160X magnification of the intestines of a CP-treated mouse, a normal mouse and a CP treated and TGFα57 treated mouse at the same doses as described above. The CP-treated mouse showed injured villi with degenerating and necrotic tips. Red blood cells were observed in the damaged villi. The crypts were irregularly shaped and in had various heights. The normal mouse showed smooth villi tips of the villi and nuclei of enterocytes were observed throughout the villus. The crypts were similar in height and had a regular shape. The CP treated and TGF-α treated mouse had normal appearing villi as described for the normal mouse. The crypts also appeared normal.

Further CP (10 µg/g) treated without TGF-α57 mice and CP (10 µg/g) and 50 ng/g of TGF-α57 treated mice intestines when examined under higher magnification showed severely injured crypt surfaces in the CP treated mice due to cell death and necrosis. Red cells were visible at the damaged surface indicating intestinal bleeding. In addition, the CP-treated mouse showed a loss of brush borders and very little of a glycocalyx or fuzzy coat. Goblet cells appeared interspersed, necrotic and fewer in number than normal. The effect of TGF-α treatment showed protection of the villi surface. Specifically, the epithelial cells appeared normal with extended brush borders. The nuclei were very densely stained and elongated.

The histological data is summarized in Figure 4 that measured average crypt height of the three groups of mice. TGFα57 and TGF-α (50 a.a.) treatment (50 ng/g) was able to more-than-restore crypt height loss from CP treatment.

An alcian blue staining method permitted differentiation of absorptive cells and goblet cells. Goblet cell mucus is stained a blue color while the absorptive cells remain less stained. Stains of intestine from normal mice, CP only treated (10 µg/g) and both CP (10 µg/g) and TGFα57 (50 ng/g) treated mice showed significant differences. In the normal intestine each villus extended from the luminal surface to the basal muscularis mucosal surface. Goblet cells were scattered and predominated in the base of the villus whereas columnar absorptive cells lined the luminal surface. In the CP treated mouse, the alcian blue staining showed villi that contained fewer number of goblet cells (than normal). The injured absorptive and goblet cells were degenerating at the tip of the villi and abundant secretory mucus material was stained in the luminal surface. In the CP/TGF-α mouse, there were an increased number of goblet cells scattered throughout the villi. The intestinal villi appeared normal with elongation. The majority of enterocytes did not appear to be alcian blue stained positive. The luminal plasma membranes of the villi were well protected by TGF-α treatment. The number of goblet cells was counted on the average unit length of intestine. TGFα treatment not only increased the number of goblet cells but also increased the number from CP treatment to a higher level than normal intestine.

Accordingly, these data show the effects of TGF α , and the functional peptides having TGF- α activity from formula I, formula II, formula III, and formula IV having therapeutic activity to treat or prevent mucositis associated with cytotoxic drug therapy and for inflammatory bowel diseases. Moreover, the histological effect showing that there was a prevention of mast cell degranulation, provides additional data supporting the gastrointestinal applications for TGF α , and the functional peptides having TGF- α activity of formula I, formula II, formula III, and formula IV.

EXAMPLE 4

10 Immune Related Diseases

In addition, TGF- α activity resulted in stimulation of proliferation of select immune cells (particularly of the T cell lineage) after administration to mice after immune-suppression of CP administration. The stimulated immune cells were phenotypically identified as CD4 positive T cells and double null CD4 negative CD8 negative T cell progenitors. Thus, TGF- α activity (*e.g.*, from TGF α 57 administration) resulted in generation of T-cells with characteristics that regulated immune functions. Therefore, these data predict that TGF α activity and the functional peptides of formula I, formula II, formula III, and formula IV will be effective in treating autoimmune diseases by mitigating over-inflammatory reactions.

20 The *in vivo* activity of TGF α (and the functional peptides of formula I, formula II, formula III, and formula IV) to stimulate early T cell progenitors in the release of TH-1 and TH-2 cytokines and this regulation of immune phenomena. The stimulation of select immune cells, in particular cells of a T cell lineage, was seen consistently in the mice who received CP and TGF- α 57 in lymphoid tissue, Peyer's Patches and the spleen. Further, recruitment of help via CD4 cells in some cases boosts immune system function in general.

TGF- α administration prevented mast cell degranulation and subsequent histamine release. In addition TGF- α has effects in downregulating TNF- α receptors *in vivo* and downregulating IL-6 and MIP *in vivo*, including blockign

neutrophil trafficking. This is a parallel activity that is in addition to the gastrointestinal anti-inflammatory activity and prevention of mucositis of TGF α (and the functional peptides of formula I, formula II, formula III, and formula IV) described herein.

5

EXAMPLE 5

In order to determine the effects of TGF- α polypeptides on weight-loss four groups of rats were tested. The experiment was designed to compare two of the peptides of TGF- α (SEQ ID NO:1 and SEQ ID NO:3) on weight-loss in the presence of a chemotherapeutic drug, cisplatin.

10 All animals were dosed over a period of 5 days. Group 1 animals received cisplatin at 10 μ g/g, Group 2 animals received cisplatin at 10 μ g/g plus TGF- α (SEQ ID NO:1) at 50 ng/g; Group 3 animals received cisplatin at 10 μ g/g plus TGF- α 57 (SEQ ID NO:3) at 50 ng/g; and Group 4 animals received TGF- α (SEQ ID NO:1) at 50 ng/g. Following completion of the dosing protocols animals from each group were measure
15 and organs/tissues were harvested and placed in buffered formalin. The tissues measured included lungs, spleens, kidneys, pancreas, intestines and tongues.

In the 9 animals in group 1 (cisplatin treatment), the average weight loss was 18.3%; in the 13 animals in groups 2 and 3 (cisplatin+TGF) the average weight loss was 12.1%; and in the 6 animals in group 4 (TGF alone) the average weight loss was 0.9%
20 (Figure 5).

In addition, studies of TGF- α for the treatment of diarrhea in non-human primates was also performed. A 6-year old non-human primate exhibiting chronic inflammatory-like gastrointestinal symptoms was treated with TGF- α at 300 ng/g intraperitoneally once and subsequently 50 ng/g S.C. for 6 days. The primate showed a
25 steady increase in stool consistency and the monkey showed steady weight gain through the treatment period (see Table 1 and 2). This weight gain was maintained at least for several weeks post treatment. In addition, the reduction of SEGs (see column 6, Table 1) neutrophils correlates with reduction in inflammation associated with neutrophil influx

and concomitant pro-inflammatory cytokines. No adverse effects were noted in hematology or serum chemistries, or in the primates attitude, behavior or appetite.

TABLE 1

Time	wt.	hemo- globin	pcv %	wbc	Seg	Bands	Lymph	Monos	Eos	Basos	Abn. Cells	Platelets	CD4 ⁺	CD8 ⁺	Dual CD8 ⁺ CD4 ⁺
1	5.80	12.6	40.3	16.6	76%	0%	19%	5%	0%	0%	0%	543	28.4%	56.3%	6.7%
2	6.33	11.1	38.0	20.2	69%	0%	20%	10%	1%	0%	0%	567			
3	6.74	9.2	32.1	10.3	61%	0%	34%	4%	1%	0%	0%	456	36.7%	53.1%	6.3%
4	8.21	10.3	34.2	8.4	48%	0%	42%	9%	1%	0%	0%	534	31.3%	54.0%	9.1%
5	8.93	10.8	37.1	11.2	46%	0%	45%	8%	0%	1%	0%	425	33.4%	49.8%	8.1%
6	9.42	11.5	38.1	15.5	56%	1%	31%	11%	1%	0%	0%	434	35.1%	50.3%	7.7%

TABLE 2

Time	Na ₊	K ⁺	Cl ⁻	Glu	BUN	Creatine	Total Protein	Albumin	Albumin corrected	Total Billirubin	Ca ²⁺	Alk Phos	ALT (GPT)	AST (GOT)	GGT
1	133	3.3	87	73	45	0.6	8.6	4.9	5.9	1.2	11.6	103	8	26	57
2	144	4.8	95	51	19	0.5	7.4	3.7	4.4						
3	146	4.6	107	68	16	0.5	7.2	2.9	3.5	0.3	9.8	116	17	45	89
4	150	4.4	107	50	19	0.7	7.1	2.9	3.5	0.3	9.7	130	25	34	91
5	148	4.0	108	25	18	0.6	6.6	2.5	3.0	0.2	9.1	107	19	37	64
6	145	3.8	108	21	22	0.5	7.0	2.5	3.0	0.3	9.3	113	15	34	58

Note: Blood glucose levels are generally well below the normal reference range. This is not an abnormality. Albumin results require a correction factor for non-human primates, which is calculated into the second "Albumin corrected" column.

While the invention has been described in detail with reference to certain preferred embodiments thereof, it will be understood that modifications and variations are within the spirit and scope of that which is described and claimed.

WHAT IS CLAIMED IS:

1. A polypeptide comprising a peptide having a sequence NH₂- X_{1a} - Cys
- His - Ser - X_{1b} - X₂ - X_{1a} - X_{1b} - X_{1a} - X₃ - Cys - COOH (SEQ ID
NO:4) wherein X_{1a} and X_{1b} are independently Val, Gly or Ala; X₂ is
5 Tyr or Phe; X₃ is Arg or Lys; and the two Cys moieties are linked via a
disulfide bond to form an at least 11-amino acid functional peptide
having TGF- α activity.
2. The polypeptide of claim 1, wherein at least one or more of the
10 following amino acids are linked to the C-terminal Cys moiety of SEQ
ID NO:4:
- X₄ - His - X_{1c} - X₄ - X₅ - X₆ - X_{1c} (SEQ ID NO:5) wherein X₄ is
Glu or Asp; X₅ is Leu or Ile; and X₆ is Asp or Glu.
3. The polypeptide of claim 2, wherein X_{1a} is Val, X_{1b} is Gly and X_{1c} is
15 Ala.
4. The polypeptide of claim 2, wherein X₂ is Tyr and X₃ is Arg.
5. The polypeptide of claim 2, wherein the functional peptide is 18 amino
20 acids in length and X_{1a} is Val, X_{1b} is Gly, X_{1c} is Ala and X₄ is Gly.
6. A method of treating a subject having or at risk of exhibiting weight-
loss comprising administering to the subject a transforming growth
25 factor-alpha (TGF- α) polypeptide in an effective amount to inhibit or
reduce weight-loss in the subject.
7. The method of claim 6, wherein the polypeptide has an amino acid
30 sequence as set forth in SEQ ID NO:1.

8. The method of claim 6, wherein the polypeptide has an amino acid sequence as set forth in SEQ ID NO:3.
- 5 9. The method of claim 6, wherein the polypeptide comprises a peptide having a sequence NH₂- X_{1a} - Cys - His - Ser - X_{1b} - X₂ - X_{1a} - X_{1b} - X_{1a} - X₃ - Cys COOH (SEQ ID NO:4) wherein X_{1a} and X_{1b} are independently Val, Gly or Ala; X₂ is Tyr or Phe; X₃ is Arg or Lys; and the two Cys moieties are linked via a disulfide bond to form an at least 11-amino acid functional peptide having TGF- α activity.
- 10 10. The method of claim 9, wherein at least one or more of the following amino acids are linked to the C-terminal Cys moiety of SEQ ID NO:4: - X₄ - His - X_{1c} - X₄ - X₅ - X₆ - X_{1c} (SEQ ID NO:5) wherein X₄ is Glu or Asp; X₅ is Leu or Ile; and X₆ is Asp or Glu.
- 15 11. The method of claim 10, wherein X_{1a} is Val, X_{1b} is Gly and X_{1c} is Ala.
12. The method of claim 10, wherein X₂ is Tyr and X₃ is Arg.
- 20 13. The method of claim 10, wherein the functional peptide is 18 amino acids in length and X_{1a} is Val, X_{1b} is Gly, X_{1c} is Ala and X₄ is Gly.
14. The method of claim 6, wherein the weight-loss is the result of a disease or disorder.
- 25 15. The method of claim 6, wherein the weight-loss is associated with treatment with of the subject with a chemotherapeutic agent.

16. The method of claim 15, wherein the chemotherapeutic agent is selected from the group consisting of carmustine (BCNU), chlorambucil (Leukeran), cisplatin (Platinol), Cytarabine, doxorubicin (Adriamycin), fluorouracil (5-FU), methoxetrate (Mexate), taxol, CPT111, etoposide, and plicamycin (Mithracin).
17. The method of claim 15, wherein the disease or disorder is ARC or AIDS.
18. The method of claim 6, wherein the subject is a mammal.
19. The method of claim 18, wherein the mammal is a human.
20. A method of increasing the body weight of a subject comprising administering to the subject prior to, simultaneously with, or substantially following weight-loss a transforming growth factor-alpha (TGF- α) polypeptide in an effective amount to increase or maintain the weight of the subject.
21. The method of claim 20, wherein the polypeptide has an amino acid sequence as set forth in SEQ ID NO:1.
22. The method of claim 20, wherein the polypeptide has an amino acid sequence as set forth in SEQ ID NO:3.
23. The method of claim 20, wherein the polypeptide comprises a peptide having a sequence NH₂- X_{1a} - Cys - His - Ser - X_{1b} - X₂ - X_{1a} - X_{1b} - X_{1a} - X₃ - Cys COOH (SEQ ID NO:4) wherein X_{1a} and X_{1b} are independently Val, Gly or Ala; X₂ is Tyr or Phe; X₃ is Arg or Lys; and the two Cys moieties are linked via a disulfide bond to form an at least 11-amino acid functional peptide having TGF- α activity.

24. The method of claim 23, wherein at least one or more of the following amino acids are linked to the C-terminal Cys moiety of SEQ ID NO:4: - X₄ - His - X_{1c} - X₄ - X₅ - X₆ - X_{1c} (SEQ ID NO:5) wherein X₄ is Glu or Asp; X₅ is Leu or Ile; and X₆ is Asp or Glu.
- 5
25. The method of claim 24, wherein X_{1a} is Val, X_{1b} is Gly and X_{1c} is Ala.
26. The method of claim 24, wherein X₂ is Tyr and X₃ is Arg.
- 10 27. The method of claim 24, wherein the functional peptide is 18 amino acids in length and X_{1a} is Val, X_{1b} is Gly, X_{1c} is Ala and X₄ is Gly.
28. The method of claim 20, wherein the weight-loss is the result of a disease or disorder.
- 15
29. The method of claim 20, wherein the weight-loss is associated with treatment of the subject with a chemotherapeutic agent.
- 20 30. The method of claim 29, wherein the chemotherapeutic agent is selected from the group consisting of carmustine (BCNU), chlorambucil (Leukeran), cisplatin (Platinol), Cytarabine, doxorubicin (Adriamycin), fluorouracil (5-FU), methoxetrate (Mexate), taxol, CPT111, etoposide, and plicamycin (Mithracin).
- 25 31. The method of claim 28, wherein the disease or disorder is ARC or AIDS.
32. The method of claim 20, wherein the subject is a mammal.
- 30 33. The method of claim 32, wherein the mammal is a human.

34. A pharmaceutical composition comprising a polypeptide having a sequence NH₂- X_{1a} - Cys - His - Ser - X_{1b} - X₂ - X_{1a} - X_{1b} - X_{1a} - X₃ - Cys COOH (SEQ ID NO:4) wherein X_{1a} and X_{1b} are independently Val, Gly or Ala; X₂ is Tyr or Phe; X₃ is Arg or Lys; and the two Cys moieties are linked via a disulfide bond to form an at least 11-amino acid functional peptide having TGF- α activity, and a pharmaceutically acceptable carrier.
35. The pharmaceutical composition of claim 34, wherein at least one or more of the following amino acids are linked to the C-terminal Cys moiety of SEQ ID NO:4: - X₄ - His - X_{1c} - X₄ - X₅ - X₆ - X_{1c} (SEQ ID NO:5) wherein X₄ is Glu or Asp; X₅ is Leu or Ile; and X₆ is Asp or Glu.
36. The pharmaceutical composition of claim 34, wherein X_{1a} is Val, X_{1b} is Gly and X_{1c} is Ala.
37. The pharmaceutical composition of claim 35, wherein X₂ is Tyr and X₃ is Arg.
38. The pharmaceutical composition of claim 35, wherein the functional peptide is 18 amino acids in length and X_{1a} is Val, X_{1b} is Gly, X_{1c} is Ala and X₄ is Gly.
39. A method for treating a neurodegenerative disease in a subject comprising administering to the subject a transforming growth factor-alpha (TGF- α) polypeptide in an effective amount to modulate the neurodegenerative disease.
40. The method of claim 39, wherein the polypeptide has an amino acid sequence as set forth in SEQ ID NO:1.

41. The method of claim 39, wherein the polypeptide has an amino acid sequence as set forth in SEQ ID NO:3.
- 5 42. The method of claim 39, wherein the polypeptide has a sequence NH₂-X_{1a} - Cys - His - Ser - X_{1b} - X₂ - X_{1a} - X_{1b} - X_{1a} - X₃ - Cys COOH (SEQ ID NO:4) wherein X_{1a} and X_{1b} are independently Val, Gly or Ala; X₂ is Tyr or Phe; X₃ is Arg or Lys; and the two Cys moieties are linked via a disulfide bond to form an at least 11-amino acid functional peptide having TGF- α activity.
- 10 43. The method of claim 42, wherein at least one or more of the following amino acids are linked to the C-terminal Cys moiety of SEQ ID NO:4: - X₄ - His - X_{1c} - X₄ - X₅ - X₆ - X_{1c} (SEQ ID NO:5) wherein X₄ is Glu or Asp; X₅ is Leu or Ile; and X₆ is Asp or Glu.
- 15 44. The method of claim 43, wherein X_{1a} is Val, X_{1b} is Gly and X_{1c} is Ala.
45. The method of claim 43, wherein X₂ is Tyr and X₃ is Arg.
- 20 46. The method of claim 43, wherein the functional peptide is 18 amino acids in length wherein X_{1a} is Val, X_{1b} is Gly, X_{1c} is Ala and X₄ is Gly.
- 25 47. A method for treating a CNS disease or disorder comprising administering to a subject a polypeptide having a sequence as set forth in SEQ ID NO:3, or a polypeptide having a sequence NH₂- X_{1a} - Cys - His - Ser - X_{1b} - X₂ - X_{1a} - X_{1b} - X_{1a} - X₃ - Cys COOH (SEQ ID NO:4) wherein X_{1a} and X_{1b} are independently Val, Gly or Ala; X₂ is Tyr or Phe; X₃ is Arg or Lys; and the two Cys moieties are linked via a disulfide bond to form an at least 11-amino acid functional peptide
- 30 having TGF- α activity.

48. The method of claim 47, wherein the CNS disease or disorder is selected from the group consisting of CNS ischemia, spinal cord injury, MS, and retinal injury.
- 5 49. The method of claim 47, wherein at least one or more of the following amino acids are linked to the C-terminal Cys moiety of SEQ ID NO:4: - X₄ - His - X_{1c} - X₄ - X₅ - X₆ - X_{1c} (SEQ ID NO:5) wherein X₄ is Glu or Asp; X₅ is Leu or Ile; and X₆ is Asp or Glu.
- 10 50. The method of claim 49, wherein X_{1a} is Val, X_{1b} is Gly and X_{1c} is Ala.
51. The method of claim 49, wherein X₂ is Tyr and X₃ is Arg.
- 15 52. The method of claim 49, wherein the functional peptide is 18 amino acids in length and wherein X_{1a} is Val, X_{1b} is Gly, X_{1c} is Ala and X₄ is Gly.
- 20 53. A method for enhancing hematopoiesis during cytotoxic or immune-suppressing therapy, comprising administering a TGF α polypeptide in an effective amount to enhance hematopoeisis.
54. The method of claim 53, wherein the polypeptide has an amino acid sequence as set forth in SEQ ID NO:1.
- 25 55. The method of claim 53, wherein the polypeptide has an amino acid sequence as set forth in SEQ ID NO:3.

56. The method of claim 53, wherein the polypeptide has a sequence
NH₂- X_{1a} - Cys - His - Ser - X_{1b} - X₂ - X_{1a} - X_{1b} - X_{1a} - X₃ - Cys-
COOH (SEQ ID NO:4) wherein X_{1a} and X_{1b} are independently Val,
Gly or Ala; X₂ is Tyr or Phe; X₃ is Arg or Lys; and the two Cys
moieties are linked via a disulfide bond to form an at least 11-amino
acid functional peptide having TGF- α activity.
57. The method of claim 56, wherein at least one or more of the following
amino acids are linked to the C-terminal Cys moiety of SEQ ID NO:4:
- X₄ - His - X_{1c} - X₄ - X₅ - X₆ - X_{1c} (SEQ ID NO:5) wherein X₄ is Glu
or Asp; X₅ is Leu or Ile; and X₆ is Asp or Glu.
58. The method of claim 57, wherein X_{1a} is Val, X_{1b} is Gly and X_{1c} is
Ala.
59. The method of claim 57, wherein X₂ is Tyr and X₃ is Arg.
60. The method of claim 57, wherein the functional peptide is 18 amino
acids in length wherein X_{1a} is Val, X_{1b} is Gly, X_{1c} is Ala and X₄ is
Gly.
61. The method of claim 53, further comprising administering a second
hematopoietic growth factor agent to stimulate the generation of more
mature hematopoietic precursor cells, wherein the second
hematopoietic growth factor is selected from the group consisting of
erythropoietin, thrombopoietin, G-CSF (granulocyte colony
stimulating factor), and GM-CSF (granulocyte macrophage colony
stimulating factor).

- 5
62. A method for treating or preventing mucositis of the gastrointestinal tract in a subject comprising administering a TGF α polypeptide in an amount effective to inhibit or prevent oral or intestinal mucositis in the subject.
63. The method of claim 62, wherein the polypeptide has an amino acid sequence as set forth in SEQ ID NO:1.
- 10 64. The method of claim 62, wherein the polypeptide has an amino acid sequence as set forth in SEQ ID NO:3.
- 15 65. The method of claim 62, wherein the polypeptide has a sequence NH₂- X_{1a} - Cys - His - Ser - X_{1b} - X₂ - X_{1a} - X_{1b} - X_{1a} - X₃ - Cys COOH (SEQ ID NO:4) wherein X_{1a} and X_{1b} are independently Val, Gly or Ala; X₂ is Tyr or Phe; X₃ is Arg or Lys; and the two Cys moieties are linked via a disulfide bond to form an at least 11-amino acid functional peptide having TGF- α activity.
- 20 66. The method of claim 65, wherein at least one or more of the following amino acids are linked to the C-terminal Cys moiety of SEQ ID NO:4: - X₄ - His - X_{1c} - X₄ - X₅ - X₆ - X_{1c} (SEQ ID NO:5) wherein X₄ is Glu or Asp; X₅ is Leu or Ile; and X₆ is Asp or Glu.
- 25 67. The method of claim 66, wherein X_{1a} is Val, X_{1b} is Gly and X_{1c} is Ala.
68. The method of claim 66, wherein X₂ is Tyr and X₃ is Arg.
- 30 69. The method of claim 66, wherein the functional peptide is 18 amino acids in length wherein X_{1a} is Val, X_{1b} is Gly, X_{1c} is Ala and X₄ is Gly.



70. The method of claim 62, wherein the oral or intestinal mucositis results from cytotoxic or immune-suppressing therapy.
71. The method of claim 62, wherein the mucositis results from ARC or AIDS.
72. The method of claim 62, wherein the subject is a mammal.
73. The method of claim 72, wherein the mammal is a human.
74. A compound as shown in formula III:
- loop peptide N-terminus -linker-cyclic $C_4H_8N_2$ -linker- loop peptide N-terminus (III)
- wherein the linker moiety is designed to link the N-terminus of the loop peptide to a nitrogen atom of the ring $C_4H_8N_2$ and wherein the loop peptide has a sequence NH_2 - X_{1a} - Cys - His - Ser - X_{1b} - X_2 - X_{1a} - X_{1b} - X_{1a} - X_3 - Cys $COOH$ (SEQ ID NO:4) wherein X_{1a} and X_{1b} are independently Val, Gly or Ala; X_2 is Tyr or Phe; X_3 is Arg or Lys; and the two Cys moieties are linked via a disulfide bond to form an at least 11-amino acid functional peptide having TGF- α activity, wherein said compound functions as a TGF- α mimetic.
75. The compound of claim 74, wherein at least one or more of the following amino acids are linked to the C-terminal Cys moiety of SEQ ID NO:4: - X_4 - His - X_{1c} - X_4 - X_5 - X_6 - X_{1c} (SEQ ID NO:5) wherein X_4 is Glu or Asp; X_5 is Leu or Ile; and X_6 is Asp or Glu.
76. The compound of claim 75, wherein X_{1a} is Val, X_{1b} is Gly and X_{1c} is Ala.

77. The compound of claim 75, wherein X₂ is Tyr and X₃ is Arg.
- 5 78. The compound of claim 75, wherein the functional peptide is 18 amino acids in length wherein X_{1a} is Val, X_{1b} is Gly, X_{1c} is Ala and X₄ is Gly.
- 10 79. The compound of claim 74, wherein the linker group is independently selected from the group consisting of substituted or unsubstituted C₁₋₆ alkyl, substituted or unsubstituted C₂₋₆ alkenyl, substituted or unsubstituted C₁₋₆ alkoxy, xilyenyl, wherein the substitutions are selected from the group consisting of oxo, epoxyl, hydroxyl, chloryl, bromyl, fluoryl, and amino.
- 15 80. A method for treating inflammatory bowel disease, colitis, and Chron's Disease of the gastrointestinal tract, comprising administering a TGF α polypeptide in an effective amount to inhibit or ameliorate the disease.
- 20 81. The method of claim 80, wherein the polypeptide has an amino acid sequence as set forth in SEQ ID NO:1.
82. The method of claim 80, wherein the polypeptide has an amino acid sequence as set forth in SEQ ID NO:3.
- 25 83. The method of claim 80, wherein the polypeptide has a sequence NH₂-X_{1a} - Cys - His - Ser - X_{1b} - X₂ - X_{1a} - X_{1b} - X_{1a} - X₃ - Cys COOH (SEQ ID NO:4) wherein X_{1a} and X_{1b} are independently Val, Gly or Ala; X₂ is Tyr or Phe; X₃ is Arg or Lys; and the two Cys moieties are linked via a disulfide bond to form an at least 11-amino acid functional peptide having TGF- α activity.

84. The method of claim 83, wherein at least one or more of the following amino acids are linked to the C-terminal Cys moiety of SEQ ID NO:4:
- X₄ - His - X_{1c} - X₄ - X₅ - X₆ - X_{1c} (SEQ ID NO:5) wherein X₄ is Glu or Asp; X₅ is Leu or Ile; and X₆ is Asp or Glu.
85. The method of claim 84, wherein X_{1a} is Val, X_{1b} is Gly and X_{1c} is Ala.
86. The method of claim 84, wherein X₂ is Tyr and X₃ is Arg.
87. The method of claim 84, wherein the functional peptide is 18 amino acids in length and wherein X_{1a} is Val, X_{1b} is Gly, X_{1c} is Ala, and X₄ is Gly.
88. A method for treating or preventing an inflammatory reaction of an autoimmune disease in a subject comprising administering a TGF α polypeptide to the subject in an effective amount to inhibit or ameliorate the inflammatory reaction.
89. The method of claim 88, wherein the polypeptide has an amino acid sequence as set forth in SEQ ID NO:1.
90. The method of claim 88, wherein the polypeptide has an amino acid sequence as set forth in SEQ ID NO:3.
91. The method of claim 88, wherein the polypeptide has a sequence NH₂-X_{1a} - Cys - His - Ser - X_{1b} - X₂ - X_{1a} - X_{1b} - X_{1a} - X₃ - Cys COOH (SEQ ID NO:4) wherein X_{1a} and X_{1b} are independently Val, Gly or Ala; X₂ is Tyr or Phe; X₃ is Arg or Lys; and the two Cys moieties are linked via a disulfide bond to form an at least 11-amino acid functional peptide having TGF- α activity.

- 5 92. The method of claim 91, wherein at least one or more of the following amino acids are linked to the C-terminal Cys moiety of SEQ ID NO:4: - X₄ - His - X_{1c} - X₄ - X₅ - X₆ - X_{1c} (SEQ ID NO:5) wherein X₄ is Glu or Asp; X₅ is Leu or Ile; and X₆ is Asp or Glu.
93. The method The method of claim 92, wherein X_{1a} is Val, X_{1b} is Gly and X_{1c} is Ala.
- 10 94. The method of claim 92, wherein X₂ is Tyr and X₃ is Arg.
95. The method of claim 92, wherein the functional peptide is 18 amino acids in length wherein X_{1a} is Val, X_{1b} is Gly, X_{1c} is Ala and X₄ is Gly.
- 15 96. The method of claim 88, wherein the autoimmune diseases are selected from the group consisting of Type II (Juvenile) Diabetes, rheumatoid arthritis, lupus, glomerular nephritis, and multiple sclerosis.
97. The method of claim 88, wherein the subject is a mammal.
- 20 98. The method of claim 97, wherein the mammal is a human.

1/4

*TGF α* **FIG. 1****FIG. 2**




FIG. 3

3/4




FIG. 4

4/4




FIG. 5




FIG. 6

SEQUENCE LISTING

<110> Stem Cell Pharmaceuticals, Inc.

<120> TGF-alpha POLYPEPTIDES, FUNCTIONAL FRAGMENTS AND
METHODS OF USE THEREFOR

<130> Stem1100

<140> Not Yet Known

<141> 2000-04-26

<150> 09/299,473

<151> 1999-04-26

<150> 09/459,813

<151> 1999-12-13

<160> 6

<170> PatentIn Ver. 2.1

<210> 1

<211> 50

<212> PRT

<213> Homo sapiens

<400> 1

Val	Val	Ser	His	Phe	Asn	Asp	Cys	Pro	Asp	Ser	His	Thr	Gln	Phe	Cys
1				5					10					15	

Phe	His	Gly	Thr	Cys	Arg	Phe	Leu	Val	Gln	Glu	Asp	Lys	Pro	Ala	Cys
			20					25					30		

Val	Cys	His	Ser	Gly	Tyr	Val	Gly	Ala	Arg	Cys	Glu	His	Ala	Asp	Leu
		35					40					45			

Leu	Ala
	50

<210> 2

<211> 50

<212> PRT

<213> Rattus norvegicus

<400> 2

Val	Val	Ser	His	Phe	Asn	Lys	Cys	Pro	Asp	Ser	His	Thr	Gln	Tyr	Cys
1				5					10					15	

Phe	His	Gly	Thr	Cys	Arg	Phe	Leu	Val	Gln	Glu	Glu	Lys	Pro	Ala	Cys
			20					25					30		

Val	Cys	His	Ser	Gly	Tyr	Val	Gly	Val	Arg	Cys	Glu	His	Ala	Asp	Leu
		35					40					45			

Asp Ala
50

<210> 3
<211> 57
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: A modified
human TGF-alpha sequence

<400> 3
Ser Leu Ser Leu Pro Ala Met Val Val Ser His Phe Asn Asp Cys Pro
1 5 10 15

Asp Ser His Thr Gln Phe Cys Phe His Gly Thr Cys Arg Phe Leu Val
20 25 30

Gln Glu Asp Lys Pro Ala Cys Val Cys His Ser Gly Tyr Val Gly Ala
35 40 45

Arg Cys Glu His Ala Asp Leu Leu Ala
50 55

<210> 4
<211> 11
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: An artificial
peptide sequence

<220>
<221> UNSURE
<222> ()
<223> X at residue 1, 5, 7 to 9 are independently V G or
A; X at residue 6 is Y or F; and X at residue 10
is R or K.

<400> 4
Xaa Cys His Ser Xaa Xaa Xaa Xaa Xaa Xaa Cys
1 5 10

<210> 5
<211> 7
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Artificial
peptide sequence

<220>

<221> UNSURE

<222> (1)..(7)

<223> X at residue 1 and 4 are E or D; X at residue 3
and 7 are V, G, or A; X at residue 5 is L or I;
and X at residue 6 is D or E.

<400> 5

Xaa His Xaa Xaa Xaa Xaa Xaa
1 5

<210> 6

<211> 18

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Artificial
Peptide Sequence

<220>

<221> UNSURE

<222> (1)..(18)

<223> X at residues 1, 5, 7-9, 14, 18 are indep. V, G or
A; X at residues 6 is Y or F; X at residue 10 is R
or K; X at residue 12, 15 is indep. E or D; X at
residue 16 is L or I; X at residue 17 is D or E

<400> 6

Xaa Cys His Ser Xaa Xaa Xaa Xaa Xaa Xaa Cys Xaa His Xaa Xaa Xaa
1 5 10 15

Xaa Xaa

1

3

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US00/11564

A. CLASSIFICATION OF SUBJECT MATTER

IPC(7) : Please See Extra Sheet.

US CL : 514/2; 530/300, 350

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 514/2; 530/300, 350

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

Issues_AA, a-geneseq36, swiss-prot38, sptrembl112, a-issued, pir64

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X --- Y --- A	US 5,633,147 A (MEISSNER et al) 27 May 1997, Abstract, column 2, line 20, column 10, lines 63-66, column 11, lines 26-30, SEQ ID NO:7 and Sequence Comparison A.	1,34 --- 9,23 --- 2 - 5 , 3 5 - 38,42,47,56,83, 74-79



Further documents are listed in the continuation of Box C.



See patent family annex.

* Special categories of cited documents:	"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
"A" document defining the general state of the art which is not considered to be of particular relevance	"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
"E" earlier document published on or after the international filing date	"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	"&" document member of the same patent family
"O" document referring to an oral disclosure, use, exhibition or other means	
"P" document published prior to the international filing date but later than the priority date claimed	

Date of the actual completion of the international search

19 OCTOBER 2000

Date of mailing of the international search report

27 NOV 2000

Name and mailing address of the ISA/US
Commissioner of Patents and Trademarks
Box PCT
Washington, D.C. 20231

Facsimile No. (703) 305-3230

Authorized officer

ROBERT LANDSMAN

Telephone No. (703) 308-0196

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US00/11564

C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X --- Y --- A	WO 91/01141 (TAM) 07 February 1991, see page 1, line 7, page 5, lines 5-6, page 15, lines 7-8 and Sequence Comparison B.	6,7,14,18 -21,28,32,33 ----- 9,23 ----- 8,10-13,15- 17,22,24-27,29- 31,39-61,80-87

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US00/11564

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This international report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:

2. ☐ Claims Nos.:
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:

3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

Please See Extra Sheet.

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☒ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
1-61, 74-87
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
☐ No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US00/11564

A. CLASSIFICATION OF SUBJECT MATTER:
IPC (7):

A01N 37/18; A61K 38/00; C07K 14/00, 16/00, 17/00, 2/00, 4/00, 5/00, 7/00, 1/00

BOX II. OBSERVATIONS WHERE UNITY OF INVENTION WAS LACKING

This ISA found multiple inventions as follows:

This application contains the following inventions or groups of inventions which are not so linked as to form a single inventive concept under PCT Rule 13.1. In order for all inventions to be searched, the appropriate additional search fees must be paid.

Group I, claims 1-38, drawn to a polypeptide and a method of treating weight loss, or increase body weight.

Group II, claims 39-52, drawn to a method of treating a neurological and CNS disease.

Group III, claims 53-61, drawn to a method of enhancing hematopoiesis.

Group IV, claims 62-73, drawn to a method of treating or preventing mucositis.

Group V, claims 74-79, drawn to a compound.

Group VI, claims 80-87, drawn to a method of treating inflammatory bowel disease.

Group VII, claims 88-98, drawn to a method of treating an autoimmune disease.

The inventions listed as Groups I-VII do not relate to a single inventive concept under PCT Rule 13.1 because, under PCT Rule 13.2, they lack the same or corresponding special technical features for the following reasons: the special technical feature of Group I is a method of treating weight loss. The special technical feature of Group II is a method of treating neurological and CNS diseases. The special technical feature of Group III is a method of enhancing hematopoiesis. The special technical feature of Group IV is a method of treating or preventing mucositis. The special technical feature of Group V is a compound. The special technical feature of Group VI is a method of treating inflammatory bowel disease. The special technical feature of Group VII is a method of treating an autoimmune disease. The methods of Groups I-VII require different method steps and reagents for achieving different goals. The Groups are not so linked by a special technical feature within the meaning of PCT Rule 13.2 so as to form a single inventive concept.